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 ABSTRACT 
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Marquette University, 2014 
 
 
Mild cognitive impairment (MCI) has an average prevalence of 18.9% and most 
often affects people 60 years of age or older.  It is a cognitive stage between normal 
functioning and dementia (Petersen, 2003; Petersen, 2011; Petersen et al., 2014).  MCI 
can be broken into two subtypes classified by the presence of memory impairment 
(amnestic MCI) or the lack thereof (nonamnestic MCI).  Medical diagnostic criteria are 
commonly used to guide research with older adults with MCI.  A theoretical framework 
that addresses the antecedents and consequences of MCI, specifically one examining the 
relationships among MCI, uncertainty, coping and psychological distress, is essential to 
guide the development of effective nursing interventions but is unapparent in published 
literature.   
The aims of this quantitative, cross-sectional study are to: (1) test select 
components of a new conceptual framework for MCI by examining the relationships 
among uncertainty, coping, psychological distress, time since diagnosis, and level of 
cognitive impairment from MCI; (2) describe the levels of uncertainty, coping, and 
psychological distress in persons with MCI; (3) examine the differences in scores on 
uncertainty, coping, and psychological distress between the two subtypes of MCI; and (4) 
examine the strength and direction of relationships between scores on uncertainty, 
coping, and psychological distress within the subtypes of MCI.   
The sample consisted of 91 primarily Caucasian (>85%) older adults receiving 
care at a neurology clinic, with a relatively even split between genders and MCI subtypes.  
Positive relationships were found between uncertainty, coping, and psychological 
distress, supporting the study framework.  In addition, subjects reported low to moderate 
levels of uncertainty and psychological distress, and most often used emotion-focused 
coping strategies.  Subjects with naMCI reported more somatic symptoms than those with 
aMCI (p<0.05); however, there were no significant relationships between the MCI 
subtypes or level of cognitive impairment on the other psychological distress subscales, 
coping instrument, or uncertainty instrument.  The long-term goal of this study is to 
provide a foundation for a program of research centered on the development and 
evaluation of interventions to assist older adults who have a diagnosis of MCI and their 
family members with coping and managing their condition.   
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I. INTRODUCTION 
Background and significance 
The average lifespan in the United States is increasing; people can now expect to 
live to be approximately 78.5 years-old (Arias, 2014).  Concurrently, advances in science 
have led to increases in quality of life through early identification of illnesses, 
impairments, and other age-related changes.  One such condition, mild cognitive 
impairment (MCI), has become increasingly of concern as a potential pre-dementia 
condition, making it a new target for early diagnosis and interventions to help maintain 
quality of life through slowing or preventing the progression to dementia.  MCI is 
currently defined as functional impairment affecting mental processes, such as memory 
or executive functioning, that is more than what is expected for normal aging and often 
precedes dementia (Petersen, 2003; Petersen et al., 2014).  It is generally diagnosed 
starting around the age of 60 years (Petersen, 2011).   
Diagnostically MCI can further be broken down into two subsets: Amnestic 
versus non-amnestic MCI (Petersen, 2014).  The main difference between these subsets is 
the presence of memory impairment (amnestic or aMCI) or lack thereof (non-amnestic or 
naMCI).  Despite fundamental differences between aMCI and naMCI, there is a 
significant lack of evidence for treating or screening one subset differently from the other 
(Gauthier & Touchon, 2005; Lin, Vance, Gleason, & Heidrich, 2012; Ross & Bell, 2014).  
In addition, older adults with either subtype of MCI are considered to be a vulnerable 
population, at risk for coercion or mistreatment directly relating to their level of impaired 
cognition, regardless of the nature of their impairment. 
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Unfortunately, the point at which it is determined that changes in cognition are 
being caused by MCI rather than normal age-associated changes or dementia is subjective 
and not completely clear cut.  In general, the diagnosis of MCI typically starts with the 
patients’ or family members’ complaint of changes in cognition (Albert et al., 2011; 
Petersen et al., 2014; Portet et al., 2006).  This complaint is accompanied by a significant 
difference in performance (within 1.5 standard deviations of what is normally expected 
for age) on a brief cognitive screening tool such as the Montreal Cognitive Assessment 
(Nasreddine et al., 2005) or Addenbrooke’s Cognitive Examination revised (Mioshi, 
Dawson, Mitchell, Arnold, & Hodges, 2006).   
Incidence and prevalence of MCI.   Recently the average incidence rate and 
prevalence for all types of MCI, calculated from 16 large scale studies, is estimated to be 
47.9/1000 person-years and 18.9% respectively (Petersen et al., 2014).  For aMCI and 
naMCI separately, incidence rates are 3.8 and 3.9/100 person-years with prevalence of 
11.6% and 9.9%, respectively (Katz et al., 2011).  Comparatively, in the same study, for 
all types of dementia the incidence rate was 2.9/100 person-years and prevalence was 
6.5% (Katz et al., 2011).  Higher rates of naMCI have also been found in persons who 
identify as African American/Black compared to those who identify as Caucasian/White 
(Katz et al., 2011; Lee et al., 2012).  African American/Black race was also found to be a 
significant risk factor for development of MCI in the Cardiovascular Health Study (Lopez 
et al., 2003).  Other studies have found conflicting results, with incidence rates of MCI 
among Hispanic/Latino and African American/Black persons similar to the incidence 
rates of MCI among Caucasian/White persons (Manly et al., 2008; Unverzagt et al., 
2011).  These conflicting results suggest that the differences of MCI incidence by race 
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may be contributed to increased misclassification of MCI (Kennedy, 2011).  In general, it 
has been estimated that MCI affects approximately up to one in five older adults globally 
(Laino, 2011).   
The general rate of progression from those diagnosed with either subset of MCI to 
dementia is estimated to be between 5.9 to 10% per year (Gao et al., 2014; Petersen, 
2011).  However, the speed of progression (i.e. months versus years) from MCI to 
dementia is inconsistent and difficult to predict (Portet et al., 2006).  In addition, there is 
little evidence to suggest which potential factors might influence or lead to one MCI 
subset over another, or which factors might influence an older adult’s transition/speed 
from MCI to dementia (Alzheimer’s Association, 2011).  The higher incidence and 
prevalence of MCI versus dementia, and the potential progressive relationship between 
MCI and dementia highlights the possibility of a large portion of adults progressing from 
MCI to dementia in the not so distant future.  It suggests a need for increased primary 
care visits to monitor potential progression from MCI to dementia, and increased use 
anti-dementive drugs at an earlier stage.   
Potential costs related to MCI.   Overall the potential direct/indirect costs, 
trajectory, and burden associated with MCI are not well understood and have only 
recently been estimated in the United States (Lin & Neumann, 2013).  Compared to older 
adults without MCI or dementia in the US, those with MCI reported significantly 
(p<0.001) higher rates of informal care use and substantially higher annual direct medical 
costs (p<0.001) with a mean difference of $3,530 (Zhu et al., 2013).  Another US-based 
study also found that unspecified direct costs for older adults with MCI compared to 
those without impairment (adjusted for age and gender) were significantly higher by an 
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average difference of $859 per year (Leibson et al., 2012).  However, in Germany, Luppa 
et al. (2008) demonstrated a difference between the average direct costs from 
outpatient/inpatient care, pharmaceuticals, medical supplies, home care, assisted living 
and transportation for older adults with MCI at €4,443 (approximately $5,710) compared 
to €3,814 (approximately $4,902) for those without MCI.  While the 14% (€629, or 
approximately $808) difference in mean costs might be clinically significant, the 
difference was statistically insignificant (n = 413, p = 0.34).   
Issues with MCI: Conceptualizations and definitions.   Conceptualizations of 
MCI stem from its’ evolving definitions branching from surrogate terms such as benign 
senescent forgetfulness and age-associated memory impairment.  These 
conceptualizations of MCI are based on the assumption that a continuum of cognitive 
functioning exists between normal aging and dementia (Petersen et al., 2014; Portet et al., 
2006).  Originally, this continuum was based on diagnostic criteria with the assumption 
of memory loss as the only source of impairment, and Alzheimer’s dementia reflecting 
greater cognitive impairment on the continuum.  Later the diagnostic definition of MCI 
was broadened to include all types of cognitive impairment (aMCI and naMCI), thereby 
introducing more heterogeneity in the theoretical continuum and relating MCI to all types 
of dementia.  Older adults transition along this continuum at differing, unpredictable 
rates; and, not all older adults diagnosed with MCI continue on to AD.  Some older adults 
revert back towards normal functioning or stay stagnant within the scope of MCI (Anstey 
et al., 2008; Banningh, Vernooij-Dassen, Rikkert, & Teunisse, 2008; Chertkow, 2002; 
Costa et al., 2010; DeCarli, 2003; Diniz, Nunes, Yassuda, & Forlenza, 2009; Fisk & 
Rockwood, 2005; Gauthier & Touchon, 2005; Lingler et al., 2006; Portet et al., 2006; 
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Roach, 2005; Tuokko & Hultsch, 2006; Werner & Korczyn, 2008).  For example, a 
recent study of older adults diagnosed with MCI in primary care practices (n=357) found 
that after 3 years, 41.5% of the sample reverted back to normal cognition, 21.3% 
fluctuated between normal cognition and MCI, 14.8% were stagnant within MCI, and 
only 22.4% had progressed to dementia (Kaduszkiewicz et al., 2014).   
As a diagnostic entity, the definition of MCI has not always been straightforward 
and clear cut, and a specific conceptual framework that encompasses attributes, 
antecedents and consequences for MCI is nonexistent.  Despite efforts to clearly and 
uniformly define MCI, it is only recently that a diagnosis for MCI was accepted within 
the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)  (Matthews et 
al., 2007; Rosenberg, Johnston, & Lyketsos, 2006).  In May 2013, the DSM-V included 
the diagnosis of “minor neurocognitive disorder” to encompass MCI, supporting it as its 
own diagnosable entity (American Psychiatric Association [APA], 2013).  However, it is 
important to note that despite work towards the inclusion of MCI as a DSM-V diagnosis, 
national or international guidelines specific to the management of MCI have not been 
published (Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012).  
The historical lack of an accepted DSM diagnosis could be related to debates 
about MCI as its own entity rather than simply a new label for early dementia or memory 
loss associated with normal aging (Davis & Rockwood, 2004).  Surrogate terms 
(including but not limited to benign senescent forgetfulness, age-associated memory loss, 
mild cognitive decline, and cognitive impairment, no dementia) have also added to the 
varying definitions of MCI as either a process of aging or a pathological decline 
(Matthews et al., 2007).  Currently, the most widely accepted definition of MCI started to 
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arise in the early 1990’s and is diagnostic: MCI represents a form of functional 
impairment affecting mental processes, more than what is normally expected with age, 
which often precedes dementia (Petersen et al., 2014; Petersen, 2003).  
MCI is a useful concept to encompass the changes in cognition that are not the 
result of aging or dementia.  Yet, other than the aforementioned theoretical continuum of 
cognitive impairment, a clear conceptual framework for MCI which addresses possible 
antecedents and consequences is not apparent in published literature.  The existing 
theoretical continuum and diagnostic criteria only provide guidance about the trajectory 
and attributes of MCI, not the antecedents or consequences of MCI.  These attributes 
contribute to understanding MCI but do not provide guidance for nursing interventions 
that might help older adults with MCI and their families cope with the illness.  Other 
theories related to chronic illnesses have limitations for addressing the unique situation of 
older adults with MCI (Corbin & Strauss, 1991, 1992; Lazarus & Folkman, 1984; 
Levanthal, Meyer, & Nerenz, 1980; Mishel, 1988, 1990; Pearlin, Menaghan, Lieberman, 
& Mullan, 1981; Pearlin & Schooler, 1978).  For example, chronic illness theories do not 
account for the unpredictable illness trajectory on consequences of having MCI or the 
impact of cognitive impairment on the older adult’s appraisal of their situation.  
Consequently, a conceptual framework that addresses antecedents and consequences 
specific to MCI is needed in order to guide the development and evaluation of specific 
interventions and further legitimize MCI as a target for research.   
Conceptual framework for MCI.   This study proposes the Sjostedt framework 
for older adults with MCI (encompassing both aMCI and naMCI) that defines MCI as an 
unstable state of limbo weighted by heterogeneity between older adults’ normal and 
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abnormal continuums (normal aging versus dementia).  While the entirety of the 
framework is discussed in chapter two, the portion which will serve as the focus of this 
dissertation will be briefly introduced now.           
In the Sjostedt framework, the main consequence of MCI is uncertainty, which 
then leads to the other consequences of coping and psychological distress.  The 
uncertainty from MCI stems mainly from aforementioned inconsistencies in MCI 
diagnosis and variability in MCI trajectories.  Uncertainty may then influence older 
adults’ coping and psychological distress resulting from MCI.  Coping and psychological 
distress from MCI result as responses to diagnosis and symptoms related to MCI. Coping 
may impact psychological distress, similar to the relationships between coping and 
psychological distress with other chronic illnesses where emotion-focused and 
dysfunctional coping have been positively correlated with psychological distress (Barron, 
2000; Lauver, Kruse, & Baggot, 1999; Lynch, Kroencke, & Denney, 2001; Sanders-
Dewey, Mullins, & Chaney, 2001) and  problem-focused coping negatively correlated 
with psychological distress (Lynch et al., 2001; Sanders-Dewey et al., 2001).   Finally, an 
older adult’s progression with MCI or lack thereof over time may further shape the 
consequences of MCI.  The potential relationships of MCI, time, uncertainty, coping, and 
psychological distress that will be tested in the Sjostedt framework are illustrated in 
figure 1. 
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Uncertainty, coping, and psychological distress with MCI.   Uncertainty is 
defined as an emotional state that occurs when a person is unable to assign definite value 
to events or objects and/or is unable to predict an outcome (Mishel, 1983).  MCI is often 
referred to as an uncertain condition in qualitative studies of the experiences of older 
adults with MCI, and within attempts to conceptualize, diagnose, and define MCI 
(Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012; Lu, Haase, & Farran, 2007; 
Portet et al., 2006; Werner & Korczyn, 2008; Yanhong, Chandra, & Venkatesh, 2013).  
Uncertainty can influence how older adults respond to any illnesses, treatments, and 
hospitalizations (Landis, 1996).  Within any chronic illness, uncertainty can stem from a 
lack of clarity regarding symptoms, treatment options, disease etiology, and/or disease 
prognosis (Mishel, 1983, 1988, 1999).  Unlike other chronic illnesses, uncertainty from 
MCI may stem from condition heterogeneity, varying trajectories, and inconsistencies in 
diagnosis.  Despite evidence from qualitative studies, no studies have quantitatively 
assessed uncertainty from MCI. 
MCI 
Uncertainty 
Coping 
Psychological 
Distress Time 
since 
diagnosis 
Figure 1.  Conceptual framework for the consequences of MCI. 
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Coping is defined as the intentional cognitive and/or behavioral efforts to manage 
internal or external demands appraised as exceeding the resources of or taxing the person 
(Lazarus, 2000; Lazarus & Folkman, 1984).  In the conceptual framework, coping results 
as a response to MCI and uncertainty.  Some older adults with MCI might use avoidance 
oriented (or dysfunctional) coping through attempts to improve memory performance, 
avoidance of activities to avoid making mistakes or masking of deficits (Banningh et al., 
2008).  Yet, older adults with MCI might also use emotion-focused or problem-focused 
coping through methods such as positive reframing, acceptance, religion, planning, and 
instrumental support (McIlvane, Popa, Robinson, Houseweart, & Haley, 2008).  
Uncertainty could affect an older adult’s ability to define and relate to MCI, thus 
impairing their ability to cope effectively with it (Banningh et al., 2008; Blieszner, 
Roberto, Wilcox, Barham, & Winston, 2007; Lingler et al., 2006; Lu et al., 2007).  
Another result could be potential role and identity shifting, such as avoidance of 
independence (Blieszner et al., 2007). 
Finally, psychological distress might result from the diagnosis of MCI and is 
likely influenced by uncertainty and coping.  Psychological distress can be defined as the 
physical, psychosomatic, or emotional reactions to a stressor which negatively affect a 
person’s well-being (Kellner, 1987).  Psychological distress from MCI may present as 
emotions or reactions including anger, depression, anxiety, somatic symptoms, sadness, 
frustration, loss of self-confidence, discouragement, loneliness, rejection, inactivity, 
shame, self-blame, helplessness or loss of control (Banningh et al., 2008; Blieszner et al., 
2007; Carpenter et al., 2008; Dean & Wilcock, 2012; Ellison, 2008; Lu et al., 2007; 
Pessin, Rosenfeld, Burton, & Breitbart, 2003; Petersen, 2003; Rosenberg et al., 2006).  
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One study found that older adults with MCI were unable to identify any positive 
consequences (Banningh et al., 2008).  Yet, other studies have found positive emotions 
stemming from MCI such as happiness or relief that the diagnosis is not dementia, 
satisfaction from professional validation of their cognitive symptoms, optimism, and 
comfort through being able to reduce uncertainty by attaching a name to their cognitive 
symptoms (Dean & Wilcock, 2012; Lingler et al, 2006; McIlvane et al., 2008). 
Uncertainty, coping and psychological distress with other conditions.   To date, 
no correlational studies exploring the relationships between MCI, uncertainty, coping, 
and psychological distress exist.  However, a variety of studies have examined these 
relationships pertaining to adults with other chronic conditions (Haisfield-Wolfe et al., 
2012; Reich, Johnson, Zautra, & Davis, 2006; Landis, 1996; Lynch et al., 2001; Mullins 
et al., 2001; Sanders-Dewey et al., 2001) and non-chronic situations  and provide support 
for the proposed hypotheses in the Sjostedt framework (Lauver et al., 1999; Taylor-Piliae 
& Molassiotis, 2001).  Levels of uncertainty concerning a chronic illness (Haisfield-
Wolfe et al., 2012; Landis, 1996; Lynch et al, 2011; Mullins et al., 2001) and emotion-
focused coping strategies (Lynch et al., 2001; Sanders-Dewey et al., 2001) have been 
significantly and positively correlated with psychological distress.  Problem-focused 
coping has been negatively correlated with psychological distress (Lynch et al., 2001; 
Sanders-Dewey et al., 2001), and while clinically significant, this relationship is not 
always statistically significant (Lynch et al., 2001).   
In addition, another study found uncertainty to be positively and significantly 
related to perceived inability to cope, and both variables were significantly and positively 
correlated with increased levels of psychological distress among women receiving 
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abnormal papanicolaou results (Lauver et al., 1999). However, this result conflicts with 
that of Taylor-Piliae and Molassiotis (2001), who found no significant relationships 
between uncertainty and coping, and no significant relationships between uncertainty or 
coping and psychological distress among men receiving cardiac catheterization.  
Differences in relationships among uncertainty, coping, and psychological distress as 
demonstrated by Lauyer et al. (1999) and Taylor-Piliae and Molassiotis (2001) may be 
attributable to gender, cultural, or illness differences. 
Summary.   Most previous studies focus on the diagnosis of MCI.  Few studies 
focus on the consequences for older adults with MCI.  Consequences of having MCI 
might include (1) uncertainty regarding diagnosis, condition trajectory, and treatment 
(Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012; Lu et al., 2007; Portet et al., 
2006; Werner & Korczyn, 2008); (2) coping with diagnosis and symptoms (Banningh et 
al., 2008; McIlvane et al., 2008); and (3) psychological distress (Banningh et al., 2008; 
Blieszner et al., 2007; Dean & Wilcock, 2012; Lu et al., 2007; Petersen, 2003).  Older 
adults’ responses to these consequences of having an MCI diagnosis are central to 
nursing’s focus on holistic care.  Understanding the consequences of having MCI is 
foundational to designing effective interventions that help to decrease uncertainty and 
facilitate coping with the condition. 
Purpose of the study 
This study is unique in quantitatively addressing consequences of MCI 
(uncertainty, coping, and psychological distress), which have been overlooked or equated 
with the consequences of dementia.  This study will be foundational in validating a 
conceptual framework that can guide the development of nursing interventions and 
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further research for older adults with MCI.  The purposes of this quantitative study are to: 
(1) test select components of a new conceptual framework for MCI by examining the 
relationships among uncertainty, coping, psychological distress, time since diagnosis, and 
level of cognitive impairment from MCI, (2) describe the levels of uncertainty, coping, 
and psychological distress in older adults with MCI; (3) examine the differences in scores 
on uncertainty, coping, and psychological distress between the two subtypes of MCI; and 
(4) examine the strength and direction of relationships between scores on uncertainty, 
coping, and psychological distress within the subtypes of MCI.  
Specific aims and hypotheses.   The specific aims and hypotheses of this study 
are: 
Aim 1.   Test select components of a conceptual framework for MCI by 
examining the relationships among uncertainty, coping, psychological distress, time since 
MCI diagnosis, and level of cognitive impairment from MCI. 
H1.   There will be a significant negative relationship between time since 
diagnosis and level of cognitive impairment from MCI.   
H2.   There will be significant positive relationships between uncertainty and 
coping.   
H3.   There will be significant positive relationships between uncertainty and 
psychological distress.      
H4.   There will be significant relationships between coping and psychological 
distress.   
H5.   The relationships between level of cognitive impairment from MCI and 
coping will either be mediated or moderated by uncertainty. 
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H6.   The relationships between level of cognitive impairment from MCI and 
psychological distress will either be mediated or moderated by uncertainty and 
coping. 
Aim 2.   Describe the levels of uncertainty, coping, and psychological distress in 
older adults with MCI. 
Aim 3.   Examine the differences in scores on uncertainty, coping, and 
psychological distress between the subtypes of MCI. 
Aim 4.   Examine the strength and direction of relationships between scores on 
uncertainty, coping, and psychological distress within the subtypes of MCI. 
H7.   There will be no significant differences between the subtypes of MCI in the 
strength and direction of uncertainty, coping, and psychological distress.   
 The hypotheses of this study in relation to the conceptual framework are 
summarized by figure 2 which displays the predicted relationships among variables 
within the conceptual framework. 
 
 
 
 
 
 
 
 
 
MCI 
Uncertainty 
Coping 
Psychological 
Distress 
Time 
since 
diagnosis 
+ (H3) 
+/- (H4) 
+ (H2) - (H1) 
 (Aim3) 
(Aim3, H5) 
(Aim3, H6) 
Figure 2.  Predicted relationships between variables of the conceptual framework. 
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Summary of key variable definitions.   The conceptual definitions for MCI, 
uncertainty, coping, and psychological distress can be summarized as follows: 
MCI is an unstable state of limbo weighted by heterogeneity between older 
adults’ normal and abnormal continuums (normal aging versus dementia). 
Uncertainty is an emotional state that occurs when a person is unable to assign 
definite value to events or objects and/or is unable to predict an outcome (Mishel, 
1983).   
Coping is the intentional cognitive and/or behavioral efforts to manage internal or 
external demands appraised as exceeding the resources of or taxing the person 
(Lazarus, 2000; Lazarus & Folkman, 1984). 
Psychological distress is the physical, psychosomatic, or emotional reactions to a 
stressor which negatively affect a person’s well-being (Kellner, 1987).   
Significance to nursing and contribution to knowledge 
With the growing population of older adults, nurses will be caring for more older 
adults with MCI at various stages in a variety of environments.  Specifically, the burden 
of providing education about MCI to patients and providing support and guidance for 
patients and family members is clearly within the scope of nursing.  A validated 
conceptual framework will not only provide guidance to nurses involved in research with 
MCI, such a framework could also serve as a guide for designing patient and family  
interventions for the management of MCI.  The consequences for older adults with MCI 
are central to nursing’s focus on holistic care.  Understanding the consequences of having 
MCI is foundational to designing appropriate interventions that help to decrease 
uncertainty and facilitate coping with the condition. 
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Potential for leading to future research.   A validated conceptual framework for 
MCI will guide future research through identifying areas for interventions.  Most 
published studies pertaining to MCI use only diagnostic criteria or do not specify a 
framework as the basis for their research.  While the current practice of using diagnostic 
criteria to serve as a framework might help practitioners diagnose MCI, the current 
criteria do not address the possible antecedents or consequences of MCI which limits the 
potential scope of research and knowledge about how older adults with MCI respond to 
their diagnosis. 
Dissertation chapters overview 
 This chapter has focused on the significance of MCI, presentation of a portion of 
a new conceptual framework for MCI, and introduction of the dissertation study’s aims, 
and hypotheses.  Chapter two will describe in more detail the historical shaping of MCI 
definitions and conceptualizations, analyze existing chronic illness theoretical 
frameworks and their limitations for MCI, then present the entirety of a new conceptual 
framework for MCI.  Chapter three will explicate the methodology that will be used to 
accomplish testing of the new conceptual framework for MCI.  Finally, chapters four and 
five will present two different data-based manuscripts associated with this dissertation.  
The first manuscript compared two commonly used instruments for the screening of MCI 
in older adults (the Montreal Cognitive Assessment and the Revised Addenbrooke’s 
Cognitive Examination), in order to provide evidence for which instrument might be 
more appropriate for use in a primary care setting and this study.  The second manuscript 
presents the main findings related to the specific aims of the dissertation. 
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II. REVIEW OF THE LITERATURE AND CONCEPTUAL-THEORETICAL 
FRAMEWORK   
This chapter will review literature pertaining to the conceptualization and 
definition of MCI, limited applicability of theoretical frameworks related to chronic 
illnesses and MCI, and the current status of knowledge related to the relationships 
between MCI, time since diagnosis, uncertainty, coping, and psychological distress.  This 
chapter begins with a brief description of the literature search, followed by an overview 
of the historical shaping of the definition and understanding of the concept of MCI.  
Next, frameworks that have been used to guide studies related to chronic illness are 
critiqued in relation to their applicability to older adults with MCI.  The chapter then 
concludes with an examination of literature supporting the proposed theoretical 
framework for MCI, which will be tested in this study. 
Literature search description 
An extensive literature search was conducted using the CINAHL, Google-scholar, 
Web-of-Science, ProQuest dissertations, and PubMed databases, followed by ancestral 
searches of articles obtained from those databases.  Initial searches were conducted 
primarily for performing a concept analysis of MCI between August and November 2010 
using only the terms “mild cognitive impairment.”  This search yielded over 34,000 
possible articles and books.  The search was then narrowed down by year (with a focus 
on literature from the last 10 years, aside from sentinel works), limited to English 
language, and the main search term, “mild cognitive impairment,” was combined with 
additional terms (or restricting terms) such as: MCI, pediatrics (to examine the use of 
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MCI in other populations), geriatrics, chemotherapy, alcohol, nursing, perception and 
concept.  Surrogate terms for MCI were also searched to try to compile a comprehensive 
collection of studies.  Articles were included if they specifically addressed the concept of 
MCI or the possible antecedents, attributes, and consequences of MCI.  Articles were 
excluded if they focused only on dementia rather than MCI.  The inability to exclude 
articles within the database searches (without accidentally excluding applicable articles) 
pertaining only to older adults with dementia or only to caregivers of older adults with 
MCI resulted in a lengthy search process and multiple duplicate articles or articles not 
meeting the inclusion criteria.  This search process was repeated in 2011, 2012, 2013, and 
2014 to update the collection of articles and books to include recently published works 
not present during initial searches. 
The primary focus within the literature search was on MCI within the geriatric 
population.  This was later followed by focusing on MCI outside of the geriatric 
population (i.e. pediatrics, or within patients suffering from “chemo-brain” or 
alcoholism) to broaden the overall view of the concept for the purposes of creating the 
conceptual framework.  Articles were chosen based upon relevance to the concept and/or 
diagnosis of mild cognitive impairment.  Literature for the historical overview of MCI 
came from articles used for the concept analysis of MCI.   
Methods specified by Rodgers (Rodgers & Knafl, 2000) were used to guide the 
concept analysis and literature search, with literature collection that focused on the 
attributes, sociocultural, temporal, and discipline variations of MCI.  The method can be 
summarized as: (1) selecting a concept of interest; (2) identifying surrogate terms and 
uses of the concept; (3) collecting relevant literature pertaining to all aspects of the 
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concept; (4) identifying attributes of the concept then identifying the antecedents, 
consequences, and other concepts related to the concept; and (5) drawing a conceptual 
model connecting the attributes, antecedents, and consequences (Rodgers & Knafl, 2000).  
Outside of literature pertaining specifically to MCI, additional searches were 
conducted in the aforementioned databases to gather information on alternative 
theoretical frameworks that might be applicable to this study.  Again, the search was not 
limited by year, but was limited to articles or books published in English.  As MCI is 
considered to be a chronic illness, the search focused on the following chronic illness 
frameworks and their relation to MCI: (1) Pearlin and colleagues’ theories of coping 
(Pearlin & Schooler, 1978) and stress (Pearlin et al., 1981), (2) Lazarus and Folkman’s 
(1984) theory of Coping in Stress, (3) Corbin and Strauss’ (1991, 1992) Chronic Illness 
Trajectory Framework, (4) Levanthal and colleagues’ (1980) Common Sense Model of 
Illness Representations, and (5) Mishel’s (1988, 1990) theory of Uncertainty in Illness.  
These frameworks were selected for their potential applicability to MCI and fit with 
study variables. 
Related concepts to MCI.   While searching for conceptualizations of MCI, 
several terms repeatedly arose within the literature search pertaining to memory.  
Specifically the concepts of memory loss, memory impairment, or forgetfulness were 
present in the majority of reviewed literature.  The relationship of memory to MCI is 
likely due to aforementioned the early conceptualizations of MCI as a pre-AD condition, 
and hence only related to deficits in memory.  There also appeared to be a major focus on 
what MCI is not.  MCI can be presented as an absence rather than presence of certain 
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attributes, for instance the absence of functional impairment or absence of dementia 
rather than solely the presence of cognitive decline. 
Brief historical overview of conceptualizing and defining MCI 
Defining MCI.   In the past, MCI was broadly identified as the increased risk but 
not definitive diagnosis of a neurodegenerative disease (Rosenberg et al., 2006).  In this 
manner, MCI encompassed any of the possible conditions between normal aging and 
diagnosable cognitive decline (Diniz et al., 2009; Matthews et al., 2007; Roberts, Clare, 
& Woods, 2009).  In younger adults (less than 65 years old), MCI has been tautologically 
defined as greater than normal cognitive impairment; seen as related to intelligence 
(rather than aging), function and developmental progression (Byrne et al., 1987; Chen et 
al., 2006; Hurria, Somio, & Ahles, 2007; Keefe, Eesley, & Poe, 2005).  These previous 
definitions of MCI resulted in several surrogate terms, including: Benign senescent 
forgetfulness, age-associated memory impairment, late-life forgetfulness, aging-
associated cognitive decline, age-related cognitive decline, mild cognitive decline, 
questionable dementia, and mild neurocognitive decline (DeCarli, 2003; Ellison, 2008; 
Matthews et al., 2007; Norlund et al., 2005; Rosenberg et al., 2006; Visser, 2006; Werner 
& Korczyn, 2008).  Cognitive impairment, no dementia (CIND) was also considered as a 
surrogate term.  However, not all patients who meet the criteria for CIND also meet the 
criteria for MCI (Chertkow, 2002; Gauthier & Touchon, 2005).  Surrogate terms have 
added to the multiple definitions of MCI as either a process of aging or a pathological 
decline (Matthews et al., 2007).   
Starting around 1998 MCI began to be defined as a uniquely geriatric-condition, 
thought to be related to dementia (Golomb, Kluger, & Ferris, 2004; Reisberg et al., 
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2008).  Currently, the most widely accepted definition of MCI is diagnostic and comes 
from the work of Dr. Ronald Petersen and colleagues: MCI represents a form of 
functional impairment affecting mental processes, more than what is normally expected 
with age, which often precedes dementia (Petersen, 2011; Petersen, 2003; Petersen et al., 
2014).  Past efforts to define MCI were likely related to the desire to classify MCI as a 
useful/diagnostic entity; allowing for more definitive selections of subjects for treatment 
and research purposes.  The philosophic underpinnings of MCI have also been largely 
shaped by pragmatic views, which are reflected, if not directly stated, in most studies 
(Fisk & Rockwood, 2005).  Legitimization of MCI as a diagnosis (rather than broad 
concept) also provides justification for reimbursement from payers for care services and 
research funding for drug or other treatment studies (Werner & Korczyn, 2008).   
Diagnostically MCI can further be broken down into two subsets: Amnestic 
versus non-amnestic (Petersen et al., 2014).  The main difference between the subsets is 
the presence of memory impairment (amnestic or aMCI) or lack thereof (non-amnestic or 
naMCI).  Evidence suggests that those with aMCI are the most likely to later progress to 
dementia, generally in the form of Alzheimer’s dementia (Davis & Rockwood, 2004; 
Petersen & Morris, 2005).  The general rate of progression from those diagnosed with 
either subset of MCI to dementia is estimated to be between 5.9 to 10% per year (Gao et 
al., 2014; Petersen, 2011).  However, the speed of progression (i.e. months versus years) 
from MCI to dementia is inconsistent and difficult to predict (Portet et al., 2006).  In 
addition, there has been little evidence to suggest which potential factors might influence 
or lead to one MCI subset over another, or which factors might cause an older adult to 
transition from MCI to dementia (Alzheimer’s Association, 2011).   
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The presence of apolipoprotein (APOE) ε4 genotype, hippocampal atrophy 
(estimated by hippocampal volume), and some cerebrospinal fluid (CSF) biomarkers 
(Aβ42, T-tau, and P-tau) have been suggested to possibly predict increased likelihood of 
transitioning from MCI to dementia (Farlow et al., 2004; Gomar, Bobes-Bascaran, 
Conejero-Goldberg, Davies, & Goldberg, 2011; Hansson et al., 2006; Jack et al., 1999; 
Mattsson et al., 2009; Okonkwo et al., 2011).  Yet, studies evaluating the predictive 
values of APOE ε4, hippocampal atrophy, and CSF biomarkers have only focused 
predominately on older adults with aMCI (Ferreira et al., 2014).  This focus on aMCI is 
related to the similarities between aMCI and Alzheimer’s dementia (presence of a 
memory deficit), and aforementioned likelihood of progression from aMCI to 
Alzheimer’s dementia.  Given study sample biases towards aMCI (Ferreira et al., 2014), 
it is questionable if APOE ε4, hippocampal atrophy, and CSF biomarkers would also 
effectively predict transitioning to dementia in older adults with naMCI.  It is possible 
that the predictive value of APOE ε4, hippocampal atrophy, and CSF biomarkers are not 
unique to older adults with aMCI.  Currently within clinical practice, APOE ε4, 
hippocampal volume, and CSF biomarkers are not routinely being used to predict older 
adults’ transitions from MCI to dementia given their low sensitivity and specificity as 
diagnostic tests, and subsequently do not influence the nursing care of older adults with 
MCI (Albert et al., 2011; Petersen & Trojanowski, 2009). 
Conceptualizing MCI.   Conceptualizations of MCI have been related to its’ 
evolving definitions branching from surrogate terms such as benign senescent 
forgetfulness and age-associated memory impairment.  Conceptualizing MCI is based on 
the assumption that a continuum of cognitive functioning exists between normal aging 
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and dementia (Portet et al., 2006).  This continuum is best represented in a figure focused 
on the relations between normal aging, MCI, and a type of dementia, Alzheimer’s 
dementia (AD) from Petersen et al. (2001): 
 
 
Figure 3.  Continuum of cognitive impairment (Petersen et al., 2001). 
 Figure 3 does not distinctly note a direction, but instead implies a unidirectional 
path from normal aging to AD.  The progression of the path becomes more evident when 
another figure from the same publication is considered that proposes a theoretical 
negative relationship between age and cognitive functioning: 
 
Figure 4. Theorized progression from MCI to AD (Petersen et al., 2001). 
Yet, as previously stated, the path and speed of transition between normal aging 
and dementia is uncertain.  Older adults transition along the continuum at differing, 
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unpredictable rates; and, not all older adults diagnosed with MCI continue on to AD, 
some revert back towards normal functioning or stay stagnant within the scope of MCI 
(Anstey et al., 2008; Banningh et al., 2008; Chertkow, 2002; Costa et al., 2010; DeCarli, 
2003; Diniz et al., 2009; Fisk & Rockwood, 2005; Gauthier & Touchon, 2005; Lingler et 
al., 2006; Portet et al., 2006; Roach, 2005; Tuokko & Hultsch, 2006; Werner & Korczyn, 
2008).  Additionally, this initial continuum from normal aging to MCI to dementia was 
based on the assumption of cognitive impairment only affecting memory and thus only 
relating to AD.  However, later conceptualizations widened the scope to include all types 
of cognitive impairment, and thus relating MCI to all types of dementia (Werner & 
Korczyn, 2008).  Outside of memory, MCI can affect an older adult’s executive 
functioning, attention, use of language, and visuospatial skills (Norlund et al., 2005; 
Petersen, 2011).  In widening the scope of cognitive impairment, greater heterogeneity 
was introduced to the concept, adding more variance to the possible speeds and trajectory 
of the continuum and resulting in the subsets of aMCI and naMCI.  Yet it is important to 
note, despite the variability in the subsets, there is a significant lack of evidence for 
treating or screening one subset differently from the other (Gauthier & Touchon, 2005; 
Lin et al., 2012).  In addition, older adults with either subtype of MCI are considered to 
be a vulnerable population, at risk for coercion or mistreatment directly relating to their 
level of impaired cognition, regardless of the nature of their impairment. 
Select chronic illness theoretical frameworks 
 Although there is not a specific theoretical framework for MCI, other chronic 
illness frameworks and theories exist that may be able to contribute to the understanding 
of MCI.  In this section, five frameworks will be described and critiqued for their 
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relevance to MCI and this study.  These frameworks  include: (1) Pearlin and colleagues’ 
theories of coping (Pearlin & Schooler, 1978) and stress (Pearlin et al., 1981), (2) Lazarus 
and Folkman’s (1984) theory of Coping in Stress, (3) Corbin and Strauss’ (1991, 1992) 
Chronic Illness Trajectory Framework, (4) Levanthal, Meyer, and Nerenz’s (1980) 
Common Sense Model of Illness Representations, and (5) Mishel’s (1988, 1990) theory 
of Uncertainty in Illness.    
Theories of coping and stress.   Theories of stress and coping are frequently 
used to guide research with older adults who have various types of chronic illnesses 
(Lazarus & Folkman, 1984; Pearlin et al., 1981; Pearlin & Schooler, 1978).  Two theories 
of coping and stress developed by Pearlin and colleagues and one developed by Lazarus 
and Folkman share some similarities in their limitations related to their applicability of 
older adults with MCI.  As such, these theories will be evaluated together, starting with a 
brief presentation of each theory. 
Pearlin and colleagues: Two theories of coping and stress.   Pearlin and 
colleagues provide two different yet connected theories pertaining to coping (Pearlin & 
Schooler, 1978) and stress (Pearlin et al., 1981).  First, coping is defined as a behavior 
that serves to avoid being psychologically stressed or harmed by a problematic 
experience (Pearlin & Schooler, 1978).  These behaviors are separated into three distinct 
categories: (1) behaviors that change a situation that is causing problems, (2) behaviors 
that control the meaning of the situation after it occurs but before it causes the person to 
experience stress, and (3) behaviors that serve to control stress after the situation has 
occurred (Pearlin & Schooler, 1978).  Coping is influenced by the social and 
psychological resources available to the person, i.e. interpersonal networks with family 
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and friends, and personality characteristics such as self-esteem, self-denigration, and 
mastery (Pearlin & Schooler, 1978).  The distinction between coping and psychological 
resources acknowledges that coping is an intentional action that is affected by 
predisposed or learned personality traits rather than being an unintentional personality 
trait.   
The efficacy of coping is determined by how well the person is able to avoid 
stress (Pearlin & Schooler, 1978).  Pearlin and Schooler (1978) suggest that using a 
variety and large number of coping responses may be the most effective way to avoid 
stress.  This leads into Pearlin and colleagues’ (1981) next theory on the stress process.  
Stress is defined as the multifaceted intentional and/or unintentional responses of a 
person to a stimulus perceived as noxious (Pearlin et al, 1981).  Sources of stress are life 
events, life strains, and self-concepts (Pearlin et al., 1981).  Coping and social supports 
are then seen as mediating resources which can happen at any point during the process to 
decrease stress (Pearlin et al., 1981).  Stress can permeate the entire person resulting in 
outcomes that are biochemical, physiological, or emotional manifestations (i.e. increased 
blood pressure and depression).  A simplified version of the stress version might look like 
Figure 5: 
 
Figure 5.  Potential model of the Stress Process adapted from Pearlin et al. (1981). 
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However, Pearlin and colleagues (1981) note from evaluating the connections 
between sources of stress and increases or decreases in depression as a manifestation of 
stress (or lack thereof), that the model is not simplistic as sources of stress may combine 
to influence one another (Figure 6): 
 
 
 
 
 
 
 
 
 
 
 
In addition, Pearlin and Schooler (1978) noted that coping is influenced by social 
resources (i.e. social supports in the stress model).  So finally, a more accurate 
representation of Pearlin et al.’s theories of coping and stress might be illustrated by 
Figure 7. 
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Figure 6.  Path model of sources of stress (Pearlin et al., 1981). 
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Figure 7.  Revised model of stress and coping adapted from Pearlin et al. (1978, 1981). 
 Previous uses and populations.   The general theories of coping and stress from 
Pearlin and colleagues (1978, 1981) have not been directly applied to research with older 
adults with MCI.  However, the theories have been applied to other chronic illnesses such 
as cancer, (Dagan et al., 2011), diabetes mellitus (Bailey, 1996), depression (Penninx et 
al., 1998), and HIV (Linn, Anema, Hodess, Sharpe, & Cain, 1996).   
Relation to MCI.   MCI could be seen as a condition which either serves as a life 
event (receiving the diagnosis of MCI), life strain (adapting to cognitive impairments 
from MCI), or something that affects a person’s self-concept, thus resulting in coping and 
stress.  However, Pearlin and colleagues’ theories assume that the life events or strains 
are perceived as noxious in order to precipitate coping and stress.  While it can be 
assumed that older adults might perceive MCI as noxious, other research has suggested 
that it can alternatively be perceived in a more positive manner for being a lack of 
dementia (Lingler et al., 2006).   
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Lazarus and Folkman: Coping in stress.   Coping is defined within the theory of 
Coping in Stress as the intentional cognitive and/or behavioral efforts to manage internal 
or external demands appraised as exceeding the resources of or taxing the person 
(Lazarus, 2000; Lazarus & Folkman, 1984).  This view of coping obviously differs from 
aforementioned view provided by Pearlin and Schooler (1978), where coping is perceived 
as a method of avoidance rather than management of stress.  Although it is not specified 
if stress is negative, positive, or neutral.  With the term “management,” it is implied that 
stress is not uniquely positive, negative, or neutral.  Always effective and always 
ineffective coping strategies do not exist (Lazarus, 2000).  In response to a stressor, 
whether a coping strategy is effective or not depends on the person and the environment.  
Figure 8 demonstrates these relationships: 
 
 
 
Figure 8.  Revised model of coping and stress (Lazarus, 1999). 
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In the model, coping results in one or more of the following 15 categorical 
emotional responses: guilt, shame, jealousy, hope, fright, relief, pride, happiness, sadness, 
gratitude, compassion, anger, anxiety, envy, and love (Lazarus, 1999).  In Lazarus’ 
(1999) revised model, appraisal directs how a person copes with stress, hence impacting 
the outcome of emotional response(s).  It also further supports the notion from Pearlin 
and Schooler (1978) that coping is an intentional action as it requires the person to take 
action in appraising the stressor.   
 Previous uses and populations.  The framework provided by Lazarus and 
Folkman (1984) has been used to guide a multitude of studies related to coping with other 
chronic illnesses, including but not limited to: cancer (Felton & Revenson, 1984), 
depression (Penninx et al., 1998), diabetes mellitus (Felton & Revenson, 1984), 
hypertension (Felton & Revenson, 1984), psoriasis (Wahl, Hanestad, Wiklund, & Moum, 
1999), and rheumatoid arthritis (Felton & Revenson, 1984; Walker, Jackson, & 
Littlejohn, 2004).  However, the theory of Coping in Stress has not been used as the 
framework in research involving older adults with MCI.   
 Relation to MCI.   In the theory of Coping in Stress, MCI could be seen as a 
source that affects the antecedents of coping, such as by role shifting which may alter the 
person’s beliefs of self and the world (Blieszner et al., 2007).  In addition, unlike the 
theories from Pearlin and colleagues, the framework provided by Lazarus and Folkman 
does not assume that the event which triggers coping is noxious.  In this way, coping can 
also result from something that could be positive or neutral in nature rather than only 
negative.  
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Limitations of all three theories for this study.   While somewhat different, all 
three of the theories are helpful in explaining the relationships between coping and stress.  
It is obvious with each framework that MCI may be seen as something that precipitates 
coping and stress.  Specific to the theories by Pearlin and colleagues, coping is 
determined to be effective in the context of avoiding stress; whereas it might be more 
appropriate to consider the efficacy of coping, as it is in Lazarus and Folkman’s 
framework, in its ability to manage rather than avoid stress (as not all stress is avoidable).  
Pearlin and colleagues’ theories also do not specify stress as either a positive or negative; 
coping centers around the avoidance of stress, thereby suggesting that stress is only 
perceived as something negative.  Consequently the theories do not account for the 
potential implications of positive stress (eustress) that could be experienced from 
receiving a diagnosis of MCI (as opposed to dementia) and may be inappropriate for use 
in evaluating stress and coping related to MCI. 
A major limitation is that none of the three coping theories account for the effect 
of cognitive impairment on appraisal leading to coping and stress, and these theories do 
not consider the relationships between uncertainty, coping and stress.  As previously 
mentioned, older adults with MCI may lack awareness of their cognitive impairment(s) 
(Tremont & Alosco, 2011), which could relate to a lack of awareness needed for 
appraisal of stress in coping.  This is not to say that those with MCI would be incapable 
of appraisal, just that the appraisal may be impacted by MCI in a way that is unique from 
other chronic illnesses.  In addition, although uncertainty could also be interpreted as a 
life event (Pearlin and colleagues) or related to personal resources (Lazarus and 
Folkman), there is the question of the neutral, positive, or negative nature of uncertainty 
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(and this relationship to stress and coping) which is not explicitly accounted for in the 
stress and coping theories.    
 Chronic Illness Trajectory Framework.   Corbin and Strauss’ chronic illness 
trajectory framework provides an understanding of problems unique to the course of 
chronic illnesses, and serves as a guide for the nursing management of chronic illnesses 
(Corbin, 1998; Corbin & Strauss, 1991, 1992; Glaser & Strauss, 1968).  Corbin (1998) 
defines illness trajectory as the condition course and actions taken by participants (i.e. 
patient, nurses, caregivers) to direct and control that course.  It is broken down into nine 
distinct phases which represent the different changes that occur within the course of 
chronic illnesses, demonstrated within Figure 9, starting with pre-trajectory: 
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Figure 9.  Trajectory phases of chronic illness adapted from Corbin (1998). 
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It is important to note that although arrows are drawn to connect the phases in 
Figure 9, a unidirectional path is not specified but implied through the numerical order 
listed (Corbin, 1998; Corbin & Strauss, 1991, 1992).  The shaping of an illness trajectory 
is complex, requiring multiple resources and/or people. The trajectory phases (Figure 9) 
are shaped within the context of projected outcomes, biographical factors, and larger 
societal issues by management strategies (not in the Figure) that are not prescribed but 
instead evolve over time to meet the needs of each phase (Corbin, 1998).  The goals of 
management strategies for each phase, and goal of definitions of the phases are explained 
by Table 1 from Corbin (1998): 
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Table 1. Trajectory phase definitions and management strategy goals from Corbin (1998). 
Stage Goal of definition Goal of 
Management 
Pre-
trajectory 
Genetic factors or lifestyle behaviors that place an individual or 
community at risk for the development of a chronic condition. 
Prevent onset of 
chronic illness. 
Trajectory 
onset 
Appearance of noticeable symptoms, includes period of diagnostic 
workup and announcement of biographical limbo as person begins 
to discover and cope with implications of diagnosis. 
Form appropriate 
trajectory 
projection and 
scheme. 
Stable Illness course and symptoms are under control. Biography and 
everyday life activities are being managed within limitations of 
illness. Illness management centers in the home. 
Maintain stability 
of illness, 
biography, and 
everyday 
activities. 
Unstable Period of inability to keep symptoms under control or reactivation 
of illness. Biographical disruption and difficulty in carrying out 
everyday life activities. Adjustments being made in regimen with 
care usually taking place at home. 
Return to 
stability. 
Acute Severe and unrelieved symptoms or the development of illness 
complications necessitating hospitalization or bed rest to bring 
illness course under control. Biography and everyday life activities 
temporarily placed on hold or drastically cut back. 
Bring illness 
under control and 
resume normal 
biography and 
everyday 
activities. 
Crisis Critical or life-threatening situation requiring emergency treatment 
or care. Biography and everyday life activities suspended until 
crisis passes. 
Remove life 
threat. 
Comeback A gradual return to an acceptable way of life within limits imposed 
by disability or illness. Involves physical healing, limitations 
stretching through rehabilitative procedures, psychosocial coming 
to terms, and biographical reengagement with adjustments in 
everyday activities. 
Set in motion and 
keep going the 
trajectory 
projection and 
scheme. 
Downward Illness course characterized by rapid or gradual physical decline 
accompanied by increasing disability or difficulty in controlling 
symptoms. Requires biographical adjustment and alterations in 
everyday life activity with each major downward step. 
To adapt to 
increasing 
disability with 
each major 
downward turn. 
Dying Final days or weeks before death. Characterized by gradual or rapid 
shutting down of body processes, biographical disengagement and 
closure, and relinquishment of everyday life interests and activities. 
To bring closure, 
let go, and die 
peacefully.  
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The goals of management present a problem for the assumed unidirectional path 
of the model as they suggest that a person might be able to revert from certain stages (not 
necessarily all stages) back into the stage that came directly before it or even further 
back.  For example, the goal of management for the unstable phase is to return to stability 
(the phase that came before it) but the goal of management for dying is not to return to 
the downward phase.  Yet, in another example, the goal of management for the crisis 
phase is to remove the life threat (causing the crisis phase), which suggests, if successful, 
that person could possibly return directly to the stable or unstable phase, rather than 
simply returning to the acute phase below it (such that if the life threat is removed, 
symptoms might be resolved by its resolution, negating the acute phase).  
Despite the question of a single or multidirectional path, it is a useful theory that 
clearly identifies important areas for nursing intervention within each phase of a chronic 
illness.  Authors note that while the framework is general to all chronic illnesses, nurses 
need to be flexible and able to individualize how they approach the framework for each 
person (Corbin, 1998).  This need for flexibility suggests that while a general path 
connecting the chronic illness phases could be assumed, the questionable theory path is 
not problematic as the path may be different dependent on the person, their condition(s), 
and other outside influences (i.e. culture).  
 Previous uses and populations.   While the Chronic Illness Trajectory 
Framework has not been used in research involving older adults with MCI, it has been 
used in relation to describing the transitions of older adults coping with other chronic 
illnesses (Corbin, 1998). These conditions include, but are not limited to: AIDS/HIV 
36 
 
(Nokes, 1998), multiple sclerosis (Gulick, 1998), rheumatoid arthritis (Shaul, 2012), and 
stroke rehabilitation (Burton, 2001).   
 Relation to MCI.   While MCI is a chronic illness whose trajectory may be 
somewhat similar to that assumed in the Chronic Illness Trajectory Framework, it is 
distinct from other chronic illnesses as it does not result in death, which completely 
negates the last phase of the framework.  Additionally, MCI is also a condition that does 
not necessarily have a downward trend (necessary for phase progression in the Chronic 
Illness Trajectory Framework).  As previously stated in chapter one, not all older adults 
with MCI have worsening cognitive impairment (or progress to dementia), some may 
have improved cognition or remain stagnant.   
 Limitations of theory for this study.   The Chronic Illness Trajectory Framework 
has several aforementioned issues related to assumptions of MCI versus other chronic 
illnesses.  Additionally, the framework does not account for all variables being assessed 
by this study.  Specifically, the model does not account for the relationships of MCI to 
uncertainty, coping, and psychological distress.  It could be argued that uncertainty, 
coping and psychological distress are projected outcomes which shape the MCI 
trajectory.  However, even under that assumption, the relationships between uncertainty, 
coping, and psychological distress are not clearly defined.  
 Common Sense Model of Illness Representations.  Levanthal’s Common Sense 
Model dictates that people create mental representations of their illness through using 
information available to them (concrete and/or abstract) to help them make sense of and 
manage their illness (Levanthal et al., 1980).  There are three sources for a person’s 
available information: (1) lay sources, information provided through social contact and 
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cultural knowledge; (2) external sources, parents, significant others, or authoritative 
sources such as doctors; and (3) personal current experience with the illness (Hagger & 
Orbell, 2003).  
 The mental representations can be considered both cognitive and emotional 
representations and are generally composed of five themes: (1) Causes of the illness, (2) 
consequences from the illness, (3) the perceived ability to control/cure the illness, (4) 
identifying with the illness, and (5) the illness timeline (Hagger & Orbell, 2003).  From 
the representation, the person copes with their representation of the illness, and the 
outcomes related to the illness.  Emotional distress results from the emotional illness 
representation, and can contribute to illness outcomes in the form of psychological 
distress.  These relationships are demonstrated by the graphical representation of the 
theory in Figure 10. 
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Figure 10.  Graphical representation of Leventhal et al. (1980) Common Sense Model of 
Illness Representations (Hagger & Orbell, 2003). 
Previous uses and populations.  The Common Sense Model has been applied in 
three studies of older adults with MCI (Lin & Heidrich, 2012; Lin, Gleason, & Heidrich, 
2012; Lingler et al., 2006).  As demonstrated by a meta-analytic review of the Common 
Sense Model (Hagger & Orbell, 2003), the framework has also been applied to describe 
coping and psychological distress in multiple other studies including older adults with 
chronic conditions, including but not limited to: Alzheimer’s dementia, chronic fatigue 
syndrome, diabetes, HIV, irritable bowel syndrome, osteoarthritis, psoriasis, and 
rheumatoid arthritis. 
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 Relation to MCI.   In a grounded theory study (Lingler et al., 2006), authors 
compared their results describing the process of making sense of a diagnosis of MCI to 
the Common Sense Model.  Authors concluded that there findings were similar to the 
Common Sense Model in that assigning meaning to the diagnosis of MCI stems from the 
older adult’s cognitive and emotional illness representations of MCI.  However, the study 
did not evaluate the outcomes of created illness representations (coping strategies, illness 
outcomes, and psychological distress).   
Lin and colleagues (2012) set out to describe the illness representations of MCI 
and evaluate the illness representations for their relationships to demographic variables 
and health history.  Lin and Heidrich (2012) then took the application of the Common 
Sense Model one step further, focusing on evaluating illness representations and their 
impact on participant coping with MCI.  Both studies included older adults with any 
subtype of MCI; however, neither study reported the distribution of subjects with aMCI 
versus naMCI, making it difficult to decipher if the results truly reflect both subtypes.  
Findings from the studies demonstrated support for the Common Sense Model, yet 
authors note that the directions of associations between illness representations differs 
from some previous studies with other chronic illnesses.  For example, emotional 
representations of MCI varied greatly between individuals with many subjects having 
few to moderate MCI symptoms and positive beliefs about MCI, unlike emotional 
representations of other illnesses. This finding demonstrates a limitation of the Common 
Sense Model for MCI in that older adults’ illness representations of MCI are unique from 
illness representations of other chronic illnesses. 
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 Limitations of theory for this study.   Aside from differences in the relationships 
of the Common Sense Model for older adults with MCI compared to those with other 
chronic illnesses, the main limitation of the Common Sense Model is the exclusion of 
uncertainty.  If one is uncertain about the themes that comprise the illness representation, 
how does that affect coping and emotional distress?  Uncertainty could be perceived as 
contributive to the model, affecting both the cognitive and emotional illness 
representations.  Accounting for uncertainty in the common sense model may help with 
understanding the uniqueness of coping and illness representations with MCI.   
Uncertainty in Illness.   Mishel’s (1988, 1990) theory of Uncertainty in Illness is 
perhaps the most well-known and widely used mid-range nursing theory related to the 
experience of uncertainty (Barron, 2000; Mast, 1995; Neville, 2003).  The theory is not 
focused on one age-group or population but can be split into uncertainty as it applies in 
acute illness (Mishel, 1988, 1990, 1997) versus chronic illness (Mishel, 1990, 1999) 
situations.  The overall purpose of the theory is to help explain how persons with acute or 
chronic illnesses cognitively process and construct meaning of their illness-related stimuli 
(Mishel, 1990).  A graphic model of this theory is presented by Figure 11. 
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Figure 11.  Mishel’s model of perceived uncertainty in illness (Barron, 2000; Mishel, 
1988, 1990; Neville, 2003). 
 In the theory, uncertainty is defined as the emotional state that occurs when a 
person is unable to assign definite value to events or objects and/or is unable to predict an 
outcome (Mishel, 1983).  Within chronic illness, it is expected that uncertainty is not 
static but instead subject to change over time (Mishel, 1990).  Additionally, with chronic 
illness, uncertainty is seen as something that happens slowly over time, rather than 
starting with one acute event (Mishel, 1999).  Causes of uncertainty in chronic illness are 
not fully explicated by the model (Figure 5), but are multifactorial and include: the nature 
of illness (severity, erratic symptoms, and ambiguous symptoms), inability to predict the 
future, concept of self, insufficient information, social support, health providers, and 
personality disposition (Mishel, 1999).   
Similar to appraisal for coping in the framework by Lazarus and Folkman (1984), 
uncertainty is perceived as a neutral state until it is appraised by one of two processes to 
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determine its value (demonstrated in Figure 5): inference and illusion (Mishel, 1990).  It 
could be argued that uncertainty is not neutral but always negative and should be avoided 
or minimized whenever possible (Sheer & Cline, 1995). Yet, the view of uncertainty as 
neutral until appraised has been supported by other authors (Hilton, 1994), and 
highlighted in a concept analysis of uncertainty in illness by McCormick (2002).  
Inference and illusion can be affected by the person, family, friends, and health 
care professionals, and with chronic illness are also subject to change over time (Mishel, 
1990; Padilla, Mishel, & Grant, 1992).  Inference is the evaluation of uncertainty as either 
a positive (opportunity) or negative (danger) state (Mishel, 1990).  Illusion is the 
construction of beliefs in the event of a situation with a negative trajectory, which allows 
for uncertainty to be perceived as a potentially positive outcome (Mishel, 1990).  If 
uncertainty is appraised as a danger, coping strategies are employed to reduce the 
presence of uncertainty.  Similarly, if uncertainty is appraised as an opportunity, coping 
strategies are employed to maintain rather than reduce uncertainty (Mishel, 1990).  In 
either event, if the coping strategies are successful, and uncertainty is reduced or 
maintained as desired, adaptation is said to occur (Mishel, 1990).   
Previous uses and populations.   The theory of Uncertainty in Illness has not 
been used in research involving older adults with MCI.  However, the theory has been 
used with older adults that have other chronic conditions to guide the evaluation of levels 
of uncertainty, determine the effects of uncertainty, and guide development and 
evaluation of interventions to decrease uncertainty.  These conditions include but are not 
limited to: atrial fibrillation (Kang, 2006; Kang, 2011), chronic hepatitis C (Bailey et al., 
2010), fibromyalgia (Anema, Johnson, Zeller, Fogg, & Zetterlund, 2009; Reich et al.; 
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2006), human immunodeficiency virus (Brashers et al., 2003), Parkinson’s disease 
(Sanders-Dewey et al., 2001), diabetes mellitus (Landis, 1996), rheumatoid arthritis 
(Landis, 1996), and multiple types of cancer (Clayton, Mishel, & Belyea, 2006; Kazer, 
Bailey, Sanda, Colbery, & Kelly, 2011; Lien, Lin, Kuo, & Chen, 2009; Padilla et al., 
1992; Sammarco & Konecny, 2010; Wallace, 2005).  It is important to note that all of the 
aforementioned conditions may involve the presence of physical pain or other outwardly 
obvious physical symptoms (i.e. shortness of breath, palpitations, etc.), whereas MCI is a 
condition that does not result in physical pain or involve outwardly obvious physical 
symptoms.  In addition, many of the aforementioned conditions involve a downward 
trajectory with no chance of a return to normal functioning or stagnation, as may be seen 
with MCI.  
Relation to MCI.   The progression of uncertainty in chronic illness proposed by 
Mishel (1990, 1999) is similar to the theorized progression of MCI, where symptoms of 
cognitive impairment do not necessarily start with an acute event but rather are slowly 
progressive over time.  As previously noted in chapter one, MCI is also a chronic 
condition, like many other chronic illnesses, where symptoms, disease trajectory, and 
treatment options can be extremely ambiguous and potentially resulting in uncertainty 
alike the causes of uncertainty noted by Mishel (1999).  Additionally, in her 
reconceptualization of the theory of Uncertainty in Illness, Mishel notes that “when the 
alternative is negative certainty, uncertainty becomes a preferable state” (Mishel, 1990, 
258).  This anecdote is apparent in a qualitative study of the experiences of older adults 
with MCI where subjects noted being happy with the diagnosis of MCI as it is not the 
diagnosis of dementia (Lingler et al., 2006).  In this manner, while being diagnosed with 
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MCI created uncertainty, older adults were able to use illusion to see this uncertainty as 
an opportunity rather than danger because it was perceived as certainty the diagnosis was 
not dementia.  
 Limitations of theory for this study.   There are two main limitations of the 
Uncertainty in Illness theory for this study: (1) fit of the theory with study variables, and 
(2) theory assumptions.  The Uncertainty in Illness theory would be a good fit for 
directing this study if the presence of uncertainty and its relationship to coping and 
psychological distress in older adults with MCI rather than the relationship of 
uncertainty, coping, and psychological distress as interrelated consequences of MCI was 
the only concern.  While the theory of Uncertainty in Illness is useful to explain how an 
older adult might experience or respond to uncertainty, it does not account for the 
antecedents or consequences that may be unique to having a diagnosis of MCI.  As noted 
by Figure 5, cognitive capacities are accounted for and might impact the older adult’s 
stimulus frame, but do not serve as the stimulus frame.  What does this mean for the older 
adult whose symptom pattern in the stimulus frame is from their cognitive capacities 
rather than affected by it?  In other words, what is uncertainty for the older adult whose 
source of uncertainty might be their cognitive capacity rather than a more traditional 
chronic illness symptom such as pain?  
 In addition, Mishel’s model assumes some level of awareness to be able to 
appraise uncertainty.  Older adults with MCI may lack awareness of their cognitive 
impairment(s) (Tremont & Alosco, 2011), thus potentially lacking the awareness needed 
to be able to appraise uncertainty.  Also, if there is no awareness of the stimulus frame, 
i.e. a lack of awareness resulting in an inability to recognize the symptom pattern, event 
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familiarity or congruence, it is entirely possible that there is no stimulus to produce 
uncertainty other than the stimulus provided by the introduction of being diagnosed with 
MCI.  This later becomes a problem for other variables in this study as the model only 
accounts for coping and potentially psychological distress (from a lack of adaptation) 
resulting from the appraisal of uncertainty.   
Grounded Theory and MCI 
There have been a few recent attempts to establish theories pertaining to MCI 
which purported using grounded theory methodology from Corbin and Strauss (1990, 
1998), and/or Glaser and Strauss (1967).  These three qualitative studies (Banningh et al., 
2008; Beard & Neary. 2012; Lingler et al., 2006) provide insight into how older adults 
experience, make sense of, or cope with their MCI diagnosis.  Results of the studies 
highlighted coping with MCI as a reaction to both the attributes of MCI (cognitive 
impairment) and consequences from MCI (i.e. coping with negative emotions) (Banningh 
et al., 2008; Beard & Neary, 2012).  Older adults with MCI also demonstrate a wide 
range of emotions (positive, negative, and neutral) in response to their diagnosis and 
symptoms (Banningh et al., 2008; Lingler et al., 2006); however, they may not identify 
with or fully understand their diagnosis (Beard & Neary, 2012; Lingler et al., 2006).  
Finally, rather than a clear conceptual framework for MCI, these three studies only 
provide themes to describe how older adults make sense of their diagnosis and cope with 
MCI.  The only study that relates their findings to a framework (the Common Sense 
Model) was Lingler and colleagues (2006).  In addition, all of the studies had small 
sample sizes (< 20 subjects), and two of the studies excluded older adults with naMCI 
(Banningh et al., 2008; Beard & Neary, 2012).  Although the studies do not provide clear 
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conceptual frameworks and have sample limitations, they provide rich description of 
concepts central to the MCI experience and were influential on the development of a 
conceptual framework for MCI. 
Sjostedt’s conceptualization of MCI 
 The lack of a specific theoretical framework related to MCI and the limitations of 
existing alternative frameworks related to chronic illnesses necessitate a new 
conceptualization of MCI to provide support for research and the development of 
interventions specific for older adults with MCI.  Sjostedt’s new conceptualization of 
MCI encompasses both subtypes. In this model, MCI is defined as an unstable limbo 
weighted by heterogeneity between older adults’ normal and abnormal continuums 
(normal aging versus dementia) rather than being solely linked to cognitive functioning.  
Older adults with MCI teeter between these continuums, and can eventually progress to 
dementia or revert back to normal functioning.  Figure 12 demonstrates the complexity of 
this conceptualization with its accompanying antecedents and consequences. In Figure 
12, the antecedents for MCI are highlighted in green, the attributes highlighted in blue, 
and the consequences highlighted in purple. 
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Figure 12.  The Sjostedt framework for MCI. 
It is important to understand that the model is pliable, subject to change over time 
and condition progression.  As the unstable limbo implies, an older adult does not simply 
get MCI at one point and then it goes away or always stays at that point.  Additionally, 
some antecedents, i.e. other chronic conditions, are subject to change over time which 
may result in changes related to MCI.  The theoretical framework is presented in detail 
below, starting with the antecedents. 
 Antecedents.   The antecedents for MCI are numerous—there is insufficient 
evidence to suggest which antecedents might have more of an influence than the others 
on the development or progression of MCI.  Many of the reviewed studies assessed the 
correlation of antecedents to MCI rather than predictive values of antecedents for MCI.  
Hence the antecedents all may contribute in some way to MCI, but it is unclear how 
much of the variance in MCI can be explained by each antecedent.  MCI’s antecedents 
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can be categorized into those that are modifiable, potentially-modifiable, or non-
modifiable.   
Modifiable.   Modifiable antecedents were identified as lifestyle factors, dietary 
deficiencies, medications, and stress.  With lifestyle factors and dietary deficiencies, 
increased levels of physical exercise and some dietary modifications or supplements to 
correct deficiencies have been shown to decrease symptoms of cognitive impairment 
associated with MCI (Lake, 2006; Rosenberg et al., 2006).  Physical exercise in mid-life 
significantly reduces the risk of MCI later in life (Geda et al., 2010).  Similarly, related to 
exercise, obesity has been correlated with increased cognitive impairment (Farr et al., 
2008).  Finally, dietary modifications such as strict adherence to the Mediterranean Diet 
and supplements such as vitamins D and E to correct dietary deficiencies have been 
correlated with lower incidences of MCI (Lake, 2006; Plassman, Williams, Burke, 
Holsinger, & Benjamin, 2010; Rosenberg et al., 2006; Scarmeas et al., 2009).   
Previous studies have demonstrated a relationship between MCI and “vascular 
risk factors” such as midlife elevated serum cholesterol and blood pressure (Kivipelto et 
al., 2001), but the relationship is not consistent (Plassman et al., 2010).  Smoking is one 
factor contributing to vascular risk that has been demonstrated to be predictive of 
cognitive impairment within sizable populations, and place older adults at increased risk 
for developing MCI (Cervilla, Prince, & Mann, 2000; Durazzo, Meyerhoff, & Nixon, 
2010; Plassman et al., 2010).  Another lifestyle factor, alcohol consumption, has also 
been demonstrated to potentially contribute to the progression or lack of progression with 
MCI (Anttila et al., 2004; Solfrizzi et al., 2007); but this result has been inconsistent 
(Plassman et al., 2010).   
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Similar to lifestyle factors and dietary deficiencies, regular medications and illicit 
or recreational drugs are also potential risk for MCI (Hurria et al., 2007; Rogers, Wiese, 
Rabheru, 2008; Shilling, Jenkins, & Trapala , 2006).  NSAIDs and gonadal steroids have 
been shown to possibly decrease risk of developing MCI, whereas other medications such 
as statins and antihypertensives have no association or no consistent association with 
MCI (Plassman et al., 2010).  In addition, cognitive impairment related to medications 
can be temporary, in which case an older adult may be inappropriately diagnosed with 
MCI or it may be inappropriately determined that the older adult has progressed 
completely from MCI to dementia.  For instance, chemotherapy has been shown to 
increase cognitive impairment, known as “chemo brain” or “chemo fog,” but is 
oftentimes temporary (Hurria et al., 2007; Shilling et al., 2006).  
Finally, stress is also a modifiable antecedent for MCI as it can be manifested as 
impaired attention which may contribute to the symptoms of MCI (Chertkow, 2002; 
Norlund et al., 2005).  Stress reduction has been demonstrated to contribute to decreased 
MCI symptoms (Troyer, Murphy, Anderson, Moscovitch, & Craik; 2008).  Stress may be 
present in many different forms, stemming from any aspect of an older adult’s life (i.e. 
accepting a new job, moving, or death of a loved one).  However, stress can also result 
from the fear of cognitive impairment, likely associated with the stigmas surrounding the 
diagnosis of dementia (Corner & Bond, 2004).   
 Potentially-modifiable.   Potentially-modifiable antecedents were identified as 
other chronic conditions, neuropsychiatric disorders or changes, and a lack of awareness 
of deficits. Neuropsychiatric disorders such as depression can potentially be reversible 
causes of MCI, where once treated, the older adult could return to normal cognition 
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(Rosenberg et al., 2006).  Yet, depression in particular, has been linked to increased risk 
for MCI development (Plassman et al., 2010).  There are also other chronic conditions 
which, while not necessarily reversible, may be controllable such as hypertension, 
diabetes, sleep apnea, schizophrenia, and other vascular diseases (DeCarli, 2003; Frisoni 
et al., 2000; Gauthier & Touchon, 2005; Keefe et al., 2005).  Finally, a lack of awareness 
does not cause MCI, but it is seen as a precursor symptom to it, influencing how quickly 
an older adult seeks treatment for MCI. Awareness could be the realization that the older 
adult has become lost in a familiar place, personality changes, change in senses (such as 
olfactory changes) or has decreases in usual activities (Blieszner et al., 2007; Chung & 
Man, 2009; Devanand et al., 2000; Roberts et al., 2009).  Increasing awareness of 
changes in cognition could lead to earlier identification of MCI and impact consequences 
related to MCI. 
 Non-modifiable.   Finally, the non-modifiable antecedents could be categorized 
into sociodemographic factors and neuropathologic changes. Sociodemographic factors 
include but are not limited to educational level, age, race/ethnicity, and gender 
(Chertkow, 2002; Plassman et al., 2010). Neuropathologic changes could potentially be 
the result of Alzheimer’s dementia or other insults such as strokes and as such are non-
modifiable (DeCarli, 2003; Petersen et al., 2006; Visser, 2006). 
Attributes.   The first attribute of MCI is an “unstable limbo.” The majority of 
articles refer to MCI in relation to dementia as a “transitional” state between normal 
aging and abnormal aging (dementia), an incipient stage to dementia or a pre-dementia 
stage. Many sources indicate that older adults with MCI are destined to have dementia 
(Anstey et al., 2008; Banningh et al., 2008; Blieszner et al., 2007; Carpenter et al., 2008; 
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Chertkow, 2002; Costa et al., 2010; DeCarli, 2003; Devanand et al., 2000; Diniz et al., 
2009; Ellison, 2008; Ellison, Harper, Berlow, & Zeranski, 2008; Fisk & Rockwood, 
2005; Frisoni et al., 2000; Gauthier & Touchon, 2005; Lee et al., 2009; Lingler et al., 
2006; Matthews et al., 2007; Mattsson et al., 2009; Meyer, Xu, Thornby, Chowdhury, & 
Quach, 2002; Narasimhalu, et al., 2009; Norlund et al., 2005; Paulsen & Duff, 2009; 
Petersen, 2003; Petersen et al., 2006; Portet et al., 2006; Ready, Ott, & Grace, 2004; 
Roach, 2005; Roberts et al., 2009; Rosenberg et al., 2006; Solfrizzi et al., 2007; Tuokko 
& Hultsch, 2006; Visser, 2006; Visser, Scheltens, & Verhey, 2005; Werner & Korczyn, 
2008). Yet, it is inaccurate to strictly refer to MCI as a “transitional” or other similar 
state, as it implies only one possible outcome.  As previously stated, MCI is not always 
progressive; in many cases it can be stagnant or even revert back to “normal” cognition. 
In this way, MCI is better seen as an unstable limbo which is capable but not necessarily 
probable of tipping towards a normal or abnormal continuum but also possible to be 
stagnating. Through viewing MCI as an unstable limbo rather than something definitively 
progressive it is possible to reach new interventions; shifting the focus from the 
prevention of dementia back to treatment of MCI.  
 The second attribute is a disconnection from normality resulting from physical, 
mental, and emotional changes. This could be with regard to memory (Banningh et al., 
2008; Chertkow, 2002; Chung & Man, 2009; Diniz et al., 2009; Ellison et al., 2008; Fisk 
& Rockwood, 2005; Gauthier & Touchon, 2005; Hurria et al., 2007; Matthews et al., 
2007; Narasimhalu, et al., 2009; Petersen, 2003; Petersen et al., 2006; Portet et al., 2006; 
Rosenberg et al., 2006; Roberts et al., 2009; Shilling et al., 2006; Tuokko & Hultsch, 
2006; Visser, 2006; Werheid et al., 2010), other functions of cognitive ability such as 
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intelligence (Byrne, Smith, and Backman, 1987; DeCarli, 2003), or expectations for how 
the older adult “should” be, such as how one should age (Banningh et al., 2008; Blieszner 
et al., 2007).  Acquiring subjects in memory clinics has led to increased emphasis on the 
memory disconnection as diagnostic criteria for MCI (Costa et al., 2010; Garand et al., 
2005; Devanand et al., 2000; Diniz et al., 2009; Ellison et al., 2008; Gauthier & Touchon, 
2005; Mattsson et al., 2009; Visser et al., 2005; Werheid et al., 2010).  Opening the 
conceptualization to include other types of disconnect from normality highlights the need 
for MCI identification within primary care—outside of memory clinics.  However, for the 
purposes of this study with the need to obtain a large sample of older adults diagnosed 
with MCI, the focus of MCI will be on the mental disconnect from normality, which will 
be assessed through subject performance on cognitive testing. 
 The third attribute is an absence of severe functional impairment and dementia 
which is determined by clinical judgment (Banningh et al., 2008; Chertkow, 2002; Diniz 
et al., 2009; Ellison et al., 2008; Gauthier & Touchon, 2005; Lee et al., 2009; Matthews 
et al., 2007; Mattsson et al., 2009; Meyer et al., 2002; Petersen, 2003; Petersen et al., 
2006; Rosenberg et al., 2006; Tuokko & Hultsch, 2006; Visser, 2006). The absence of 
severe functional impairment and dementia is evident through the presence of intact 
“normal” activities of daily living.  Although intact, some studies have demonstrated 
minor impairments in “normal” activity areas of older adults with MCI such as 
geographical orientation, speed, and multitasking (Banningh et al., 2008; Costa et al., 
2010; Visser, 2006); but, the impairments were not “severe.”  
The last attribute is heterogeneity, which results in the varied trajectory of the 
older adult with MCI to worsening cognition, stagnation, or improving cognition. Among 
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older adults, MCI is recognized as having several different forms with a wide variety of 
associated symptoms such as the differences mentioned between aMCI and naMCI, but 
also where one older adult may have multiple impaired cognitive domains whereas others 
may have only one (Anstey et al., 2008; Ellison et al., 2008; Fisk & Rockwood, 2005; 
Gauthier & Touchon, 2005; Lingler et al., 2006; Matthews et al., 2007; Norlund et al., 
2005; Petersen, 2003; Petersen et al., 2006; Portet et al., 2006; Roach, 2005; Roberts et 
al., 2009; Rosenberg et al., 2006; Tuokko & Hultsch, 2006).  Contributing to 
heterogeneity is the relationship of MCI to dementia, where some older adults with MCI 
progress to dementia (worsening cognition), others stay always with MCI (stagnation), 
and others still improve back towards normal cognitive functioning (improving 
cognition) (Anstey et al., 2005; Banningh et al., 2008; Blieszner et al., 2007; Chertkow, 
2002; Costa et al., 2010; DeCarli, 2003; Diniz et al., 2009; Fisk & Rockwood, 2005; 
Frisoni et al., 2000; Garand, Dew, Eazor, DeKosky, & Reynolds, 2005; Gauthier et al., 
2006; Gauthier & Touchon, 2005; Lingler et al., 2006; Narasimhalu, et al., 2009; 
Petersen et al., 2006; Portet et al., 2006; Roach, 2005; Roberts et al., 2009; Tuokko & 
Hultsch, 2006; Visser et al., 2005; Werner & Korczyn, 2008; Zaudig, 1992).  There is the 
potential that the variability in MCI symptoms created by heterogeneity can also lead to a 
lack of information or misdiagnosis, such as an erroneous diagnosis of dementia, in turn 
causing increased stress for the patient and family (Banningh et al., 2008).   
Some would argue that heterogeneity results in a need to treat each type of MCI 
on a case by case basis as opposed to treating all types the same (Gauthier & Touchon, 
2005).  For example, it is possible that older adults with aMCI versus those with naMCI 
may experience the consequences of MCI in different ways, given that those with aMCI 
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are more likely to lack an awareness of their deficits (Tremont & Alosco, 2011).  
However, there is opposition to this idea who believe that if treatment works for one type 
of MCI it might work for all types (Roach, 2005).  Current recommendations for nursing 
care are consistent with this later view and do not vary based on MCI subtype (Lin et al., 
2012). 
Consequences.   In the Sjostedt model, the main consequence of MCI is 
uncertainty, which leads to the other consequences of coping and psychological distress.  
Yet, it is important to note that most of the evidence to support the consequences of MCI 
comes from qualitative or limited descriptive studies.  Therefore at this time, it cannot 
fully be determined how the trajectory of MCI (worsening cognition, stagnation, or 
improving cognition) impacts the consequences of MCI.  In the model it is assumed that 
the trajectory does not cause the consequences of MCI to differ (aside from the 
progression towards a normal or abnormal continuum); that all older adults with MCI 
will experience (in some way) the consequences of uncertainty, coping, and 
psychological distress.  In the future, longitudinal studies will be needed to determine the 
impact of the trajectory on the consequences of MCI.    
Uncertainty.   MCI is often referred to as an uncertain condition within attempts 
to both conceptualize and define it (Portet et al., 2006; Werner & Korczyn, 2008).  The 
attribute of heterogeneity results directly in uncertainty stemming from ambiguity, 
confusion, and variability, impacting all of the consequences of MCI and leading to 
differing opinions on diagnosis and selections of MCI populations (Anstey et al., 2008; 
Banningh et al., 2008; Blieszner et al., 2007; Chertkow, 2002; DeCarli, 2003; Frisoni et 
al., 2000; Gauthier & Touchon, 2005; Lee et al., 2009; Mattsson et al., 2009; Norlund et 
55 
 
al., 2005; Paulsen & Duff, 2009; Tuokko & Hultsch, 2006; Visser, 2006; Werner & 
Korczyn, 2008).  Uncertainty can influence how older adults respond to illnesses, 
treatments, and hospitalizations (Landis, 1996). Yet, uncertainty is not a phenomenon 
unique to MCI.  In general, uncertainty is said to occur when a person is unable to assign 
definite value to events or objects and/or is unable to predict an outcome (Mishel, 1983). 
Within any illness, uncertainty can stem from a lack of clarity regarding symptoms, 
treatment options, disease etiology, and/or disease prognosis (Mishel, 1983; Mishel, 
1988).  
Qualitative studies about the experiences of living with MCI have provided 
further evidence supporting the presence of uncertainty in MCI.  Findings indicated that 
uncertainty can greatly affect an older adult’s ability to define and relate to MCI 
(Banningh et al., 2008; Blieszner et al., 2007; Lingler et al., 2006; Lu et al., 2007).  In 
addition, uncertainty about the nature of MCI was frequently identified, related to 
symptoms of MCI being dismissed as normal ageing or dementia (Banningh et al., 2008; 
Dean & Wilcock, 2010; Lu et al., 2007).   
Nurses, physicians, and other practitioners can directly contribute to the presence 
of uncertainty with MCI through variance in practice and dissemination of information 
about MCI (Derksen, Graff, Visser, Vermooij-Dassen, & Rikkert, 2009).  One study 
found inconsistencies from participant report in the frequency of clinicians informing 
them of their prognosis and likely condition trajectory (Derksen et al., 2009).  Such 
variance with resulting uncertainty can cause unjustified stress or anxiety for older adults 
with MCI. 
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Coping.   It is proposed that coping will result from MCI, similar to the result of 
coping with other chronic illnesses, but that coping may also result from or be shaped by 
uncertainty.  Within Mishel’s model of perceived uncertainty in illness, coping results 
from either the danger or opportunity appraised from uncertainty (Mishel, 1988), 
suggesting that coping might also result from or be shaped by the uncertainty resulting 
from MCI.  Uncertainty could affect a older adult’s ability to define and relate to MCI, 
thus impairing their ability to cope with it (Banningh et al., 2008; Blieszner et al., 2007; 
Lingler et al., 2006; Lu et al., 2007). An example would be avoidance oriented coping 
through attempts to improve memory performance, avoidance of activities to avoid 
making mistakes or masking of deficits (Banningh et al., 2008). Another result could be 
potential role and identity shifting, such as avoidance of independence (Blieszner et al., 
2007). 
Coping has been evaluated quantitatively in two studies involving older adults 
with MCI (Lin & Heidrich, 2012; McIlvane et al., 2008).  Using the Brief COPE, 
findings from both studies indicated that older adults with MCI use significantly more 
emotion-focused coping and problem-focused coping strategies in comparison to 
dysfunctional coping strategies to manage with their MCI.  Emotion-focused coping 
strategies included positive reframing and seeking emotional support; problem focused 
strategies included seeking out information or treatments; and dysfunctional strategies 
included substance use, self-blame or behavioral disengagement (McIlvane et al., 2008).  
Lin and Heidrich (2012) also found positive correlations between months since MCI 
diagnosis and problem-focused coping (r = 0.31, p = 0.034) and dysfunctional coping (r 
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= 0.64, p < 0.001).  However, neither study evaluated the relationship between measured 
cognitive impairment or other demographic variables and coping strategies.  
Psychological distress.   Psychological distress is the final consequence of MCI in 
the Sjostedt framework and is influenced by uncertainty and coping.  Psychological 
distress was commonly identified through reactions such as anger towards self or family 
members, sadness, loss of or low self-confidence or self-worth, loneliness, rejection, 
inactivity, shame, self-blame, helplessness or loss of control and exacerbation of existing 
relational problems (Banningh et al., 2008; Blieszner et al., 2007; Carpenter et al., 2008; 
Ellison et al., 2008; Pessin et al., 2003; Petersen, 2003; Rosenberg et al., 2006).  These 
reactions are sometimes coupled with hypersensitive concerns of becoming a burden to 
others, needing to abandon complex activities, or becoming overly aware to how others 
react to the diagnosis (Banningh et al., 2008).  Such responses can lead to increased 
hostility within the family system, future-oriented worry, or impede rational decision 
making (Pessin et al., 2003).    
Although previous studies have not evaluated the relationships between 
psychological distress, uncertainty, and coping in older adults with MCI, these 
relationships have been examined in older adults with other types of chronic illness and 
lend support to the hypotheses proposed in the Sjostedt framework.  Psychological 
distress has been demonstrated to be significantly and positively correlated with subjects’ 
levels of uncertainty and coping strategies with other chronic illnesses such as 
fibromyalgia, diabetes mellitus, cancer, and multiple sclerosis (Anema et al., 2009; 
Landis, 1996; Lien et al., 2009; Lynch et al, 2001; Mullins et al., 2011; Reich et al., 
2006).  These relationships remained significant when controlled for subjects’ 
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educational levels (Lynch et al, 2001).  Among individuals with Parkinson’s disease, one 
study reported no significant relationship between psychological distress and uncertainty; 
but a significant relationship between psychological distress and uncertainty for the 
caregivers of those individuals (Sanders-Dewey et al., 2001).  Yet it has also been 
demonstrated that the relationship between uncertainty and psychological distress is 
affected by whether or not the uncertainty is appraised as a danger or opportunity.  Kang 
(2006) demonstrated a significant negative relationship in patients with atrial fibrillation 
between uncertainty being appraised as an opportunity and depression; and, a significant 
positive relationship between uncertainty being appraised as a danger and depression. 
Assumptions of the study 
 This study assumes that MCI is a diagnosable, and valid chronic condition that 
does not cause physical pain or result in death.  As a chronic condition it is expected that 
the relationships demonstrated between psychological distress, uncertainty, and coping in 
older adults with MCI may be similar to what has already been demonstrated in other 
chronic conditions (Anema et al., 2009; Landis, 1996; Lien et al., 2009; Lynch et al, 
2001; Mullins et al., 2011; Reich et al., 2006).  Finally, consistent with current 
suggestions for care, this study also assumes that while the subtypes of MCI may be 
fundamentally different, nursing care related to MCI will not vary based on subtype (Lin 
et al., 2012).   
Summary 
The current status of knowledge about MCI indicates diagnostic criteria clearly 
delineate the attributes of MCI.  However, a specific theoretical framework that addresses 
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the relationships of antecedents and consequences of MCI, in particular the relationships 
among uncertainty, coping, and psychological distress, is nonexistent.  In addition, 
frameworks pertaining to other chronic illnesses are limited in their applicability to older 
adults with MCI as they do not account for the varying illness trajectory of MCI or 
impact of MCI on appraisal of their situation.  A framework that addresses the 
relationships of antecedents and consequences of MCI is imperative to improve the care 
of older adults with MCI through the development of effective nursing interventions.  
This study will be foundational in quantitatively evaluating select components of the 
Sjostedt framework with the goal of providing a theoretical base for effective 
interventions and evidence-based practice specific to older adults with MCI.  
60 
 
III. RESEARCH DESIGN AND METHODS 
 This quantitative study used a descriptive correlational design. Data were 
collected using one-time in-person interviews.  The advantages of this study’s design are 
the ability to demonstrate relationships among variables in the model, reduce dropout rate 
related to single point data collection, and decrease missing data that might occur with 
other survey methodologies (Polit & Beck, 2008).  The limitations of this study’s design 
are the inability to track participant changes over time, and the inability to identify causal 
relationships among the variables (Polit & Beck, 2008). 
Subjects and setting 
 Subjects.   A convenience sample of 91 older adults from an outpatient neurology 
clinic comprised the sample.  Subjects were included if they were over 54 years of age, 
had been given a diagnosis of MCI (either aMCI or naMCI) by their attending physician 
based on neuropsychological testing, and could understand, speak and write in English.  
Participants were excluded if they did not meet the above inclusion criteria, if their 
physician suspected that other neuropsychiatric disorders or chronic conditions might be 
complicating their diagnosis of MCI, or if they progressed from MCI to dementia. 
 Sample size.   Analyses for aim 1 necessitate the largest sample, hence aim 1 was 
used to guide the sample size estimation.  Sample size was initially estimated using a 
method from Cohen & Cohen (1983): 
Effect size (f
2
) = R
2 
/ (1 - R
2
) was calculated assuming a potential small squared multiple 
correlation (R
2
) of 0.13 
 f
2
 = 0.13 / (1 – 0.13) = 0.15 (medium effect size) 
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L determined from tables in Cohen & Cohen (1983), assuming a maximum of 12 
variables (given the number of instrument subscales) and α = 0.05 for a power of 0.80 
Estimated sample size (n*) = L / f
2
 +k (number of variables) + 1 
 n* = 17.34 / 0.15 + 12 + 1 = 128.6 
In short, it was initially estimated that a sample of 129 older adults would yield a 
power of 0.80 at α = 0.05.  From experience in a previous study, it was estimated that the 
neurology clinic on Thursdays would see an average 3 older adults per week with MCI.  
From the clinic load, the resulting duration to achieve the desired sample size was 
estimated to be 43 weeks.  Unfortunately, sample accrual did not occur as quickly for the 
main dissertation study as it was predicted from a previous study at the clinic.  After 25% 
of the initial sample was collected (n=33), preliminary analysis was performed to assess 
the variables predicted for aim 1.  It was determined from this analysis that the variables 
related to MCI type, duration, and level of cognitive impairment were not strongly related 
to the other main variables of uncertainty, coping, and psychological distress and should 
not be included in the analysis for aim 1.  By removing those variables from the model, 
the sample size needed was recalculated.  It was determined that only 91 people would be 
needed to yield a power of 0.80 at α = 0.05.  
 Sampling procedure.   Participant recruitment occurred over the course of 62 
consecutive weeks (excluding federal-holidays or other weeks such as physician vacation 
when the clinic was not operational) starting immediately after IRB approval.  Potential 
participants were identified prior to their scheduled appointment in the neurology clinic 
by clinic staff.  After completing their scheduled appointment with their physician, all 
62 
 
potential participants were invited to participate and instructed to contact Jennifer 
Sjostedt, RN, GNP-BC if they had an interest in participating in the study.   
If the potential subject expressed interest, Sjostedt discussed the study in detail 
with them and (when present) their family caregiver(s).  After discussion of the study 
details, if the potential subject was willing to participate and met inclusion criteria, the 
informed consent process immediately followed.  Data collection then began after written 
consent was obtained. 
 Setting.   The sample for the study was recruited from a clinic in the area that 
specializes in the diagnosis of MCI (the Memory Disorders Clinic at Froedtert Hospital / 
Medical College of Wisconsin).  The Memory Disorder Clinic (MDC) was chosen for its 
volume of patients with MCI.  A preliminary cognitive screening instrument study by 
Sjostedt and Dr. Malgorzata Franczak at the MDC was able to recruit on average 3 
subjects per week after a < 10% refusal rate (total of 49 subjects in 4.5 months) with a 
relatively equal amount of aMCI or naMCI diagnoses.  The clinic is part of an academic 
facility focused on research located in Milwaukee, WI and serves Milwaukee, Waukesha, 
Ozaukee, Kenosha and Racine counties in Wisconsin.  Between 30% to 75% of clinic’s 
target population (dependent by county) are considered to be members of minority 
populations (Froedtert Hospital, 2011).  It is expected that study participants from the 
clinic reside mainly in a diverse, urban, mid-western area of the United States, and the 
results of this study may not be applicable to other populations (such as those in rural 
communities). 
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Instruments 
All instruments in this study were selected to be consistent with the conceptual 
definitions of the variables, and their reliability and validity (see summary of 
psychometrics and expected data in table 1).  Instruments to assess the study variables by 
order of administration were: Montreal Cognitive Assessment (level of cognitive 
impairment from MCI), a Demographic Survey, Uncertainty Stress Scale (uncertainty), 
Brief COPE (coping), and Kellner Symptom Questionnaire (psychological distress).  The 
demographic survey measured time since initial MCI diagnosis in months and years, and 
select antecedents which could potentially have an effect on uncertainty, coping, and 
psychological distress: subject gender, age, race/ethnicity, educational level, marital 
status, religious affiliation, and socioeconomic status. The demographic survey was 
administered as part of the in person interview; however, time since initial MCI diagnosis 
was obtained from the participant’s electronic medical record by Sjostedt after 
completing the in person interview. 
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Table 2. Theoretical constructs, instruments, and reliability by order of administration. 
  
Theoretical 
Construct 
Instrument Scale 
 
α* Expected 
Data 
Cognitive 
Impairment 
Montreal Cognitive 
Assessment 
(MoCA) 
11 items 
0-30 
points 
0.83 Scale Level 
Select MCI 
Antecedents 
Demographic Survey 10 items 
N/A 
points 
Not Available Nominal and 
Ordinal 
Level 
Uncertainty Uncertainty Stress Scale 
(USS) 
59 items 
0-397 
points 
0.92-0.96 Scale Level 
Coping Brief COPE 28 items 
0-84 
points 
0.50-0.90 Scale Level 
Psychological 
Distress 
Symptom Questionnaire 
(SQ) 
92 items 
0-92 
points 
0.76-0.95 Scale Level 
 
*MoCA (Nasreddine et al., 2005), USS (Agretelis, 1999; Barron, 2000; Ford, 1989), 
Brief COPE (Carver, 1997; Lin & Heidrich, 2012; McIlvane et al., 2008), SQ (Bull, Luo, 
& Maruyama, 1994; Williams, 1993) 
 Montreal Cognitive Assessment (MoCA).   MCI was operationalized by the 
level of cognitive impairment determined using the MoCA (Nasreddine, 2011).  The 
MoCA was developed to be sensitive enough to detect subtle changes in cognition 
associated with MCI, easy to use/interpret, and could be administered within a short time 
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frame (Nasreddine et al., 2005).  Outside of testing within memory clinics, the MoCA has 
been used to test for MCI in populations ranging from persons with subacute stroke or 
transient ischemic attacks (Dong et al., 2010; Pendlebury, Cuthbertson, Welch, Mehta, & 
Rothwell, 2010), to those with other cardiovascular diseases (McLennan, Mathias, 
Brennan, & Steward, 2011) or Parkinson’s disease (Chou et al., 2010;  oops et al., 2009; 
Nazem et al., 2009). 
 The initial instrument was tested with a sample of 46 patients with either MCI or 
AD and 46 healthy controls.  After testing, the instrument was revised to the “final” 
version and retested with a larger sample of 94 older adults with MCI, 93 older adults 
with AD, and 90 health controls (Nasreddine et al., 2005).  It does not appear that the 
final version of the MoCA was revised beyond the initial report revisions. 
The first version of the MoCA assessed 10 different cognitive domains, but was 
later limited to 8 domains (11-items, 30-points) after it was concluded that 5 items did not 
discriminate well between MCI, dementia, and healthy controls (Nasreddine et al., 2005).  
The 8 domains included in the final version include: Short term memory, visuospatial 
abilities, executive functioning, attention, concentration, working memory, language, and 
orientation.  The final version of the MoCA was first validated in both English and 
French (in Canada), and is now available in over 31 different languages (Nasreddine, 
2011; Nasreddine et al., 2005); a copy of the English version and scoring instructions are 
included in the appendix. 
 Psychometrics.  The sensitivity and specificity of the MoCA for identifying MCI 
with a cut-off score of 26 was reported as 90% and 87% respectively (Nasreddine et al., 
2005), which has since been closely replicated in other studies (Smith, Gildeh, & 
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Holmes, 2007).  Item analysis demonstrated differences between participants with 
dementia versus those with MCI and normal cognition; supporting the MoCA’s ability to 
detect slight differences in cognition.  Specifically, participants with dementia performed 
more poorly than those with MCI (and those with MCI more poorly than participants 
with normal cognition) on items assessing visuospatial abilities, executive functioning, 
short-term memory, and orientation (Nasreddine et al., 2005).  
 The resulting positive and negative predictive values for MCI with the MoCA 
were 89% and 91% respectively (Nasreddine et al., 2005).  In a comparison between a 
widely used tool for dementia screening (the Mini-Mental State Exam, MMSE) and 
MoCA with a sample of 93 participants with MCI, 73% of participants scored within the 
“abnormal” range (<26 points) on the MoCA but in the normal range (≥26 points) on the 
MMSE (Nasreddine et al., 2005).  A similar trend was found in other samples of people 
who had either an acute stroke, transient ischemic attacks or Parkinson’s disease, where 
32% to 58% of the subjects who had normal MMSE scores scored within the abnormal 
range on the MoCA (Dong et al., 2010; Nazem et al., 2009; Pendlebury et al., 2010).  In 
addition to supporting the MoCA for identifying MCI, these results highlight the 
limitations of the MMSE for differentiating between MCI and normal cognition. 
 The MoCA appears to have good internal consistency, with a Cronbach’s alpha of 
0.83 (Nasreddine et al., 2005).  Similar Cronbach’s alpha levels ranging from 0.74 to 0.83 
have also been reported for the Japanese and Arabic language translations of the MoCA 
(Fujiwara et al., 2010; Rahman & El Gaafary, 2009).  Test-retest reliability also has been 
demonstrated with a small sample (15 older adults with MCI and 20 health controls), 
finding no significant differences in how either group scored on the MoCA between 
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initial testing and a 1-month follow up with the same test (Ahmed, de Jager, & Wilcock, 
2012). 
 Construct validity of the MoCA was not reported by the instrument authors 
(Nasreddine et al., 2005).  Only one study presented a factor analysis of the MoCA, and 
the results were unclear and difficult to interpret (Berstein, Lacritz, Barlow, Weiner, & 
DeFina, 2011).  Despite the lack of factor analysis, several other studies have supported 
the face validity of the MoCA (Chou et al., 2010; Dong et al., 2010; Hoops et al., 2009; 
McLennan et al., 2011; Nazem et al., 2009; Smith et al., 2007); likely related to the high 
aforementioned predictive validity (sensitivity and specificity of the instrument for 
detecting MCI).  The high sensitivity and specificity of the MoCA demonstrates its 
ability to correctly identify and rule-out MCI (to measure what it was made to measure); 
adequately providing evidence for its clinical validity. 
Limitations.   Authors reported that the initial instrument development was based 
on the “clinical intuition” of their initial study’s main author (Nasreddine et al., 2005).  
Given the lack of clarity or framework with MCI conceptualization, diagnosis, and 
language; clinical intuition might not have been the most appropriate initial method of 
development.  In addition, low Cronbach’s alpha (0.55) was reported for the MoCA when 
used in a sample from a cardiac and diabetic/endocrine outpatient clinic in Australia; 
suggesting that it may be inappropriate to use the MoCA with that population (McLennan 
et al., 2011).  Another study also reported lower standardized coefficient alphas ranging 
from 0.66 to 0.77 for the MoCA, after calculating a MoCA score for participants from 
other existing data from population or volunteer samples of health older adults or those 
with known or suspected brain pathology (Bernstein et al., 2011); although the alpha 
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levels could potentially be related to data collection methods.  In addition, many other 
studies that have used the MoCA did not report reliability statistics (Dong et al., 2010; 
Hoops et al., 2009; Nazem et al., 2009; Pendlebury et al., 2010; Smith et al., 2007).  
Consequently, the lower alpha levels and lack of reliability statistics support the need for 
further in-depth evaluations of the reliability of the MoCA. 
Uncertainty Stress Scale (USS).   The USS was chosen to measure uncertainty 
from MCI as it does not contain items on uncertainty related to physical pain.  The USS 
was developed based on a prior mixed methods study by Hilton using the community 
version of Mishel’s Uncertainty in Illness Scale (MUIS) and qualitative interviews 
(Hilton, 1994).  The USS was created to meet the needs specified within the qualitative 
interviews that were not addressed in the MUIS; specifically the USS measures 
uncertainty in illness-related situations and the stress, threat, or positive feelings 
generated by uncertainty.  The USS has not been used in research involving older adults 
with MCI or any other type of cognitive impairment.  However, the USS lends itself to 
research in uncertainty with MCI as it does not focus on uncertainty related to physical 
pain. 
The USS can be separated into 2 sub-scales, one focused on uncertainty and the 
other focused on stress from uncertainty.  Both scales were used in this study.  The USS 
contains 54 items where subjects are asked to rate on a 0 to 4 (none to very high) or N/A 
Likert-scale their level of uncertainty related to a statement such as “I am uncertain 
whether changes in my mild cognitive impairment (MCI) will be detected early.”  After 
rating their uncertainty, the subject then rates their stress from that uncertainty on a 0 to 2 
(none or very low to high or very high).  After the 54 items, there are 4 additional items 
69 
 
that ask the subject to place an X on a line indicating their overall uncertainty, overall 
stress related to uncertainty, overall threat related to uncertainty, and overall positive 
feelings from uncertainty.  There is also one yes/no question asking subjects if they have 
any positive feelings from their uncertainty.  Higher numbers on the scale equate to 
higher levels of uncertainty and/or stress. 
Psychometrics.   Hilton’s 1994 article discussed in detail the narrowing down of 
the USS to its current fourth version.  Unfortunately, the only reported measure of 
internal consistency in Hilton (1994) comes from one of the previous iterations of the 
USS in Ford (1989), where the Cronbach’s alpha was reported as acceptable, 0.92 for the 
total scale.  The most recent version of the USS, used in this study, has been reported as 
having acceptable internal consistency of 0.95 on the uncertainty subscale and 0.97 on 
the stress subscale (Agretelis, 1999; A. Hilton, personal communication, October 15, 
2012). 
Limitations.   The biggest limitations are the lack of published support for use of 
the USS and lack of studies involving older adults with MCI and the USS.  The USS was 
originally designed for use in persons with cancer but has been adapted to fit other 
populations.  The USS in this study was reworded with permission from the author (A. 
Hilton, personal communication, October 15, 2012) using the published cancer USS 
(Hilton, 1994), where MCI replaced the word cancer.  This study may help to validate use 
of the USS in condition, such as MCI, where other uncertainty measures may be 
inappropriate because physical pain and medications or treatments resulting from the 
condition are near to non-existent.  
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Brief COPE.   The Brief COPE is the only measure of coping that has been used 
in older adults with MCI.  It is also shorter than other available instruments to measure 
coping, which will help to prevent test fatigue from the multiple instruments in this study.  
The Brief COPE contains 28 items which assess fourteen coping reactions (with two 
items for each for each reaction): active coping, planning, positive reframing, acceptance, 
humor, religion, using emotional support, self-distraction, denial, venting, substance use, 
behavioral disengagement, and self-blame (Carver, 1997).  The fourteen coping reactions 
can be reduced into three sub-scales of coping: (1) emotion-focused coping (acceptance, 
emotional support, positive reframing, religion, and humor), (2) problem-focused coping 
(active coping, planning, instrumental support), and (3) dysfunctional coping (self-
distraction, venting, self-blame, behavioral disengagement, denial, and substance use) 
(McIlvane et al., 2008).  Initially, items on the Brief COPE were scored on a 0-3 scale 
where 0 = I haven’t been doing this at all and 3 = I’ve been doing this a lot (Carver, 
1997).  However, a 4-point scale where 1 = I haven’t been doing this at all and 4 = I’ve 
been doing this a lot has also been used (McIlvane et al., 2008). 
For this study, subjects were asked to complete the entirety of the Brief COPE by 
responding to the following with regard to each of the items: “The next set of questions 
asks you about ways that you have coped with your cognitive impairment over the past 
month.  In the past month, how often have you done the following things to cope with 
your cognitive impairment?”  Each item will then be graded by the subject on the 
aforementioned 3-point scale.  The rationale for using the 3-point scale rather than 
alterative 4-point scale is to allow the study results to be comparable to recent research 
involving coping in older adults with MCI, where the 3-point scale was used (Lin & 
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Heidrich, 2012).  With the Brief COPE both grading scales have demonstrated acceptable 
internal consistency, which is discussed below. 
Psychometrics.   The current version of the Brief COPE (Carver, 1997) resulted 
from a factor analysis and item reduction from the original COPE inventory by Carver et 
al. (1989).  Carver (1997) demonstrated acceptable internal consistency with the Brief 
COPE in a convenience sample of 168 participants from a community affected by a 
hurricane.  Cronbach’s alpha was reported for each of the fourteen coping reactions 
(Carver, 1997) and ranged from 0.50 (venting) to 0.90 (substance use).  
For older adults with MCI, McIlvane et al. (2008) found acceptable internal 
consistencies on the sub-scale measures of the Brief COPE: 0.80 (emotion-focused 
coping), 0.88 (problem-focused coping), and 0.62 (dysfunctional coping).  Authors also 
reported reliability statistics for their comparison group of care partners for older adults 
with MCI, which also demonstrated acceptable internal consistencies: 0.84 (emotion-
focused coping), 0.88 (problem focused coping), and 0.81 (dysfunctional coping).  
Another study of older adults with MCI (Lin & Heidrich, 2012) also found acceptable 
internal consistency on the sub-scales: 0.77 (emotion-focused coping), 0.88 (problem-
focused coping), and 0.73 (dysfunctional coping).  However, neither pre nor post power 
analyses were reported in either of the studies.  Consequently, it is possible that the 
demonstrated Cronbach’s alphas are related to the smaller sample sizes in McIlvane et al. 
2008 (n = 46 older adults with MCI and 29 care partners) and Lin and Heidrich 2012 (n = 
63 older adults with MCI). 
Limitations.  Only two studies have been published where the Brief COPE was 
used in older adults with MCI, and both studies used differing grading criteria for the 
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scale items.  While this study will help to further validate the use of the Brief COPE with 
a larger sample of older adults with MCI using the original grading criteria, it is also 
considered a limitation.  Another limitation is the instrument’s ability to assess coping at 
one point in time rather than over time.  To assess coping with MCI over time an 
additional study will need to be conducted which longitudinally evaluates coping. 
Symptom Questionnaire (SQ).   Kellner’s (1987) SQ has been widely used since 
its initial publication to operationalize psychological distress in older adults.  The SQ has 
not been used in research involving older adults with MCI; however, the SQ is brief and 
contains simple to follow yes/no or true/false items (Kellner, 1987).  The SQ was used in 
its entirety in this study.  The SQ was developed from the Symptom-Rating Test (SRT) 
(Kellner & Sheffield, 1973) to evaluate psychological distress.  Unlike the questions on 
the SRT, the SQ contains brief items to which subjects respond yes/no or true/false.  The 
items on the SQ were developed based on a review of literature on neuropsychological 
symptoms in normal controls and psychiatric patients, followed by statements selected 
from interview between investigators and neurotic patients or those with personality 
disorders (Kellner, 1987).  
The SQ consists of 92 dichotomous items of which 68 items indicate symptoms of 
psychological distress and 24 items are antonyms indicating psychological well-being 
(Kellner, 1987).  The items can be separated into four main subscales of depression, 
anxiety, anger-hostility, and somatic.  These four subscales can then further be divided 
into symptom (depressive symptoms, anxiety symptoms, anger-hostility symptoms, or 
somatic symptoms) or wellbeing (contented, relaxed, friendly, somatic well-being) 
subscales for a total of eight possible subscales.  For the symptom subscales, the items 
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are all either yes/no or true/false and scored as 0 = no or false, and 1 = yes or true with a 
maximum score of 17, with higher scores indicating more distress.  On the well-being 
subscales, the items are reverse coded (0 = yes or true, and 1 = no or false) with a 
maximum score of 6, and again with higher scores indicating more distress. 
Psychometrics.   Criterion-related validity was established through using the SQ 
to differentiate between normal controls or people receiving treatment for their 
psychiatric condition to those with untreated psychiatric conditions, and through 
correlating the SQ scales to other existing instruments such as the Hopkins Symptom 
Checklist and the Hamilton Rating Scale for Depression (Kellner, 1987).  Reliability of 
the SQ was demonstrated by Kellner (1987) using test-retest reliability, where after 2 
weeks the split-half reliability of change in each scale for persons who were anxious and 
depressed (n = 22) was +0.92 (anxiety), +0.94 (depression), +0.91 anger-hostility, and 
+0.86 (somatic).  Kellner (1987) also reported the conventional split-half reliability of the 
scales in other studies to be: +0.75 to +0.95 (anxiety), +0.74 to +0.93 (depression), +0.78 
to +0.95 (anger-hostility), and  0.57 to  0.84 (somatic).  Cronbach’s alpha for the four 
main scales and total scale with adults were not reported by Kellner (1987) but has been 
reported elsewhere and found to be sufficient: ranging between 0.83-0.95 for depression, 
0.76-0.92 for anxiety, 0.91-0.93 for anger-hostility, 0.90-0.92 for somatic, and 0.80 for 
the total scale (Bull, 2011; Bull et al., 1994; Lewis et al., 2009; Williams, 1993).  
Limitations.   Alike the instrument for uncertainty, the SQ has not been used in 
older adults with MCI.  It is possible that the psychometrics of the SQ may be different in 
older adults with MCI compared to normal older adults.  In addition, despite the 
simplicity of the instrument, it is a lengthy instrument and survey fatigue may be a factor 
74 
 
when giving this instrument last.  This will be limited by providing subjects with breaks 
in between instruments, and frequently reminding subjects that they may stop the study at 
any point. 
Procedure 
 Data collection.   Sjostedt completed the Collaborative Institutional Training 
Initiative (CITI) program, institutional offered Health Insurance Portability and 
Accountability Act (HIPAA) training, and National Institute of Health (NIH) protecting 
human research participants training prior to beginning the study.  Data were collected in 
person by Sjostedt as described within the above section on sampling procedure.  Date of 
diagnosis of MCI was obtained from the participant’s electronic medical record by 
Sjostedt after completing the in person interview. Data and consent forms was recorded 
using paper and pen.  Caregivers when available were present during the informed 
consent process and study at the request of the participant. After informed consent, 
subjects completed the MoCA followed in order by the (1) demographic questionnaire, 
(2) USS, (3) Brief COPE, and (4) SQ.   
As part of a normal clinic appointment, subjects received the Addenbrooke’s 
Cognitive Exam revised (ACE-R).  Consequently, only portions of the MoCA which are 
not repetitive of those in the ACE-R were completed for the study, and the subjects were 
asked for permission to obtain the results of the ACE-R from their clinic record.  
Repetitive sections in the MoCA that were excluded and instead obtained from the ACE-
R include: cube copy, clock draw, serial 7’s, and orientation (date, month, year, day, 
place, and city).  When the ACE-R was not completed during the subjects’ appointment, 
the MoCA was given in its entirety.   
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The responses were transferred into a password-protected electronic data file by 
Sjostedt and original papers filed in a locked file-box for the remainder of the study (after 
which time they will be shredded).  Other than signatures required on the consent form, 
all remaining forms and electronic copies were assigned an arbitrary number to help 
protect subject confidentiality.  This data management procedure is described in detail 
below. 
Data management and analysis 
 Data management.   Data were abstracted by Sjostedt directly from completed 
paper records of the participant interview into an Excel spreadsheet on an encrypted 4 Gb 
flash-drive dedicated solely to the research project.  After paper records were entered into 
the electronic system, they were kept in a locked file-box until they can be destroyed.  
The Excel spread sheet had cell-parameters set to help minimize data entry errors; as data 
were entered, numbers which are outside of the cell parameters or are potentially outliers 
were highlighted and researcher prompted to recheck the data.  Collected data did not 
include any participant-identifying information; subsequently, there will be no way to 
link collected data back to individual participants in the final data-set.  In addition, all 
Microsoft Word and Excel files were assigned an additional password (different from that 
of the flash-drive) to provide further protection against any loss of confidentiality.  After 
collection was completed, responses were entered into an Excel file an subsequently 
imported into SPSS for analysis.  All paper data and consent forms will be destroyed after 
3 years, and unidentifiable electronic files will be kept indefinitely. 
Expected data.   Aside from the demographic questionnaire, responses from each 
instrument were summed to result in scale level data as follows: (MoCA) the sum of 
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correct responses on the MoCA, (USS) the sum of item responses on the subscales of 
uncertainty and stress, (Brief COPE) the sum of item responses on the subscales of 
emotion-focused coping, problem-focused coping, and dysfunctional coping, and (SQ) 
the sum of item responses for each of the subscales: depression, anxiety, anger/hostility, 
and somatic. 
Analysis.   Data analysis was performed using SPSS statistical software.  All data 
were assessed for frequencies, mean, median, mode, outliers (scatter plots), skewness and 
kurtosis.  Prior to conducting data analysis to meet the study aims, differences related to 
demographic variables (i.e. gender) on the other variables of level of cognitive 
impairment from MCI, subtypes of MCI, time since initial diagnosis with MCI, 
uncertainty, coping, and psychological distress were examined using one-way analysis of 
variance or χ² tests as appropriate.  Any differences related to demographic variables 
were considered as possible confounding variables within the remaining analyses to meet 
study aims.  Below is a detailed description of the specific statistical analyses that were 
conducted to assess each study aim: 
Aim 1 with related hypotheses.   Test select components of a conceptual 
framework for MCI by examining the relationships among uncertainty, coping, 
psychological distress, time since MCI diagnosis, level of cognitive impairment from 
MCI, and (if determined appropriate in the analyses for aims 3 and 4) subtypes of MCI.  
Hypotheses 1 through 6 dictate the expected relationships within the Sjostedt framework, 
as demonstrated by Figure 2 in Chapter 1.  Structural equation modeling (SEM) was 
considered as potential method for evaluating the fit of variables within the framework.  
However, SEM is unlikely to demonstrate the unique contributions of each of the 
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subscales, which is especially important when evaluating the variable of coping.  Instead, 
to evaluate this aim and the associated hypotheses predicting relationships within the 
conceptual framework, multivariate hierarchical regression analyses were used with each 
psychological distress subscale as a separate dependent variable, and the scales associated 
with uncertainty (first block) and coping (second block) as the independent variables.  
The variables of time since diagnosis, level of cognitive impairment from MCI, and 
subtype of MCI were also considered as potential independent variables in the regression 
analyses predicting psychological distress.  However, preliminary analyses demonstrated 
a lack of significant relationships between the outcome variables and time since 
diagnosis, level of cognitive impairment from MCI, and subtype of MCI.  Given the lack 
of significant relationships, and concerns related to the speed of sample accrual, the 
variables of time since diagnosis, level of cognitive impairment from MCI, and subtype 
of MCI were excluded from the final regression analyses.  
It was suspected that coping might act as either a moderating or mediating 
variable between uncertainty and psychological distress (anxiety, anger/hostility, 
depression, and somatic symptoms).  An example of these potential relationships is 
demonstrated by figure 13: 
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Barron and Kenny’s (1986) approach for assessing moderation/mediation was 
followed to determine if the relationships between uncertainty and psychological distress 
are moderated or mediated by coping. 
Aim 2.   Describe the levels of uncertainty, coping, and psychological distress in 
older adults with MCI.  This aim was addressed by calculating response frequencies, 
means, and descriptive statistics.  Following assessment of variable frequencies, outliers 
(scatter plots), skewness and kurtosis, reliability statistics were conducted for each of the 
instrument sub-scales and whole scales.   
Aim 3.   Examine the differences in scores on uncertainty, coping, and 
psychological distress between the subtypes of MCI.  This aim was addressed by 
calculating t-tests or one way analysis of variance to evaluate the differences between 
group means (subtypes of MCI) on time since diagnosis, uncertainty, coping, and 
psychological distress.  
Figure 13. Moderation vs. mediation of coping between uncertainty and psychological 
distress. 
Uncertainty 
Uncertainty 
Coping 
Coping 
Psychological Distress 
Psychological Distress 
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Aim 4 with related hypothesis.   Examine the strength and direction of 
relationships between scores on uncertainty, coping, and psychological distress within the 
subtypes of MCI.  This aim was addressed by calculating Pearson’s r or Spearman’s rho 
as determined appropriate by the scatter plots calculated in aim 2 to investigate the 
relationships between scores on uncertainty, coping, and psychological distress and the 
subtypes of MCI.  It was hypothesized that there will be no significant differences 
between the subtypes of MCI in the strength and direction of uncertainty, coping, and 
psychological distress.   
Limitations 
The limitations of this study are (1) recruitment from one academic-focused clinic 
in the Midwest; (2) cross-sectional design; and (3) instrument limitations.  Recruiting 
subjects from one academic-focused clinic in the Midwest and cross-sectional design 
limits generalizability of results.  To address these concerns, further research is needed 
with other populations within different care settings and areas of the US or other 
countries.  Specific to cross-sectional limitations, longitudinal studies will be needed to 
evaluate if the study variables change over time.  Finally, two instruments have not been 
used in older adults with MCI (USS, SQ).  It is possible that the psychometrics may be 
different in older adults with MCI compared to older adults with other chronic illnesses.  
Consequently, while this study may support the use of these instruments in older adults 
with MCI, future studies will still be needed to support the psychometrics demonstrated 
in this study.  
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Treatment of human subjects 
IRB approval was obtained from Froedtert Hospital / Medical College of 
Wisconsin (FH/MCW) and Marquette University (MU) prior to the start of the study.  
Both the IRB at FH/MCW and MU provided approval for the study, including 
coordinated IRB form(s). Participants had the right to refuse participation, stop or 
withdraw from the study at any point.  Decisional ability of the participants was assessed 
by their physician prior to consent (Simpson, 2010), and caregivers or other family 
members were requested to be present with the participant if available during the consent 
process to protect the rights of the participants.  The caregivers and family members were 
not invited to participate in the interview of the participant unless the participant 
specifically requested that their caregiver or family member remain present for their 
comfort.  The benefits to participants for being in the study included potential emotional 
benefits from discussing their experience, societal benefits from potential improvements 
in care designed based on the information that they provide, and compensation with a $10 
grocery store (Pick-n-Save) gift-card.   
The risks posed to the participants included the potential for coercion, increased 
stress, fatigue, or distress from the lengthy interview process or interview content, and the 
potential loss of confidentiality.  To prevent coercion, participants were recruited with the 
aid of a flier and only a researcher not affiliated with the clinic discussed the study, 
performed consent, and interviewed the participants.  Additionally, to prevent potential 
coercion from caregivers or family members, participants were asked again prior to the 
start of the interview if they wished to proceed with the study and reminded of their right 
to refuse participation and their right for their caregiver or family not to know of their 
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refusal to participate.  If participants decided to stop participating after consent, 
caregivers or family members who were present at the consent were simply informed 
(only if the researcher was asked) that it was decided that the participant was ineligible 
for the study and nothing more.  Participants were also reminded that staff at the clinic 
would not be notified of their decision to participate in the study or not.  To prevent 
increased stress, fatigue, or distress, subjects were reminded periodically that they could 
end the interview at any point and the researcher would end the interview if the 
participant appeared to become upset.  Finally, to address the potential loss of 
confidentiality, several protection measures were in place including the use of numerical 
identification rather than participant names on study papers, and password-protections on 
files and hardware. 
Vulnerable population.   Older adults with either subset of MCI are considered 
to be vulnerable, and at risk for coercion or mistreatment directly relating to their level of 
impaired cognition, regardless of if the impairment is related to their memory.  It is 
important to clarify that cognition does not simply refer to one’s general knowledge or 
IQ, and is not a stagnant process.  Instead, cognition can broadly be defined as the skill to 
organize thought and action towards obtaining goals (Miller & Wallis, 2009).  To be able 
to organize thought and action, abilities such as memory and judgment are needed.  These 
abilities are considered necessary for obtaining informed consent and subject to change 
over time.  Vulnerability related to impaired cognition is an important ethical concern for 
clinicians, researchers, and institutional review boards, necessitating special protections 
for involving older adults with MCI in research. 
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The ethical concerns of research participant vulnerability and issues related to 
informed consent from impaired cognition are not new concepts.  Informed consent 
processes and concerns in clinic and research settings for older adults with dementia have 
been well explored (Simpson, 2010).  However, the level of cognitive impairment seen 
with dementia is greater than that with MCI (Petersen, 2003).  Extra precautions or 
cognitive testing taken for determining informed consent in older adults with dementia 
may be inappropriate or excessive for older adults with MCI.  Extra precautions or testing 
could potentially result in a loss or violation of dignity or autonomy, confusion, or 
emotional distress (Krohne, Slettebø, & Bergland, 2011).  For researchers and clinicians, 
inappropriate or excessive testing could also translate to increased time and expenses, 
decreased retention or recruitment rates, or even impact study results through subjecting 
participants to multiple tools or procedures. 
In order to provide informed consent, a person must be able to demonstrate a 
relatively high level of competence to ensure that their decision meets the ethical 
requirements for informed consent.  These requirements for informed consent are that the 
decision is fully informed, voluntary, and given by a decisional person (Jefferson et al., 
2008; Mittal et al., 2007).  With MCI, competence appears to be most affected in varying 
degrees by deficits in abilities pertaining to memory, executive functioning, and 
information processing (Jefferson et al., 2008; Okonkwo et al., 2007; Okonkwo et al., 
2008).  Despite these deficits, MCI does not appear to greatly impact an older adult’s 
ability to express choice.  
Similar to determining the presence of MCI, the line at which someone 
determines a person’s competence or capacity to give informed consent is not straight 
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and clear cut (Grebe, 2008; Simpson, 2010).  Including family members or significant 
others on the informed consent process could be considered a loss of the participant’s 
autonomy and a breach of confidentiality.  Given the potential risks of coercion or loss of 
autonomy or confidentiality, potential participants were recruited using a flier and asked 
if they would like their caregiver present for the informed consent process and/or study.   
In addition, all possible efforts were made to maintain participant confidentiality through 
de-identifying and coding of the participant data. 
Time frame 
Months 1 - 11: Participant recruitment and data collection.  Additional time 
included in the estimate to account for potential problems with participant 
recruitment/retention. Also during this time, the first manuscript (comparing the MoCA 
to ACE-R) was prepared for publication.   
Months 9 – 15: Continued and finalized participant recruitment and data 
collection, performed preliminary data analysis and started drafting of the second 
manuscript (study results).  
Months 15 – 16: Submission of first and second manuscript for publication and 
public dissertation defense. 
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Abstract 
Currently there is not a gold standard of screening for mild cognitive impairment (MCI).  
The purpose of this study was to compare two cognitive screening tools for persons with 
MCI: the Montreal Cognitive Assessment (MoCA) and revised Addenbrooke Cognitive 
Exam (ACE-R). 
 
The sample consisted of 50 older adults (>54 years old) diagnosed with MCI, who, 
following a routine clinic appointment were administered the ACE-R and portions of the 
MoCA not included on the ACE-R.  
 
As expected, Pearson’s r indicated significant correlations between the instrument total 
scores (r=0.80, p < 0.001).  A majority of the instrument subscales indicated a high 
degree of correlation, except the abstraction, fluency/naming, and language subscales.  
Gender and diagnosis differences were identified with both instruments. 
 
These findings suggest using the MoCA for cognitive screening in primary care settings 
may be  more sensitive for MCI with  fewer items than and a high degree of consistency 
with the ACE-R.   
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Mild cognitive impairment (MCI) is becoming an increasing concern as a 
potential pre-dementia condition, making it a new target for early diagnosis and 
interventions to maintain quality of life through slowing or preventing the progression to 
dementia.  From major population-based studies, the recently reported average 
prevalence of MCI in older adults is 18.9% (Petersen et al., 2014).  MCI is generally 
diagnosed starting around the age 60 years and is defined as functional impairment 
affecting mental processes, such as memory or executive functioning, that is more than 
what is expected for normal aging and often precedes dementia (Petersen, 2003; Petersen, 
2011).  Diagnostically MCI can further be broken down into two subsets: Amnestic 
versus non-amnestic MCI (Petersen, 2011).  The main difference between these subsets is 
the presence of memory impairment (amnestic or aMCI) or lack of significant memory 
impairment (non-amnestic or naMCI).  However, despite fundamental differences 
between aMCI and naMCI, there is a significant lack of evidence for screening or treating 
one subset differently from the other (Lin, Vance, Gleason, & Heidrich, 2012). 
In general, the diagnosis of MCI typically starts with the patients’ or family 
members’ observation of changes in the individual’s cognition such as forgetting things 
or trouble with job performance (Albert et al., 2011; Petersen, 2011; Portet et al., 2006).  
These observations are accompanied by declines in cognitive functioning greater than 1.5 
standard deviations of what is normally expected for age on a brief cognitive screening 
instrument.  A variety of instruments that assess cognitive functioning are commonly 
administered in a primary care setting to indicate  if further cognitive functioning testing 
is warranted.  Further testing beyond the primary care setting consists of comprehensive 
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neuropsychological testing in combination with the health practitioner’s assessment to 
assign the diagnosis of MCI (Smith & Bondi, 2013).   
Presently there is no gold-standard instrument for screening for MCI in primary 
care settings.  Historically, the majority of instruments used to screen for MCI were 
originally developed to screen for dementia and not the more subtle cognitive changes 
that accompany MCI (Smith & Bondi, 2013).  Many of these screening instruments for 
dementia lack sensitivity and are unable detect signs of MCI.  Thus, persons with MCI 
are likely to be incorrectly screened as normal rather than MCI using such instruments.  
For example, Nasreddine and colleagues have demonstrated that the Mini-Mental State 
Examination [MMSE] can accurately identify dementia but is less specific in identifying 
MCI (Nasreddine et al., 2005).  This has led to the creation of number of instruments 
designed to detect MCI.  Such instruments include but are not limited to the Montreal 
Cognitive Assessment [MoCA] (Nasreddine et al., 2005) and Addenbrooke’s Cognitive 
Exam revised [ACE-R] (Mioshi, Dawson, Mitchell, Arnold, & Hodges, 2006).  The 
MoCA and ACE-R have some similar items to the MMSE but have more items which 
test higher levels of cognitive functioning such as abstraction, language, and fluency.  
Thus, a need exists to identify an instrument that accurately detects MCI in the primary 
care setting. 
Purpose 
The purpose of this study was to compare two commonly used instruments for the 
screening of MCI in older adults (MoCA and the ACE-R), in order to provide evidence 
for which instrument might be more appropriate for use in a primary care setting.  This 
purpose will be addressed through evaluating 3 research questions:  
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1. What is the internal consistency and correlation of total and subscale scores 
between the MoCA and ACE-R in a sample of older adults with MCI?   
2.  To what degree do the MoCA and ACE-R accurately identify older adults with 
MCI? 
3.  Are there any differences or relationships in total and subscale scores on the 
MoCA and ACE-R by demographic variables such as age, gender, and diagnosis 
subtype: aMCI vs. naMCI? 
Methods 
This cross-sectional study recruited a convenience sample of 50 older adults 
diagnosed with MCI from an out-patient neurology clinic at an academic medical center 
over a 5 month period while they attended routine follow-up appointments.  Informed 
consent was obtained from all subjects and their care-partners as part of this institutional 
review board-approved study.  Subjects were included in this study if they were over the 
age of 54 years old, had a diagnosis of MCI supported by neuropsychological testing and 
neurologist assessment, and could speak/write in English.  Subjects were excluded if they 
did not meet the above inclusion criteria or if their neurologist documented in the patient 
record that a neuropsychiatric disorder(s) might be complicating their diagnosis of MCI. 
As part of their clinical care, all subjects completed the ACE-R during their 
scheduled clinic appointment.  Following the appointment, subjects were invited to 
participate by clinic staff and the study PI performed informed consent then administered 
a brief demographic questionnaire followed by the MoCA excluding portions which were 
repetitive of items in the ACE-R (which were then rescored from the ACE-R for a total 
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MoCA score).  The items which were excluded from the MoCA included: (1) Cube copy, 
(2) clock draw, (3) serial 7’s, and (4) orientation (date, month, year, etc.). 
Instruments 
 Montreal Cognitive Assessment (MoCA).   The MoCA was first presented in 
2003 as one of the few available instruments specifically developed to screen for MCI 
(Nasreddine, 2011; Nasreddine et al., 2005).  The target population for the MoCA is 
patients who present with “mild” cognitive complaints who might perform within the 
normal range on the MMSE (Nasreddine et al., 2005).  The first draft of the MoCA 
assessed 10 different cognitive domains, but was later limited to 8 domains (11-items, 30-
points) after it was concluded that 5 items did not discriminate well between MCI, 
dementia, and healthy controls (Nasreddine et al., 2005).  The 8 domains addressed in the 
final version include: Short term memory, visuospatial abilities, executive functioning, 
attention, concentration, working memory, language, and orientation.  Lower scores 
indicate higher levels of cognitive impairment.  The MoCA exhibits acceptable internal 
consistency (Cronbach’s alpha = .83) (Nasreddine et al., 2005).   
 Addenbrooke’s Cognitive Assessment, revised edition (ACE-R).   Unlike the 
MoCA, the ACE-R was not developed to screen solely for MCI but instead to screen for 
the early stages of dementia (including MCI) and differentiate between the many 
subtypes of dementia (Mioshi et al., 2006).  The ACE-R contains 26 item components 
(over double the number of items on  the MoCA) which can be combined to produce 5 
subscales and produce the total score out of 100 points: (1) Attention/Orientation (18 
points), (2) Memory (26 points), (3) Fluency (14 points), (4) Language (26 points), and 
(5) Visuospatial (16 points) (Mioshi et al., 2006).  Again, lower scores equate to higher 
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levels of cognitive impairment.  Similar to the MoCA, the ACE-R exhibits acceptable 
internal consistency (Cronbach’s alpha= .80) (Mioshi et al., 2006). 
Data analyses 
 Data analyses were performed using SPSS statistical software. To describe 
participants in the study, frequencies and group differences on baseline demographics 
were examined using one-way analysis of variance or χ² tests where applicable. For 
research question one, total and subscale ranges were calculated for both instruments.  In 
addition, bivariate correlations were calculated between the total and subscale scores on 
the two instruments.  Cronbach's alpha was used to assess the internal consistency of both 
instruments. Research question two was addressed by comparing the percentage of 
participants identified as exhibiting normal cognition (false negative) rather than MCI in 
both instruments.  The threshold score for MCI was previously identified by the 
instrument authors as 88 for the total ACE-R and 26 for the total MoCA score.  Finally, 
for research question three, group differences between scores with regard to demographic 
variables (gender, and diagnosis) were assessed using t-tests and the relationship between 
scores and age was evaluated using bivariate correlation. 
Results 
 A total of 50 people were recruited for the study with an average age of 75.88 
(SD=7.80). The sample was largely Caucasian (98.0%) and highly educated with at least 
98.0% having some college education.  The sample included a similar number of males 
and females with either an aMCI (males n= 18, females n=10) or naMCI (males n=14, 
females n=8) diagnoses (χ²(1)=0.002, p=0.96).  There was also no significant difference 
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(t(48)=1.01, p=0.32) in the mean age of participants by gender (male mean age=76.72, 
females mean age=74.39).  However, there was a significant difference in mean age by 
diagnosis (t(48)=2.56, p=0.01) with aMCI subjects being older (mean age=78.25) than 
those with naMCI (mean age=72.86).  54.0% of subjects had their MCI diagnosis for less 
than one year, and there were no significant differences in the length of diagnosis by 
gender (χ²(5)=4.73, p=0.45) or diagnosis (χ²(5)=3.60, p=0.61).  
Research question 1: What is the internal consistency and correlation of total and 
subscale scores between the MoCA and ACE-R in a sample of older adults with 
MCI? 
 
 
Score distributions on the ACE-R and MoCA appear in table 1. As expected, the 
mean total score for both scales indicated the sample exhibited MCI with mean scores 
less than the threshold scores 88 (ACE-R) and 26 (MoCA).  Internal consistency of both 
instruments was somewhat lower than expected (α~0.60), which may be related to sample 
homogeneity (Bernardi, 1994).  For research question one, bivariate correlations were 
assessed on the total scales and subscale scores of the MoCA and ACE-R (table 2).  
While the total scores of the ACE-R and MoCA were significantly positively correlated 
(r=0.80, p<0.001), the instrument subscales did not all positively correlate.  Specifically, 
the abstraction and language subscales from the MoCA did not correlate with any of the 
ACE-R subscales.  
Research question 2: To what degree do the MoCA and ACE-R accurately identify 
older adults with MCI? 
 
 
For research question two, scores on the ACE-R and MoCA were examined using 
cut off scores of 88 (ACE-R) and 26 (MoCA) to determine the percentage of subjects 
who screened positive for cognitive impairment (figure 1).  Of the 50 subjects, 20% (n = 
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10) screened within normal range on either one (MoCA n=2, ACE-R n=5) or both 
instruments (n=3).  Of those, 90% were male, and 100% were college educated.  The 
resulting sensitivity was 90.00% for the MoCA and 84.00% for the ACE-R.  Specificity 
was not calculated as the study only included older adults with a diagnosis of MCI. 
Research question 3: Are there any differences or relationships in total and subscale 
scores on the MoCA and ACE-R by demographic variables such as age, gender, and 
subtype of MCI? 
 
 
Finally, to address research question three, total and subscale scores on the ACE-
R and MoCA were compared by subject gender, MCI subtype, and age.  The bivariate 
correlation indicated there was no significant relationship between scores and age. 
However, the t-tests demonstrated significant group differences in scores by MCI subtype 
and diagnosis (table 3).  Males scored significantly higher than females on both 
instruments (indicating less impairment).  Males scored significantly better than females 
(p=0.003-0.04) on the visuospatial (MD=1.99) and memory (MD=2.43) subscales of the 
ACE-R and the visuospatial (MD=1.00) and attention (MD=0.83) subscales of the 
MoCA.  In addition, subjects with aMCI scored significantly lower than those with 
naMCI on both instruments (indicating more impairment).  Subjects with aMCI scored 
lower than those with naMCI (p=0.004-0.04) on the attention/orientation (MD=-0.76) and 
memory (MD=-2.67) subscales of the ACE-R, and the orientation (MD=-0.21) and 
abstraction (MD=-0.63) subscales of the MoCA.  
Discussion 
The purpose of the study was to compare two commonly used instruments for the 
screening of MCI in older adults (MoCA and the ACE-R), in order to provide evidence 
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for which instrument might be more appropriate for use in a primary care setting.  The 
results indicated that the ACE-R and MoCA are highly correlated (with the exception of a 
few subscales) with both instruments exhibiting a high degree of sensitivity for detecting 
MCI in older adults.  The internal consistency of both instruments was lower than 
expected for both instruments which could be attributed to homogeneity of the relatively 
small sample (Bernardi, 1994).  These findings must be considered within the framework 
of previous studies, clinical implications, instrument bias, and limitations of the study’s 
design. 
There have been two other studies which compared the ACE-R and MoCA 
directly, neither of which has reported differences in the instruments by diagnosis or 
gender.  In one pilot study, the ACE-R and MoCA were compared with a very small 
sample of 15 persons with MCI versus 20 healthy controls (Ahmed et al., 2011).  The 
results reported sensitivity and specificity for both instruments was 90% and 67% 
(respectively), using a cut off score of 88.5 for the ACE-R and 23.5 for the MoCA (as 
opposed to the recommended score of 26) (Ahmed et al., 2011).  Researchers used a cut 
off of 23.5 as it was found to discriminate between controls and MCI in their sample 
(Ahmed et al., 2011).  If the cut off score of 23.5 for the MoCA was used in this study, 
the sensitivity of the instrument would have dropped to 62.00%, supporting the need to 
use the instrument author’s recommended cut off of 26 (Nasreddine et al., 2005). 
Another study compared the two instruments in 91 patients with MCI greater than 
or equal to one year after a stroke or transient ischemic attack (Pendlebury, Mariz, Bull, 
Mehta, & Rothwell, 2012).  Similar to the results of this study, total MoCA and ACE-R 
scores were significantly, positively correlated (Spearman r
2
=0.76).  Using a cut off score 
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of 26, the sensitivity and specificity of the MoCA were reported as 87% and 63% 
respectively.  For the ACE-R, a cut off of 88 resulted in sensitivity and specificity rates of 
56% and 100% respectively.  The resulting sensitivity for the ACE-R was significantly 
different from this study (84%), but can likely be attributed to differences in sampling 
where Pendelbury and colleagues (2012) used participants whose MCI may be related to 
prior transient ischemic attacks or stroke.  
Clinical implications 
Both instruments have been validated in several languages and adapted cultural 
differences (Mioshi et al., 2006; Nasreddine, 2011; Nasreddine et al., 2005).  Both 
contain some identical items: (1) cube copy, (2) naming animals, (3) serial 7 subtraction, 
and (4) orientation questions.  However, while both instruments contain similar items 
(and similar subscales), there are some notable differences between the instrument 
subscales.  For example, the MoCA contains the subscale “abstraction” which contains 
two items asking the participant to identify how two things are similar (e.g. banana and 
orange).  The ACE-R does not contain an abstraction scale and does not have any similar 
items.  In addition, the abstraction subscale from the MoCA was not correlated with any 
of the ACE-R subscales.  Lack of significant correlations between the subscales suggests 
that the scales may not be measuring the same things.  Clinically, abstraction is a higher 
form of cognitive functioning which is necessary for performing daily tasks and can be 
predictive of behavior such as medication adherence (Insel, Morrow, Brewer, & 
Figueredo, 2006; Jeste et al., 2003) and glycemic control in older adults with diabetes 
(Amer et al., 2014).  The MoCA may be useful for identifying older adults in need of 
medication management interventions, however further research is needed. 
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Although the visuospatial subscales of the ACE-R and MoCA were significantly 
correlated (r=0.67, p<0.001), the relationship is likely attributed to both instruments 
containing the cube copy and clock draw tasks.  It is important to note that the ACE-R, 
unlike the MoCA, does not contain a trail-making or similar type of task.  Trail-making 
tasks, specifically Trails B, are indicative of executive functioning (Sánchez-Cubillo et 
al., 2009), which is commonly impaired in persons with naMCI and necessary for 
complex tasks such as medication adherence (Insel et al., 2006) and driving (Richardson 
& Marottoli, 2003).  Performance on trail-making tasks might aid practitioners in 
deciding what patients need to be referred for driving evaluations.  The MoCA contains 
Trails B, making it more useful for primary care practitioners for the quick evaluation of 
executive functioning. 
Finally, while the ACE-R and MoCA both contain the item “tell me all of the 
words that you can think of that begin with the letter p [ACE-R] or f [MoCA]” the 
subscales which contain the item were not correlated. There are several reasons why there 
may be no relationship between the subscales: (1) Test fatigue, (2) Other questions within 
the subscales could be measuring different things, (3) Item order could possible cause 
more perseveration in one test than the other, and (4) Broader differences between the 
letter (p or f) in the item, e.g. participants having an easier time naming p words than f 
words.   
Instrument bias? 
 The differences between genders and diagnoses on the ACE-R and MoCA scores 
noted in this study raise questions of possible instrument bias.  With regard to gender, 
differences in performance could potentially be related to participants’ educational 
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background and/or employment (e.g. more men than women employed in technical 
backgrounds necessitating the use of visuospatial skills more often), which were not 
widely explored in this study.  In addition, gender differences on the instruments may be 
related to broader differences in brain anatomy, function, or chemistry between genders 
(Cahill, 2006).  Differences in performance by diagnosis on the other hand are likely 
mostly related to memory tasks being weighted more heavily than other tasks in the total 
instrument scores or study limitations.   
Limitations 
The relationship of educational level to score on the ACE-R and MoCA could not 
be fully assessed in this study given the highly educated, homogeneous sample.  Both 
instruments are affected by educational level, despite not being measures of general 
knowledge or IQ (Nasreddine et al., 2005).  Consequently, the educational background of 
participants should be accounted for in any evaluation of instruments of cognitive 
functioning.  However, educational level is only taken into account in scoring on the 
MoCA: those at a high school education or below receive one extra point.   
Alike many previous studies on MCI, collecting data from only one clinic resulted 
in a very homogeneous sample which limits the generalizability of these results.  In 
addition, the focus of the clinic is “memory disorders,” consequently; results may not be 
applicable to the other populations where the MoCA has been used (such as persons with 
cardiovascular disease, stroke, or Parkinson’s disease).  Potentially impacting reliability, 
different test administrators (clinic staff vs. PI), the timing between instruments, and 
altered timing between questions on the MoCA through omission of repeated questions 
may have affected study results.   
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Finally, internal consistency (Cronbach’s alpha) was surprisingly low in this study 
and may not be the best way to evaluate the reliability of cognitive examinations with this 
small, homogenous sample (n=50).   igher Cronbach’s alphas have been reported in 
other literature with larger and more diverse samples ranging around 0.84 to 0.83 for both 
instruments (Fujiwara et al., 2010; Mioshi et al, 2006; Nasreddine et al., 2005; Rahman & 
Gaafary, 2009).   
Recommendations for future research 
Since the conclusion of this study, a new edition of the ACE-R (the ACE-III) has 
been published and has been validated in older adults with Alzheimer’s disease and 
frontotemporal dementia (Hsieh et al., 2013).  However, it is important to note that the 
ACE-III also does not contain items pertaining to abstraction or trail-making.  Future 
studies will be needed to determine the reliability and validity of the ACE-III in 
comparison to the MoCA for the screening of MCI.  Additionally, larger and more 
diverse sample sizes are needed to consider exploratory or confirmatory factor analysis to 
further assess the structure of each instruments’ subscales (Pawlowski, Segabinazi, 
Wagner, & Bandeira, 2013).  Finally, further studies are also needed to determine if 
group differences between aMCI vs. naMCI on the abstraction subscale of the MoCA are 
consistent.  Such studies could support the clinical use of the MoCA for targeting older 
adults at risk for problems such as medication noncompliance or glycemic control issues. 
Conclusions 
The MoCA includes fewer items and requires less time to complete in comparison 
to the ACE-R.  Both instruments appear to be reliable and valid for the screening of MCI 
98 
 
in a well educated sample.  However, the recommendation of this study is to use the 
MoCA as a brief screening instrument for MCI for three reasons.  (1) The MoCA is 
shorter than the ACE-R, which is an important consideration for primary care settings or 
other areas where assessment time may be limited or where subjects may be at risk for 
instrument fatigue.  (2) The MoCA was slightly more sensitive than the ACE-R for 
detecting MCI in this sample.  And (3) the MoCA contains a trail-making task and an 
abstraction subscale on which aMCI vs. naMCI subjects scored differently.  Although 
future research is needed, the abstraction subscale may help clinicians to identify patients 
at risk for medication non-compliance or glycemic control issues.   
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Tables and figures 
Table 1 
Instrument psychometrics 
Variable M SD Range α 
ACE-R 80.02 7.58 57 - 94 0.68 
MoCA 22.10 3.00 14 - 28 0.64 
 
Table 2 
Correlations between instrument totals and subscales 
 MoCA 
 
 
A
C
E
-
R 
 Total Attention Orientation Delayed 
Recall 
Abstractio
n 
Naming Language Visuospati
al 
Total .80** .46** .54** .45** .18 .27 .08 .52** 
Attention- 
Orientation 
.53** .29** .70** .28* .02 .36* .05 .10 
Memory .56** .25 .43** .57** .10 .32* -.14 .21 
Fluency .26 .10 .13 -.09 .06 -.01 .26 .34* 
Language .46** .15 .26 .28 .26 .26 .11 .24 
Visuospatia
l 
.57** .55** .18 .14 .11 -.13 .11 .67** 
 
Note. Shaded areas represent subscales that should measure similar constructs. 
*p<0.05, **p<0.001 
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Table 3.  
Significant differences in ACE-R and MoCA scores by demographic variables 
Variable Instrument t df p MD 
Male vs.  
Female 
ACE-R 3.29 48 0.002 6.72 
MoCA 2.46 48 0.018 2.07 
aMCI vs.  
naMCI 
ACE-R -2.29 48 0.030 -4.75 
MoCA -2.15 48 0.040 -1.77 
 
 
 
Figure 1. Percentage of subjects screening positive or negative for cognitive impairment. 
 
Positive
Negative
84% 
90% 
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Abstract 
A diagnosis of mild cognitive impairment (MCI) can result in uncertainty, dysfunctional 
coping, and psychological distress; all potentially influenced by time and level of 
cognitive impairment.  A conceptual framework that addresses these consequences of 
MCI could guide the development of nursing interventions.  However, such a framework 
does not currently exist.  The primary aim of this study was to test components of 
Sjostedt’s conceptual framework for MCI by examining the relationships among 
uncertainty, coping, psychological distress, time since diagnosis, and level of cognitive 
impairment from MCI.  A cross-sectional design was used with surveys completed by 91 
older adults receiving care for MCI at a neurology clinic.  Participants reported low to 
moderate levels of uncertainty and psychological distress, and often used emotion-
focused coping strategies.  However, 25.27% of the sample reported moderate/severe 
psychological distress.  Significant relationships (p<0.05) were found between 
uncertainty, coping, and psychological distress, providing support for the proposed 
conceptual framework. 
Keywords: Mild cognitive impairment, uncertainty, coping, and psychological distress  
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 Mild cognitive impairment (MCI) is considered a cognitive stage between normal 
functioning and dementia.  MCI usually affects older adults starting around 60 years of 
age with an average prevalence of 18.9% (Petersen, 2003; Petersen, 2011; Petersen et al., 
2014).  Older adults with MCI report higher rates of indirect care use, such as informal 
assistance with activities of daily living, and annual direct medical costs (approximately 
$808-3,530 more per year) compared to those without MCI (Leibson et al., 2012; Luppa 
et al., 2008; Zhu et al., 2013).  MCI can be broken down into two main subtypes that 
include amnestic (aMCI) featuring predominately deficits in memory or nonamnestic 
(naMCI) with deficits outside of memory, such as executive functions, visuospatial 
ability or language (Petersen et al., 2014).  Despite fundamental differences between 
aMCI and naMCI, there is a significant lack of evidence for treating or screening one 
subset differently from the other (Gauthier & Touchon, 2005; Lin, Vance, Gleason, & 
Heidrich, 2012).  Both subtypes of MCI result in challenges from cognitive alterations 
and uncertainty that can contribute to psychological distress, resulting in anxiety, social 
withdrawal, anger, relationship disturbances, or depression (Banningh, Vernooij-Dassen, 
Rikkert, & Teunisse, 2008; Blieszner, Roberto, Wilcox, Barham, & Winston, 2007; 
Lyketsos et al., 2002; Petersen et al., 2014).  Effective coping with MCI might help to 
decrease uncertainty and psychological distress; but the relationships between coping, 
uncertainty, and psychological distress have not been explored in older adults with MCI.  
Nurses are in a unique position to provide interventions to older adults to promote 
understanding and to help them overcome challenges associated with MCI (Lin et al., 
2012).  A framework to assist in addressing the consequences of MCI, specifically one 
that examines the relationships among MCI diagnosis, uncertainty, coping and 
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psychological distress, is essential to guide the development of nursing interventions that 
might help older adults with MCI cope effectively. 
A conceptual framework for MCI 
Diagnostic criteria for MCI and a theoretical progression of cognition from 
normal aging to dementia provide some justification for research and practice, but do not 
provide sufficient guidance for nursing interventions that might help older adults with 
MCI and their families cope.  In addition, while the theoretical progression suggests that 
cognition will worsen over time, the path and speed of the progression is often uncertain; 
older adults with MCI transition along the continuum at differing and unpredictable rates 
where their cognition may improve, remain stagnant within the range of MCI, or progress 
to dementia (Banningh et al., 2008; Gauthier & Touchon, 2005; Lingler et al., 2006; 
Werner & Korczyn, 2008).  Other theories that discuss coping with chronic illnesses, do 
not account for this sometimes unpredictable MCI trajectory on the older adult’s ability 
to appreciate the appraisal of their situation or psychological distress.  Consequently, a 
framework that addresses the relationships of antecedents and consequences of MCI is 
imperative to improve the nursing care for these older adults. 
Development a framework 
The lack of a specific theoretical framework describing the antecedents and 
consequences of MCI and limitations of existing frameworks related to other chronic 
illnesses necessitated the new conceptualization of MCI to provide support for research 
and the development of interventions specific for older adults with MCI.  The Sjostedt 
framework for older adults with MCI (Figure 1) encompasses both aMCI and naMCI and 
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was developed to meet this need using concept analysis methods proposed by Rogers 
(Rodgers & Knafl, 2000).  This framework evolved from a literature search that 
encompassed years 2000 to 2014 using the CINAHL, Google-scholar, Web-of-Science, 
Proquest dissertations, and PubMed databases, followed by ancestral searches of articles 
obtained.  Search terms included “mild cognitive impairment,” and surrogate terms for 
MCI combined with terms such as: older adults, geriatrics, chemotherapy, alcohol, 
nursing, perception and concept.    
Sjostedt framework for MCI 
In the Sjostedt framework, MCI is defined as an unstable state of limbo weighted 
by heterogeneity between older adults’ normal and abnormal continuums (normal aging 
versus dementia).  Figure 1 illustrates the antecedents, attributes, and consequences of 
MCI proposed within the framework.  The main consequence of MCI is uncertainty, 
which then leads to the other consequences of coping and psychological distress.  
Uncertainty from MCI stems mainly from inconsistencies in MCI diagnosis and 
variability in MCI trajectories (Bensadon & Odenheimer, 2013; Dean & Wilcock, 2012; 
Lu, Haase, & Farran, 2007; Werner & Korczyn, 2008; Yanhong, Chandra, & Venkatesh, 
2013).  Uncertainty can influence how older adults respond and relate to any illness, 
treatments, or hospitalizations (Landis, 1996), thus potentially influencing the coping and 
psychological distress which result from MCI (Banningh et al., 2008; Blieszner et al., 
2007; Lingler et al., 2006; Lu et al., 2007).  Guided by the Uncertainty in Illness Theory 
(Mishel, 1988) or other modifications or proposed frameworks influenced by it, 
uncertainty has been quantitatively explored in chronic conditions such as cancer 
(Agretelis, 1999; Kazer, Bailey, Sanda, Colbery, & Kelly, 2011; Lien, Lin, Kuo, & Chen, 
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2009; Sammarco & Konecny, 2010), Parkinson’s disease (Sanders-Dewey, Mullins, & 
Chaney, 2001), and fibromyalgia (Anema, Johnson, Zeller, Fogg, & Zetterlund, 2009; 
Reich et al.; 2006).  The Uncertainty in Illness Theory’s assumptions regarding the 
stimulus frame and appraisal do not account for the potential impact of MCI and lack of 
awareness of deficits in older adults with MCI; this limits the theory’s applicability.  In 
addition, uncertainty has not been quantitatively addressed in older adults with MCI.   
The Sjostedt framework hypothesizes that coping and psychological distress from 
MCI result as responses to the diagnosis and symptoms related to MCI.  Findings from 
one study suggest that some older adults with MCI might use avoidance oriented (or 
dysfunctional) coping through attempts to improve memory performance, avoidance of 
activities to keep from making mistakes or masking of deficits (Banningh et al., 2008).  
Yet, findings from other studies have indicated that older adults with MCI might also use 
emotion-focused or problem-focused coping through methods such as positive reframing, 
acceptance, religion, planning, and instrumental support (Lin & Heidrich, 2012; 
McIlvane, Popa, Robinson, Houseweart, & Haley, 2008).  Emotional-focused and 
dysfunctional coping might increase psychological distress whereas problem-focused 
coping might reduce psychological distress, similar to the relationships demonstrated 
within other chronic illnesses (Barron, 2000; Lauver, Kruse, & Baggot, 1999; Lynch, 
Kroencke, & Denney, 2001; Sanders-Dewey et al., 2001).   
Psychological distress from MCI may present as anger, depression, anxiety, 
somatic symptoms, sadness, frustration, loss of self-confidence, discouragement, 
loneliness, rejection, inactivity, shame, self-blame, helplessness or loss of control 
(Banningh et al., 2008; Blieszner et al., 2007; Carpenter et al., 2008; Dean & Wilcock, 
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2012; Ellison, 2008; Lu et al., 2007).  One study found that older adults with MCI were 
unable to identify any positive consequences related to the condition (Banningh et al., 
2008).  Yet, other studies have found more positive emotions, such as happiness or relief 
that it is not dementia, satisfaction from professional validation of their cognitive 
symptoms, optimism, and comfort by being able to reduce uncertainty in naming their 
cognitive symptoms (Dean & Wilcock, 2012; Lingler et al, 2006; McIlvane et al., 2008). 
Based upon the literature, MCI is a diagnosable and valid chronic condition that 
does not cause physical pain or result in death.  As a chronic condition, it is expected that 
the relationships demonstrated between uncertainty, coping, and psychological distress in 
older adults with MCI may be similar to what has been observed among older adults with 
other types of chronic conditions.  Finally, consistent with current recommendations for 
care (Lin et al., 2012), this study also assumes that while the subtypes of MCI may be 
fundamentally different, nursing care related to MCI will not vary greatly based upon the 
subtype of MCI.   
Purpose 
This study is unique in quantitatively addressing consequences of MCI and is 
foundational in validating aspects of a conceptual framework that can guide the 
development of nursing interventions and further research for older adults with MCI.  
The primary purpose of this study was to test select components of a new conceptual 
framework for MCI by examining the relationships among uncertainty, coping, 
psychological distress, time since diagnosis, and level of cognitive impairment from 
MCI.  Secondary aims were to: (a) to describe the levels of uncertainty, coping, and 
psychological distress in older adults with MCI; (b) examine the differences in scores on 
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uncertainty, coping, and psychological distress between the two subtypes of MCI; and (c) 
examine the strength and direction of relationships between scores on uncertainty, 
coping, and psychological distress within the subtypes of MCI.   
The hypotheses generated from the proposed  framework that will be tested in this 
study are: (a) there will be a significant negative relationship between time since 
diagnosis and level of cognitive impairment from MCI, where longer time since 
diagnosis will be associated with lower scores of cognition; (b) there will be significant 
positive relationships between uncertainty and use of coping strategies (emotion focused, 
problem focused, or dysfunctional coping); (c) there will be significant positive 
relationships between uncertainty and psychological distress; (d) there will be significant 
positive or negative relationships between use of coping strategies and psychological 
distress; (e) the relationships between level of cognitive impairment from MCI and use of 
coping strategies will be mediated by uncertainty; (f) the relationships between level of 
cognitive impairment from MCI and psychological distress will be mediated by 
uncertainty and coping; and (g) there will be no significant differences between the 
subtypes of MCI in the strength and association of uncertainty, coping, and psychological 
distress.   
Methods 
Prior to approaching any subjects, institutional review board approval for the 
study was obtained from the study site.  The study design used was descriptive, cross-
sectional, and correlational.  A convenience sample of 91 older adults was recruited from 
an outpatient neurology clinic.  Subjects were included if they were over 54 years of age, 
had been given a diagnosis of MCI by their attending physician supported with 
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neuropsychological testing, and could understand and speak English.  Participants were 
excluded if they did not meet the above inclusion criteria, if their physician suspected that 
other neuropsychiatric disorders or chronic conditions might be complicating or masking 
their diagnosis of MCI, or if they had progressed to dementia.  Analyses for aim 1 
necessitated the largest sample, hence aim 1 was used to guide the sample size 
estimation.  Sample size was estimated using a method from Cohen & Cohen (1983), 
resulting in estimating a sample of 91 older adults to yield a power of 0.80 at α = 0.05. 
Participant recruitment occurred over the course of 62 consecutive weeks 
(excluding federal-holidays or weeks when the clinic was not operational) starting in July 
2013.  Potential participants were identified prior to their scheduled appointment in the 
neurology clinic by clinic staff.  After completing their scheduled appointment, all 
potential participants were invited to participate in the study that same day.  Consent and 
data collection then occurred as an in person interview with the study PI (unaffiliated 
with the clinic) in an available exam room at that clinic. 
Instruments 
All instruments in this study were selected to be consistent with the conceptual 
definitions of the variables, and their reliability and validity (see table 1).  Instruments to 
assess the variables by order of administration were: Montreal Cognitive Assessment 
(lower scores equate to a higher level of cognitive impairment from MCI) (Nasreddine, 
2011), a Demographic Survey, Uncertainty Stress Scale (higher scores indicate more 
uncertainty) (Hilton, 1996), Brief COPE (higher scores indicate more use of that coping 
strategy) (Carver, 1997), and Kellner Symptom Questionnaire (higher scores indicate 
more psychological distress) (Kellner, 1987).  The demographic survey measured time 
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since initial MCI diagnosis in months and years, and select antecedents which could 
potentially have an effect on uncertainty, coping, and psychological distress: subject 
gender, age, race/ethnicity, educational level, marital status, religious affiliation, and 
socioeconomic status.  The demographic survey was administered as part of the in person 
interview; however, time since initial MCI diagnosis was obtained from participants’ 
electronic medical records after completing the in person interview. 
Data analysis 
 Data analysis was performed using SPSS statistical software version 21.0 (IBM 
Corp, 2012).  All data were assessed for frequencies, mean, median, mode, outliers 
(scatter plots), skewness and kurtosis.  Prior to conducting data analysis to meet the study 
aims, differences related to demographic variables (i.e. gender) on the other variables of 
level of cognitive impairment from MCI, subtypes of MCI, time since initial diagnosis 
with MCI, uncertainty, coping, and psychological distress were examined using one-way 
analysis of variance (ANOVA) or χ² tests as appropriate.  Any differences related to 
demographic variables were considered as possible confounding variables within the 
remaining analyses to meet study aims.  Descriptive statistics were then calculated for 
each study instrument and assessed for group differences between MCI subtypes or other 
descriptive variables using t-tests and ANOVA.  To evaluate the primary study purpose 
and associated hypotheses, first bivariate correlations were calculated to determine the 
relationship of study variables and continuous descriptive variables.  Next hierarchical 
multivariate regression analyses were conducted with each psychological distress 
subscale as separate dependent variables.  Differences in the strength or direction of study 
variables by MCI subtype were assessed using methods for determining the region of 
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significance in multiple linear regression 2-way interactions (Preacher, Curran, & Bauer, 
2006); and Sobel tests were calculated to assess for potential mediating effects in the 
models (Preacher & Leonardelli, 2001). 
Results 
A total of 91 older adults were recruited for the study with a mean age of 75.22 
(SD = 0.49, range 58-89 years).  Participants were primarily Caucasian (94.5%), 
Christian (87.91%), married (76.9%), retired (85.7%) and had an average of 15.37 years 
of education (SD=3.52, range 4-27 years).  The mean employment duration was 28.21 
years (SD = 13.85, range 2-60 years) with professions split between office/law/sales 
(49.5%), health/education/service (27.5%), and engineering/manual (23.1%).  The sample 
contained a relatively even split of aMCI (57.14%) and naMCI (42.86%) diagnoses, and 
participants had a mean MCI duration of 2.36 years (SD = 2.29, range <1-10 years).  
There were no significant differences (p ≤ 0.05) between aMCI vs. naMCI subtypes on 
any of the demographic variables. 
 Table 2 describes the participants’ responses on each of the study instruments by 
order of administration with group differences noted between the MCI subtypes.  The 
only demographic group difference on study instrument means was with marital status; 
older adults who were divorced (n=6) reported significantly higher rates of depression, 
SQ-D (F(4, 86) = 2.85, p = 0.03), compared to those who were married (MD = 5.52).  
Bivariate correlation revealed only a few relationships between the continuous 
demographic variables and study instruments.  Age was significantly negatively 
correlated with scores on the MoCA (r = -0.23, p = 0.03), emotion focused coping (r = -
0.45. p < 0.001), problem focused coping (r = -0.47, p < 0.001), dysfunctional coping (r = 
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-0.34, p = 0.001), and anxiety (r = -0.26, p = 0.01).  In addition, MCI duration was 
significantly positively correlated with somatic symptoms (r = 0.35. p = 0.001). 
Participants indicated the least uncertainty (USS-U) and stress from uncertainty 
(USS-S) about whether they are being told the truth regarding their cognitive impairment 
(USS-U M = 0.51 ± 1.11; USS-S M = 0.33 ± 0.63) and if they will be well cared for by 
the nurses (USS-U M = 0.57 ± 1.17; USS-S M = 0.24 ± 0.67) or other hospital staff 
(USS-U M = 0.59 ± 1.12; USS-S M = 0.27 ± 0.56).  Participants indicated the most 
uncertainty and stress about whether their MCI will be the same in 5 years (USS-U M = 
1.65 ± 1.42, USS-S M = 0.87 ± 0.79), if their MCI will interfere with their ability to do 
their usual activities (USS-U M = 1.49 ± 1.41, USS-S M = 0.76 ± 0.81), and the stability 
of their MCI (USS-U M 1.43 ± 1.10, USS-S M = 0.78 ± 0.70).  Close to half of the 
sample (42%) indicated that they had no positive feelings, such as hope or optimism, 
about uncertainty from MCI.  However, there were no significant differences between 
those who reported positive feelings vs. those who did not on the subscales of the USS, 
MoCA, Brief COPE, and Symptom Questionnaire or by subtype of MCI (p = 0.08 – 
0.77). 
Table 3 illustrates the bivariate correlations between the USS-U, USS-S, and 
other study variables.  A strong significant positive correlation was noted between the 
USS-U and USS-S, indicating that the subscales likely measure the same concepts.  In 
addition, when completing the instruments, some participants made comments about 
equating uncertainty with worry or stress accompanied by circling their response on the 
USS-U items to indicate that worry or stress rather than uncertainty.  Consequently, only 
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the USS-S was considered as a variable for uncertainty within the testing of the 
conceptual framework. 
The mean of average responses on the Brief Cope indicated that participants 
reported significantly higher (p < 0.001) use of emotion focused coping strategies (M = 
1.23 ± 0.69) and problem focused strategies (M = 1.11 ± 0.82) in comparison to 
dysfunctional coping (M = 0.48 ± 0.41).  The most frequently reported strategies fell 
within the emotion focused coping subscale and were acceptance (M = 1.81 ± 0.90), use 
of emotional support (M = 1.42 ± 0.94), and religion (M = 1.36 ± 1.14).   
Mean responses on the psychological distress subscales (table 2) fell within the 
“normal range” for depression (≤ 6), anxiety (≤ 7), anger/hostility (≤ 8), and somatic 
symptoms (≤ 8) (Kellner, 1987).   owever, it is important to note that almost a quarter of 
the sample fell within the moderate to severe range for depression (20.88%), anxiety 
(25.27%), or somatic symptoms (21.98%).  In addition, 9.89% of participants fell within 
the moderate to severe range for anger/hostility.  Although a higher proportion of 
participants with naMCI versus aMCI scored within the moderate to severe range, a 
significant difference between the subtypes only existed for somatic symptoms (χ2(2) = 
5.98, p = 0.05).  Of participants with naMCI, 30.77% reported moderate (n = 6) to severe 
(n = 6) somatic symptoms versus 15.38% with aMCI (n = 7 moderate, n = 1 severe). 
The first hypothesis, there will be a significant negative relationship between time 
since diagnosis and level of cognitive impairment from MCI, was not supported (r = 0.03, 
p = 0.76).    In addition, although a significant difference was noted between aMCI and 
naMCI on the MoCA (F(1,89) = 4.18, p = 0.04, MD = -1.46), mean levels of cognitive 
impairment for both subtypes fell within the expected range for MCI on the MoCA (≤ 
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26).  There were no significant relationships between the MoCA and other study 
instruments, and all of those relationships were < 0.20 (table 3); consequently, scores on 
the MoCA were excluded from further analyses.   
The second study hypothesis, there will be significant positive relationships 
between uncertainty and coping, was partially supported.  Both uncertainty (USS-U) and 
stress from uncertainty (USS-S) were significantly and positively correlated with problem 
focused coping (BC-P), and dysfunctional coping (BC-D).  However, the positive 
relationship with emotion focused coping (BC-E) was not significant.   
The third study hypothesis, there will be significant positive relationships between 
uncertainty and psychological distress, was also partially supported.  There were 
significant positive relationships with both the USS-U and USS-S on depression (SQ-D), 
anxiety (SQ-A), and anger/hostility (AQ-AH).  However, somatic symptoms (SQ-S) only 
had a significant positive correlation with the USS-S and not the USS-U.   
The fourth study hypothesis, there will be significant positive and negative 
relationships between coping and psychological distress, was also only partially 
supported. Use of emotion focused coping strategies (BC-E) was positively correlated 
with the other measures of coping, but it was not significantly correlated with uncertainty 
or psychological distress (table 3).  Given the significant relationships between the BC-E, 
BC-P, and BC-D, the decision was made not to exclude BC-E from coping step of testing 
the conceptual framework. 
Four hierarchical multiple regression equations were constructed to assess the 
final hypotheses and determine the fit of variables to predict each of the four 
psychological distress variables in the conceptual model.  MCI duration (Time) and 
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MoCA were excluded from the analysis as it was determined that they were not strongly 
related to psychological distress (see table 3); and these variables are not amenable to 
modification by nursing intervention.  Consequently, the hypotheses, (a) the relationships 
between level of cognitive impairment from MCI and coping will be mediated by 
uncertainty; and (b) the relationships between level of cognitive impairment from MCI 
and psychological distress will be mediated by uncertainty and coping, were not 
supported as they could not be assessed with the exclusion of MoCA from the analyses.   
Age and MCI subtype were included as control variables in step one of each 
analysis given their significant relationships between the variables in the models.  The 
USS-S was inserted to represent uncertainty in step 2, and BC-E, BC-P, and BC-D were 
inserted in step 3 to represent coping.  Finally, interaction terms for the subtypes of MCI 
by USS-S, BC-E, BC-P, and BC-D were added to step 4 in order to assess for possible 
differences by subtype of MCI in the strength and/or direction of the relationships 
between the dependent psychological distress variables and the independent variables of 
USS-S, BC-E, BC-P, BC-D.  
All models significantly predicted psychological distress to some extent (table 4).  
The weakest model predicted somatic symptoms where MCI subtype was a significant 
predictor in each step, explaining approximately 9% of the variance in somatic 
symptoms.  Stress from uncertainty (USS-S) was a significant positive predictor in every 
model indicating that as stress from uncertainty increases, psychological distress also 
increases.  The USS-S accounted for 40% of the variance in anxiety, 19% in depression, 
18% in anger/hostility, and 5% in somatic symptoms.  With the addition of coping, USS-
S remained a significant predictor in every model except somatic symptoms.  
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The addition of coping helped to explain an additional 13% of the variance in 
depression, 11% in anger/hostility, 7% in anxiety, and 4% in somatic symptoms.  
Problem focused coping was not a significant predictor in any model.  Dysfunctional 
coping was a significant positive predictor in every model except somatic symptoms, 
indicating that as use of dysfunctional coping strategies increases, psychological distress 
also increases.  Finally, emotion focused coping was a significant negative predictor only 
in the model for anger/hostility, indicating that use of emotion focused coping reduces 
anger/hostility.  The significant predictive relationship between BC-E and SQ-AH was 
somewhat unexpected given their lack of significant correlation, which suggests that their 
relationship might be moderated by another variable.  Considering that inclusion of 
coping variables occurred in step 3 of the regression models, variables in steps 1 (age, 
MCI subtype) and step 2 (USS-S) were investigated as potential moderating variables 
between BC-E and SQ-AH.  The regression analysis for SQ-AH was repeated with only 
the interaction terms for BC-E and age, BC-E and USS-S, and BC-E and MCI subtype 
added as step 4.  The resulting model demonstrated a significant change between step 3 
and 4 (F(3,81) = 2.95, p = 0.04, R
2
 change = 0.06), and both USS-S (β = -0.26, p = 0.01) 
and age (β = -0.18, p = 0.05) were demonstrated to be significant moderating variables 
between the BC-E and SQ-AH.   
A significant change in R
2
 when interaction terms for MCI-subtypes were 
included was apparent only in the model predicting anger/hostility.  Upon further 
exploration, a significant difference was detected in the strength but not direction of the 
relationship between USS-S and SQ-AH for those with aMCI (r = 0.35, p = 0.01) versus 
naMCI (r = 0.62, p < 0.001).  Consequently, the final hypothesis, there will be no 
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significant differences between the subtypes of MCI in the strength and direction of 
uncertainty, coping, and psychological distress, was not supported given the difference in 
the relationship of USS-S and SQ-AH.   This difference in the strength of relationship 
and possible clinical implications is demonstrated by figure 2.   
Sobel tests demonstrated that BC-D was the only significant mediating variable in 
the regression models.  BC-D provided significant partial mediation between the USS-S 
and SQ-D (p < 0.01), SQ-A (p < 0.01), and SQ-AH (p < 0.03).  It is important to note that 
while the strength of the relationship between the USS-S and SQ-AH was significantly 
different between MCI subtypes, the relationship between BC-D and SQ-AH was not 
significantly different between the MCI subtypes. 
Discussion 
The results of this study support the hypothesized relationships between 
uncertainty, coping, and psychological distress within the conceptual framework. 
However, these results also suggested some possible areas for refining the framework.  
The regression models indicated that (a) increased uncertainty and dysfunctional coping 
resulted in increased psychological distress for older adults with MCI; (b) other than 
somatic symptoms, the relationships between uncertainty and psychological distress are 
mediated by dysfunctional coping; and (c) increased emotion focused coping resulted in 
decreased anger/hostility only when older adults’ age and levels of uncertainty are 
accounted for.  These relationships are demonstrated in Figure 3.  
Responses on the Brief Cope were similar to those reported with the same 
instrument in other studies of persons with MCI in which participants also reported more 
emotional focused coping than problem focused or dysfunctional coping (Lin & Heidrich, 
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2012; McIlvane et al., 2008).  The three coping subscales were all positively correlated 
with both uncertainty and psychological distress variables as predicted by the framework, 
but those relationships were not always significant as was found with the emotional 
coping subscale.  Dysfunctional coping was the most significant coping variable 
predictive of psychological distress, and a significant mediating variable between 
uncertainty and psychological distress.  This finding suggests that interventions to 
decrease uncertainty and psychological distress in persons with MCI might focus on 
decreasing dysfunctional coping behaviors such as self-distraction, venting, self-blame, 
denial, or behavioral disengagement. 
 Overall levels of uncertainty and stress from uncertainty were similar to findings 
from the USS in women with breast cancer (Agretelis, 1999).  As expected, items which 
resulted in the most uncertainty were those that pertain to the unforeseeable future with 
MCI.  Conversely, items that resulted in the least uncertainty pertained to trust in 
diagnosis (being told the truth), nurses and other health practitioners.  This finding 
highlights the certainty in being able to trust nurses and other health practitioners which 
indicates the potential role they might provide to reduce uncertainty for older adults with 
MCI.  Many participants talked about items on the USS or told a story about an item 
while completing the survey.  In addition to making comments equating uncertainty with 
worry or stress, some participants indicated that if a loved one was filling out their form, 
or if they were receiving care at a different clinic, then they might indicate a higher 
degree of uncertainty.  Others reflected that they had never thought about the items on the 
USS and had a desire to obtain more information about MCI.  Such comments suggest 
there might be potential differences in uncertainty from MCI based upon trust of the 
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provider making the diagnosis of MCI, explanation of the diagnosis, and educational 
materials provided. 
 Although mean responses on the psychological distress subscales fell within the 
“normal range” for distress, 28.27%  of the sample scored within the moderate to severe 
range of distress.  This finding is supported by previous research which found greater 
levels of psychological distress, in particular depression and anxiety, in persons with MCI 
compared to those without MCI or dementia (Petersen et al., 2014; Shahnawaz et al., 
2013).  In addition, in this study, those with naMCI reported higher degrees of distress 
than those with aMCI; however, this finding is not well supported by previous literature.  
For example, one study found no significant differences in report of psychological 
distress by MCI subtype (Lee, Cho, Hong, Kim, & Oh, 2008); and yet, in another study, 
those with aMCI reported significantly more depression than those with naMCI 
(Shahnawaz et al., 2013).  One confounding factor not explored in this study is 
differences in the amount and type of chronic conditions experienced between those with 
aMCI versus naMCI which may result in differences of reported somatic symptoms.    
This study includes a number of limitations.  Recruiting subjects from one 
academic-focused clinic in the Midwest and cross-sectional design resulted in a 
homogeneous sample and limits generalizability of results.  To address these concerns, 
further research is needed with more diverse populations within different care settings 
and areas of the US or other countries.  Specific to cross-sectional limitations, 
longitudinal studies will be needed to evaluate if the study variables change over time.  
Finally, two instruments had not been used in older adults with MCI (USS, SQ).  While 
this study demonstrated acceptable alpha levels and may support the use of these 
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instruments in older adults with MCI, future studies will still be needed to support the 
psychometrics demonstrated and determine the appropriateness of these instruments over 
time. 
Understanding the consequences of having MCI is foundational to designing 
appropriate interventions that help to decrease uncertainty and dysfunctional coping, and 
promote emotional focused coping in order to reduce psychological distress from MCI.  
The Sjostedt framework provides direction to nurses involved in research with MCI, and 
can also guide the development of interventions for the management of MCI.  The 
findings of this study demonstrates the framework’s proposed relationships between 
uncertainty, coping, and psychological distress as a consequence of MCI, independent of 
the level of one’s cognitive impairment.  Important clinical considerations from this study 
are the level of and differences in psychological distress between the subtypes of MCI 
and the sources of uncertainty.  Psychological distress frequently presents as somatic 
symptoms in older adults but can be misattributed to chronic illnesses (National Ageing 
Research Institute, 2009).  Persons with naMCI need to be assessed for interventions 
needed to address somatic symptoms of psychological distress.  Interventions might 
include educational materials and support groups should address concerns about the 
future with MCI and offer guidance for future planning in order to reduce anxiety and 
uncertainty.  
This study provides preliminary evidence to support the hypothesized 
relationships between the constructs in the Sjostedt framework for older adults with MCI.  
The next step in validating the framework will be to replicate the study results with more 
diverse samples over time and evaluate the potential interactions between the modifiable 
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antecedents and the consequences of MCI.  Given the cross-sectional nature of this study, 
it is likely that if cognitive status were assessed over a given time rather than at one time 
point, a significant relationship between cognition and the study variables might be 
observed as it would allow for calculation of differences in cognition over time for each 
participant.  Future studies will also need to contain cognitive comparison groups to 
further assess for the possible impact of cognitive impairment on uncertainty, coping, and 
psychological distress.  Finally, while the design of this study was not mixed methods, 
several comments from participants were noted pertaining to the USS.  It is important to 
consider those comments in planning future studies or interventions focused on 
uncertainty with MCI.  For example, future studies might involve family members and/or 
paid caregivers in the assessment of uncertainty or explore differences in the uncertainty 
experienced between caregivers and older adults with MCI.  
Notes 
 This study was funded by a $2,500 dissertation grant awarded by the Southeastern 
Wisconsin Nursing Research Consortium.  The authors would also like to thank the 
neurology clinic staff for their assistance with participant recruitment, collection space, 
and support. 
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Tables and figures 
Table 1 
Theoretical constructs, instruments, and reliability by order of administration 
Theoretical Construct Instrument with Subscales Scale α* 
Cognitive Impairment Montreal Cognitive Assessment  
Total Scale 
11 items 
0-30 points 
 
0.66 
Select MCI Antecedents Demographic Survey 10 items 
N/A points 
 
N/A 
Uncertainty Uncertainty Stress Scale 
Uncertainty 
Stress from Uncertainty 
59 items 
0-316 points 
0-308 points 
 
0.85 
0.76 
Coping Brief COPE 
Emotion Focused 
Problem Focused 
Dysfunctional 
28 items 
0-30 points 
0-18 points 
0-36 points 
 
0.85 
0.86 
0.76 
Psychological Distress Symptom Questionnaire 
Depression 
Anger/Hostility 
Anxiety 
Somatic 
Total Scale 
92 items 
0-23 points 
0-23 points 
0-23 points 
0-23 points 
0-92 points 
 
0.89 
0.83 
0.89 
0.88 
0.95 
 
*Observed in this study
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Table 2.  
Levels and differences of uncertainty, coping, and psychological distress for older adults 
with aMCI vs naMCI (mean ± SD). 
Variable aMCI (n=52) naMCI (n=39) Total (n=91) Range 
MoCA 21.52 ± 2.80 22.97 ± 3.99 22.14 ± 3.42 12-30 
Uncertainty Stress Scale: 
Uncertainty (USS-U) 
Stress of Uncertainty (USS-S) 
 
90.49 ± 80.11 
84.06 ± 80.80 
 
77.78 ± 53.16 
82.24 ± 63.71 
 
85.04 ± 69.79 
83.28 ± 73.58 
 
0-291.00 
0-279.91 
Brief COPE: 
Emotion Focused Coping (BC-E) 
Problem Focused Coping (BC-P) 
Dysfunctional Coping (BC-D) 
 
11.54 ± 6.78 
6.19 ± 4.29 
5.15 ± 4.62 
 
13.36 ± 6.99 
7.28 ± 5.70 
6.44 ± 5.17 
 
12.32 ± 6.89 
6.66 ± 4.94 
5.70 ± 4.88 
 
0-30 
0-18 
0-20 
Symptom Questionnaire: 
Depression (SQ-D) 
Anxiety (SQ-A) 
Anger-Hostility (SQ-AH) 
*Somatic (SQ-S) 
Total Scale (SQ-T) 
 
3.38 ± 4.22 
4.25 ± 4.76 
2.23 ± 2.69 
4.17 ± 3.65 
14.04 ± 12.37 
 
3.69 ± 4.50 
4.64 ± 4.88 
3.54 ± 3.65 
6.90 ± 5.40 
18.77 ± 15.64 
 
3.52 ± 4.32 
4.42 ± 4.79 
2.79 ± 3.19 
5.34 ± 4.66 
16.07 ± 13.99 
 
0-17 
0-21 
0-13 
0-21 
0-52 
 
*Denotes significant difference, t-test (p = 0.005), between aMCI and naMCI 
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Table 3.  
Pearson’s correlations between instrument scales (n = 91). 
 Age Time-
MCI 
MoCA USS-
U 
USS-S BC-E BC-P BC-D SQ-D SQ-A SQ-
AH 
SQ-S 
Age 1            
Time 0.06 1           
MoCA -0.23* 0.03 1          
USS-
U 
-0.07 -0.08 -0.05 1           
USS-S -0.20 -0.06 0.02 0.86** 1        
BC-E -
0.45** 
-0.07 -0.05 0.13 0.21 1       
BC-P -
0.47** 
-0.19 0.06 0.21* 0.34** 0.72** 1      
BC- D -
0.34** 
-0.13 0.05 0.35** 0.46** 0.42** 0.59** 1     
SQ-D -0.18 -0.02 0.08 0.36** 0.47** 0.08 0.26* 0.51** 1    
SQ-A -0.26* 0.04 0.06 0.46** 0.67** 0.17 0.37** 0.55** 0.81** 1   
SQ-
AH 
-0.18 0.07 0.17 0.35** 0.44** 0.01 0.21* 0.44** 0.57** 0.62** 1  
SQ-S -0.09 0.35** 0.16 0.08 0.23* 0.08 0.17 0.31** 0.44** 0.51** 0.46** 1 
 
Significant relationships shaded: *p < 0.05, **p < 0.01  
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Table 4.  
Testing of relationships between uncertainty, coping, and psychological distress (n = 91) 
 Depression Anxiety Anger-Hostility Somatic 
Variables1 B (SE) β B (SE) β B (SE) β B (SE) β 
Block 1: Control 
(Constant) 
10.89 (4.21) 15.73 (4.59) 7.96 (3.06)  9.14 (4.42)  
Age 
-0.10 (0.06) -0.18 -0.15 (0.06) -0.26* -0.06 (0.04) -0.15 -0.03 (0.06) -0.05 
MCI Type 
-0.10 (0.92) -0.01 -0.07 (1.00) -0.01 -1.18 (0.67) -0.19 -2.66 (0.96) -0.28** 
R2 Change 
0.03 0.07 0.07 0.09 
F Ratio for 
R2 Change 
1.56 3.08* 3.04* 4.21** 
Block 2: Uncertainty 
(Constant) 
5.17 (3.98)  6.59 (3.66)  3.95 (2.91)  5.96 (4.53)  
Age 
-0.05 (0.05) -0.09 -0.07 (0.05) -0.12 -0.03 (0.04) -0.07 -0.01 (0.06) -0.01 
MCI Type 
-0.25 (0.83) -0.03 -0.31 (0.76) -0.03 -1.29 (0.60) -0.20* -2.74 (0.94) -0.29** 
USS-S 
0.03 (0.01) 0.45*** 0.04 (0.01) 0.65*** 0.02 (0.01) 0.43*** 0.02 (0.01) 0.23* 
R2 Change 
0.19 0.40 0.18 0.05 
F Ratio for 
R2 Change 
21.73*** 65.72*** 20.02*** 5.18* 
R2(Adjusted 
R2) 
0.23 (0.20) 0.47 (0.45) 0.24 (0.21) 0.14 (0.11) 
Block 3: Coping 
(Constant) 
3.99 (4.51)  4.31 (4.23)  5.03 (3.36)  4.25 (5.50)  
Age 
-0.04 (0.05) -0.07 -0.05 (0.05) -0.08 -0.03 (0.04) -0.09 0.02 (0.07) 0.03 
MCI Type 
0.01 (0.77) 0.00 -0.09 (0.73) -0.01 -1.19 (0.58) -0.19* -2.56 (0.94) -0.27** 
USS-S 
0.02 (0.01) 0.29** 0.03 (0.01) 0.52*** 0.01 (0.01) 0.31** 0.01 (0.01) 0.14 
BC-E 
-0.13 (0.08) -0.21 -0.12 (0.08) -0.18 -0.14 (0.06) -0.28* -0.06 (0.10) -0.09 
BC-P 
0.02 (0.13) 0.02 0.12 (0.12) 0.12 0.04 (0.09) 0.06 0.03 (0.15) 0.03 
BC-D 
0.38 (0.10) 0.43*** 0.28 (0.10) 0.28** 0.22 (0.08) 0.34** 0.23 (0.13) 0.24 
R2 Change 
0.13 0.07 0.11 0.04 
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F Ratio for 
R2 Change 
5.71*** 4.42** 4.57** 1.39 
R2(Adjusted 
R2) 
0.36 (0.31) 0.54 (0.51) 0.35 (0.30) 0.18 (0.12) 
Block 4: Interaction Terms (IT) 
(Constant) 
4.37 (4.63)  4.05 (4.27)  4.74 (3.27)  3.49 (5.44)  
Age 
-0.03 (0.06) -0.06 -0.04 (0.05) -0.08 -0.05 (0.04) -0.13 0.01 (0.07) 0.01 
MCI Type 
0.01 (0.79) 0.01 -0.07 (0.73) -0.01 -1.12 (0.56) -0.18* -2.52 (0.93) -0.27** 
USS-S 
0.02 (0.01) 0.25 0.04 (0.01) 0.67*** 0.03 (0.01) 0.66*** 0.03 (0.01) 0.53** 
BC-E 
-0.19 (0.14) -0.31 -0.12 (0.13) -0.17 -0.05 (0.10) -0.10 -0.02 (0.16) -0.03 
BC-P 
0.01 (0.20) 0.01 0.05 (0.19) 0.05 -0.18 (0.14) -0.27 -0.07 (0.24) -0.08 
BC-D 
0.44 (0.17) 0.49** 0.23 (0.16) 0.23 0.33 (0.12) 0.50** 0.16 (0.21) 0.17 
IT USS-S 
0.01 (0.01) 0.02 -0.02 (0.01) -0.23 -0.02 (0.10) -0.43* -0.04 (0.02) -0.52** 
IT BC-E 
0.10 (0.17) 0.11 0.02 (0.16) 0.02 -0.11 (0.12) -0.17 0.01 (0.20) 0.01 
IT BC-P 
0.05 (0.27) 0.04 0.17 (0.25) 0.11 0.31 (0.19) 0.31 0.16 (0.31) 0.11 
IT BC-D 
-0.06 (0.22) -0.05 0.13 (0.20) 0.09 -0.17 (0.16) -0.18 0.14 (0.26) 0.10 
R2 Change 
0.01 0.02 0.07 0.07 
F Ratio for 
R2 Change 
0.22 0.92 2.46* 1.78 
R2(Adjusted 
R2) 
0.37 (0.29) 0.56 (0.51) 0.42 (0.35) 0.25 (0.15) 
 
1
Note: MCI type coded as aMCI = 1, naMCI = 0 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 
 135 
 
Figure 1. The Sjostedt framework for older adults with MCI. 
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Figure 2. Demonstration of the differences between aMCI and naMCI on the relationship 
between stress from uncertainty and anger/hostility. 
 
 
*Note: Dashed lines represent separation between clinical levels of anger/hostility. 
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Figure 3. Illustration of relationships within the conceptual framework.  
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APPENDIX A: SUPPLIMENTAL TABLES FOR MANUSCRIPT 2 
Table 3. Participant demographics (n=91). 
Variable aMCI (n=52) naMCI (n=39) Total (n=91) 
Age (years), mean ± SD  
(Range) 
76.13 ± 8.05  
(58-89) 
74.00 ± 8.19  
(58-88) 
75.22 ± 0.49  
(58-89) 
MCI Duration (years), mean ± SD 
(Range) 
1.98 ± 1.87  
(0-9.33) 
2.86 ± 2.70  
(0-10) 
2.36 ± 2.29  
(0-10) 
Gender: 
Male, % 
Female, % 
 
61.5% 
38.5% 
 
61.5% 
38.5% 
 
61.5% 
38.5% 
Race/Ethnicity: 
Caucasian/White, % 
African American/Black, % 
Hispanic/Latino, % 
 
94.2% 
3.8% 
1.9% 
 
94.9% 
5.1% 
0% 
 
94.5% 
4.4% 
1.1% 
Marital Status: 
Married, % 
Widowed, % 
Divorced, % 
Single, % 
Dating/Engaged, % 
 
76.9% 
5.8% 
7.7% 
7.7% 
1.9% 
 
76.9% 
10.3% 
5.1% 
5.1% 
2.6% 
 
76.9% 
7.7% 
6.6% 
6.6% 
2.2% 
Religious Affiliation: 
Catholic, % 
Lutheran, % 
Other Christian Religions, % 
Non-Christian Religions, % 
No religion, % 
 
40.4% 
21.2% 
25.0% 
3.8% 
9.6% 
 
61.5% 
17.9% 
10.3% 
5.1% 
5.1% 
 
49.5% 
19.8% 
18.7% 
4.4% 
7.7% 
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Education (years), mean ± SD 
(Range) 
15.16 ± 3.71  
(4-25) 
15.65 ± 3.28  
(12-27) 
15.37 ± 3.52  
(4-27) 
Currently Employed: 
No (Retired), % 
Yes, % 
No (Disabled), % 
No (Never Employed), % 
 
88.5% 
9.6% 
0% 
1.9% 
 
82.1% 
7.7% 
7.7% 
2.6% 
 
85.7% 
8.8% 
3.3% 
2.2% 
Employment (years), mean ± SD 
(Range) 
28.07 ± 13.22  
(2-55) 
28.40 ± 14.83  
(7-60) 
28.21 ± 13.85  
(2-60) 
Current/Former Professions: 
Office/Law/Sales, % 
Health/Education/Service, % 
Engineering/Manual, % 
 
46.2% 
30.8% 
23.1% 
 
53.8% 
23.1% 
23.1% 
 
49.5% 
27.5% 
23.1% 
 
*Denotes significant difference, One-way ANOVA or χ2 (p < 0.05), between aMCI and 
naMCI 
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Table 4. Correlations and ANOVA: Relationships and group differences in instrument 
variables by demographic variables (n = 91). 
Bivariate 
correlations 
MoC
a 
USS-
U 
USS-
S 
BC-E BC-P 
BC-
D 
SQ-
D 
SQ-
A 
SQ-
AH 
SQ-S 
Age -0.23* -0.68 -0.20 -0.45** -0.47** -0.34** -0.18 -0.26* -0.18 -0.09 
MCI 
Duration 
0.03 -0.08 -0.06 -0.07 -0.19 -0.13 -0.02 0.04 0.07 0.35** 
Education -0.03 -0.03 -0.01 0.19 0.11 -0.16 -0.16 -0.02 0.03 -0.10 
Employment 0.03 -0.05 -0.08 -0.02 -0.18 -0.01 -0.09 -0.14 -0.16 -0.12 
F-Statistic           
Gender 0.19 0.15 0.37 0.60 0.27 1.47 3.68 2.43 0.34 3.53 
Marital 
Status 
0.74 0.99 0.82 0.29 0.69 0.47 3.42** 1.51 1.12 0.94 
Religion 0.38 0.19 0.47 2.44 0.98 1.92 0.24 0.36 0.70 1.18 
Profession 0.50 0.23 0.18 0.48 2.73 1.77 0.57 0.54 1.66 0.20 
 
Significant relationships shaded: *p<0.05, **p<0.01 
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Table 5. Mean uncertainty and stress from uncertainty by items on the USS (n = 91) 
Item 
“I am uncertain...” 
Mean 
Uncertainty 
Mean Stress 
from Uncertainty 
15.  whether my MCI situation will be the 
same in 5 years 
1.648 0.868 
4.      whether I will be able to maintain my 
present level of functioning 
1.6 0.733 
17.   whether my MCI situation will 
interfere with my ability to do my usual 
activities 
1.489 0.756 
2.      about the stability of my MCI 1.427 0.778 
14.  about my chances to be well 1.398 0.716 
3.      what caused my MCI 1.385 0.648 
16.   whether my symptoms can be 
controlled  
1.371 0.798 
5.      about the present state of my MCI 
situation 
1.352 0.659 
35.  about the unpredictability of my 
symptoms 
1.296 0.679 
38.  how long my symptoms will last  1.263 0.638 
45.  about the cause of my symptoms 1.262 0.595 
36.  whether I will have difficulty coping 1.253 0.663 
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with my MCI situation 
10.  whether my MCI condition is under 
control 
1.23 0.58 
33.  about the seriousness of my condition 1.217 0.687 
21.   whether my MCI disorder will return 1.188 0.667 
52.  what to look for to check the state of 
my MCI situation  
1.183 0.61 
11.  whether my MCI condition will cause 
me to have symptoms 
1.178 0.611 
50.  about how to choose the treatments I 
should have 
1.171 0.526 
6.      what questions to ask my doctors 
about my MCI situation 
1.167 0.567 
49.  what symptoms I should be aware of 1.148 0.543 
19.   how to manage my symptoms 1.144 0.633 
27.  whether any changes brought about by 
my MCI affects my relationships 
1.12 0.627 
12.  what to say to others about my MCI 
situation 
1.101 0.449 
7.      whether changing my lifestyle will 
help my condition 
1.1 0.511 
53.  whether treatments will eliminate the 1.099 0.556 
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MCI 
41.  what unusual symptoms mean in terms 
of my MCI situation 
1.088 0.488 
51.  whether following the treatment plan 
recommended to me will help  
1.088 0.55 
30.  whether I can depend on test results as 
an indicator of my condition 
1.082 0.424 
8.      how to make sense of what I am told 
about my MCI  
1.077 0.516 
34.  about my ability to handle my 
emotions related to the MCI  
1.071 0.583 
1.      whether changes in my mild cognitive 
impairment (MCI) will be detected early  
1.068 0.648 
26.  whether my treatments have corrected 
my condition 
1.063 0.594 
28.  whether my MCI situation will affect 
my life goals 
1.049 0.568 
29.  whether what I am doing about my 
MCI situation will help me 
1.047 0.494 
9.      about the effectiveness of my 
treatments  
1.038 0.526 
23.   about my understanding of the 
treatments I have received or am receiving 
0.988 0.458 
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20.  about choices made regarding my 
treatments 
0.953 0.424 
13.  about differing explanations I have 
been given 
0.952 0.422 
54.  how to manage my medical care  0.94 0.518 
40.  whether I would choose to have all the 
treatments recommended to me 
0.936 0.462 
32.  whether delays in treatment will 
influence my chances of successful 
recovery 
0.92 0.48 
42.  whether they might find something 
wrong when I go for a checkup 
0.878 0.463 
37.  about the quality of information I have 0.867 0.427 
24.   how to approach health care workers 
about my care (for example, nurses, 
doctors, dietitians) 
0.835 0.353 
47.  whether insurance can be obtained 
because of my condition 
0.816 0.447 
22.   about the adequacy of the follow-up I 
am having 
0.809 0.337 
25.  whether the MCI situation will be 
involved in my death  
0.753 0.395 
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48.  whether I can manage financially 
because of my condition  
0.735 0.434 
46.  whether I can depend on people who 
are important to me to be there when I 
need them 
0.729 0.4 
18.   about my doctor's(s') abilities 0.682 0.341 
31.  whether my MCI condition will affect 
my sex life 
0.614 0.357 
44.  whether I will be well cared for by the 
health professionals other than the nurses   
0.59 0.265 
43.  whether I will be well cared for by the 
nurses 
0.573 0.244 
39.  whether I am being told the truth about 
my MCI situation 
0.512 0.329 
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Table 6. Differences in bivariate correlations between instrument scales by MCI subtype 
(n = 91). 
aMCI 
naMCI 
1 2 3 4 5 6 7 8 9 
1. USS-U 1          
2. USS-S 0.86** 
0.87** 
1        
3. BC-E 0.19 
0.05 
0.34* 
-0.01 
1       
4. BC-P 0.23 
0.26 
0.43** 
0.25 
0.68** 
0.76** 
1      
5. BC- D 0.32* 
0.50** 
0.52** 
0.39* 
0.31* 
0.52** 
0.44** 
0.72** 
1     
6. SQ-D 0.35* 
0.41* 
0.51** 
0.41** 
0.15 
-0.02 
0.30** 
0.22 
0.57** 
0.45** 
1    
7. SQ-A 0.41** 
0.62** 
0.68** 
0.68** 
0.29* 
0.02 
0.47** 
0.28 
0.64** 
0.44** 
0.82** 
0.80** 
1   
8. SQ-AH 0.26 
0.60** 
0.35* 
0.62** 
-0.01 
-0.02 
0.23 
0.17 
0.41** 
0.45** 
0.64** 
0.53** 
0.61** 
0.64** 
1  
9. SQ-S -0.07 
0.39* 
0.09 
0.44** 
0.11 
-0.01 
0.20 
0.11 
0.34* 
0.24 
0.34* 
0.56** 
0.36** 
0.67** 
0.31* 
0.52** 
1 
 
Significant relationships: *p<0.05, **p<0.01  
Shaded areas indicate a difference of 0.1 or greater between aMCI and naMCI 
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Table 7. Sobel Statistic (standard error) to test for mediation of coping variables between 
uncertainty and psychological distress (n = 91). 
 Depression Anxiety Anger/Hostility Somatic 
BC-E -0.64 (<0.01) -0.28 (<0.01) -1.03 (<0.01) -0.08 (0.94) 
BC-P 0.71 (<0.01) 1.29 (<0.01) 0.15 (<0.01) 0.64 (<0.01) 
BC-D 2.84** (<0.01) 2.64** (<0.01) 2.56* (<0.01) 1.78 (<0.01) 
 
*p<0.05, **p<0.01, ***p<0.001 
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APPENDIX B: SUPPLIMENTAL FIGURES FOR MANUSCRIPT 2 
 
Figure 14. Clinical distribution of depression (n = 91) 
*Note: Green = Normal, Yellow = Moderate, Red = Severe 
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Figure 15. Clinical distribution of anxiety (n = 91). 
*Note: Green = Normal, Yellow = Moderate, Red = Severe 
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Figure 16. Clinical distribution of hostility (n = 91). 
*Note: Green = Normal, Purple = Moderate, Red = Severe 
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Figure 17. Clinical distribution of somatic symptoms (n = 91). 
*Note: Green = Normal, Purple = Moderate, Red = Severe 
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Figure 18. Distribution of depression by aMCI and naMCI (n = 91). 
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Figure 19. Distribution of anxiety by aMCI and naMCI (n = 91). 
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Figure 20. Distribution of hostility by aMCI and naMCI (n = 91). 
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Figure 21. Distribution of somatic by aMCI and naMCI (n = 91). 
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Figure 22. Distribution of coping behaviors (n = 91). 
Note: 0 = Not at all, 1 = A little bit, 2 = A medium amount, and 3 = A lot.  
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Figure 23. Interaction plot of USS-S on the relationship of BC-E and SQ-AH. 
Note: Y = SQ=AH, X = BC=E, CVz(1) = USS-S Mean + SD, CVz(2) = USS-S Mean, 
CVz(3) = USS-S Mean – SD 
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Figure 24. Interaction plot of age on the relationship of BC-E and SQ-AH. 
Note: Y = SQ=AH, X = BC=E, CVz(1) = Age Mean + SD, CVz(2) = Age Mean, CVz(3) 
= Age Mean – SD 
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APPENDIX C: STUDY FORMS 
The following appendix pages contain a copy of the consent form, recruitment flyer, and 
study instruments. 
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Human Subjects Consent Form 
Please note, while the Institutional Review Board process has been started, approval has 
 
not yet been obtained for the following consent document. 
 
CONSENT TO PARTICIPATE IN RESEARCH 
 
Name of Study Subject: ____________________________ 
 
Consequences of mild cognitive impairment. 
 
Jennifer Sjostedt, Marquette University PhD-Student and Dr. Malgorzata Franczak Marquette 
University with the Department of Neurology 
 
414-805-5224 Medical College of Wisconsin 8701 Watertown Plank Road 
 
Milwaukee WI 53226 
 
You are invited to take part in this research study. This form tells you why this research study is 
being done, what will happen in the research study, possible risks and benefits to you, your 
choices, and other important information. If there is anything that you do not understand, please 
ask questions. Then you can decide if you want to join this study or not. 
 
A1. INTRODUCTION – WHY ARE WE ASKING YOU ABOUT THIS STUDY? 
 
You are being invited to participate in this research study because you have been given a 
diagnosis of Mild Cognitive Impairment (MCI). Because of your diagnosis of MCI, you may be 
eligible for a research study which is investigating how people with MCI experience uncertainty, 
coping, and psychological distress (like depression). 
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A total of about 130 people are expected to participate in this study all at the Medical College of 
Wisconsin/Froedtert Hospital. 
 
The Director of the study is Jennifer Sjostedt with Dr. Malgorzata Franczak in the Department of 
Neurology and at Marquette University. You can ask who these people are. 
 
At this time, no funding has been received for this study. 
 
A2. DO I HAVE TO BE IN THIS STUDY? 
 
You can decide whether to take part in this study or not. You are free to say yes or no. Even if 
you join this study, you do not have to stay in it. You may stop at any time. 
 
A3. WHY IS THIS RESEARCH STUDY BEING DONE? 
 
In this study we want to find out more about the consequences of having MCI. The only way to 
find this out is to survey people with MCI about their levels of uncertainty, coping, and 
psychological distress from having a diagnosis of MCI. 
  
 
B1. WHAT WILL HAPPEN IF I TAKE PART IN THE STUDY? Summary of study procedures: 
 
To participate in this study, you will be asked to complete a number of directed paper and pencil 
surveys. Jennifer Sjostedt, a PhD student from Marquette University, or a hired research assistant 
from Marquette University will assist you with completing the surveys. Prior to starting the 
surveys, if you were not tested during your normal clinic visit using the Montreal Cognitive 
Assessment, you will first be screened using that instrument to make sure you fit the study’s 
requirements. Next, you will be asked questions about your age, gender, educational level, marital 
status, religious beliefs, income, and profession. Finally, you will be given 3 surveys to complete 
regarding uncertainty, coping, and psychological distress. It is expected that participation in the 
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study will take up to 45 minutes. Data will be recorded for the study on an electronic password 
protected file with no identifying information such as your name, clinic visit date, or birthdate. 
 
B2. HOW LONG WILL I BE IN THE STUDY? 
Participation in this study will be a one-time commitment of up to 45 minutes. 
 
B3. CAN I STOP BEING IN THE STUDY? 
 
You are free to quit the study at any time. If you are thinking about quitting, please tell the study 
director. 
 
The director can tell you about the effects of stopping, and you and the doctor can talk about what 
follow-up care would help you the most. 
 
The study director may take you out of this study at any time. This would happen if: 
• They think it is in your best interest.  
• You do not follow the study rules.  
• The whole study is stopped.  
If this happens, the study director will tell you. 
 
 
 
 
C1. WHAT RISKS OR PROBLEMS CAN I EXPECT FROM THE STUDY? 
 
We watch everyone in the study for unexpected problems. You need to tell the study director or a 
member of the study team immediately if you experience any problems or become too upset. 
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C2. RISKS OF PARTICIPATION 
 
You may feel that some of the questions we ask are stressful or upsetting. If you do not wish to 
answer a question, you may skip it and go to the next question, or you may stop immediately. 
You will also be asked some questions about psychological distress, which may tell us if you are 
potentially experiencing depression. If your responses suggest that you might be experiencing 
depression, we will request your permission to inform your physician in the Neurology 
Department that you may be experiencing depression, so that they might follow-up with you on 
treatment of depression. 
 
C4. ARE THERE ANY BENEFITS TO TAKING PART IN THE STUDY? 
  
 
This study will not help you, but we hope the information from this study will help us provide 
better health services for persons with MCI. 
 
D1. ARE THERE ANY COSTS TO BEING IN THE STUDY? 
There are no costs to you for participating in this study. 
 
D2. WILL I BE PAID FOR PARTICIPATING IN THE STUDY? 
 
If funding is received for this study, you will be compensated for participation with a $10 Pick-n-
Save gift card. 
 
D3. WHAT OTHER CHOICES DO I HAVE? 
You do not have to join this study. You are free to say yes or no. 
 
If you do not join this study, your usual medical services will not change. 
 
D4. WILL I BE GIVEN NEW INFORMATION ABOUT THE STUDY? 
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If we learn any important new information [about the intervention] that might change your mind 
about being in the study, we will tell you about it right away. You can then decide if you want to 
stay in the study. 
 
D5. WHAT HAPPENS IF I AM HARMED BECAUSE I TOOK PART IN THE STUDY? 
 
No funds have been set aside to pay any costs if you are harmed because of this study. If you 
think that you were harmed because of this study, let the study director, Jennifer Sjostedt know 
right away by calling (414)-810-2756. By signing this form, you do not give up your right to seek 
payment for harm you receive while participating in this study. 
 
D6. WHO CAN ANSWER MY QUESTIONS ABOUT THE STUDY? 
 
• If you have more questions about this study at any time, you can call Dr. Franczak at 
414-805-5224.  
 
• If you have questions about your rights as a study participant, want to report any 
problems or complaints, obtain information about the study, or offer input, you can call the 
MCW/Froedtert Hospital Research Subject Advocate at 414-456-8844.  
 
E. PERMISSION TO COLLECT, USE AND SHARE HEALTH INFORMATION E1. What 
health information will be collected and used for this study? 
 
To do this research study, we need your permission to collect and use some health information 
from you, or you cannot be in the study. This information may come from questions we ask, 
forms we ask you to fill out, or your medical record, as described below. We will only collect and 
use information needed for the study. 
 
The health information we will collect and use for this study is: 
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Health information collected during this study such as questionnaires, and performance on 
cognitive testing. 
 
Medical records dating from when you join this study until the end of the study. 
  
E2. Who will see the health information collected for this study? 
 
The only people allowed to handle your health information are those on the study team at the 
Medical College of Wisconsin/Froedtert Hospital and at Marquette University, those on the 
Institutional Review Board (IRB) and those who check on the research activities to make sure the 
hospital’s rules are followed. 
 
The study team may share your information with people who are not part of the study team 
because they planned, pay for, or work with us on this study. If this happens, the federal Privacy 
Rule may no longer protect your health information. For this study, we plan to share information 
with those doctors, researchers or government representatives working with us on this study at the 
institutions or companies listed here: Marquette University, Milwaukee, WI. 
 
We may record your research information, including results of tests, procedures or questionnaires 
done for research, in your Froedtert Hospital and/or Medical College of Wisconsin medical 
record. As a result, this research information may be seen by people allowed to see your medical 
records for healthcare operations or treatment; by those you allow to see your medical records by 
giving written permission; and by others when required by law. 
 
We will not use your personal health information for a different study without your permission or 
the permission of a hospital research review board (IRB). Once all personal identification is 
removed, the information might be used or released for other purposes without asking you. 
 
Results of the study may be presented in public talks or written articles, but no information will 
be presented that identifies you. 
 
E3. What are the risks of sharing this health information? 
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One risk of taking part in a research study is that more people will handle your personal health 
information collected for this study. The study team will make every effort to protect the 
information and keep it confidential, but it is possible that an unauthorized person might see it. 
Depending on the kind of information being collected, it might be used in a way that could 
embarrass you or affect your ability to get insurance. If you have questions, you can talk to the 
study director about whether this could apply to you. 
 
E4. How long will you keep the health information for this study? 
 
If you sign this form, we plan to keep your information for 3 years in case we need to check it 
again for this study. 
 
E5. Can I cancel my permission to share this health information? 
 
If you change your mind later and do not want us to collect or share your health information, you 
need to send a letter to Dr. Malgorzata Franczak at 9200 W. Wisconsin Avenue, Milwaukee, WI 
53226. The letter must say that you have changed your mind and do not want the researcher to 
collect and share your health information. At that time, we may decide that you cannot continue 
to be part of the study. We may still use the information we have already collected. If your health 
information is no longer identified as yours, it is not possible to remove it from the study. 
 
CONSENT TO PARTICIPATE IN THE STUDY 
  
By signing my name below, I confirm the following: 
 
• I have read (or had read to me) this entire consent document. All of my questions have 
been answered to my satisfaction.  
 
• The study’s purpose, procedures, risks and possible benefits have been explained to me.  
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• I agree to let the study team use and share the information gathered for this study.  
 
• I voluntarily agree to participate in this research study. I agree to follow the study 
procedures as directed. I have been told that I can stop at any time.  
 
 
IMPORTANT: You will receive a signed and dated copy of this Consent Form. Please keep it 
where you can find it easily. It will help you remember what we discussed today. 
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Recruitment Flyer 
 
 
 
 
 
 
 
 
Have you been told that you have mild cognitive impairment 
(MCI)? 
Are you willing to share some details of your experience with 
it? 
 
After your normal clinic appointment today you will have the 
opportunity to talk with a student researcher from Marquette University who 
is interested in learning more about the consequences of having a diagnosis 
of mild cognitive impairment.  The study involves a one-time guided 
interview using paper questionnaires, which may take up to 30 minutes total 
to complete.  Please let your physician or nurse know if you would like to 
hear more about the study, and the student researcher will visit with you 
after your appointment today! 
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Instruments 
 
Copies of all scoring instructions and study instruments are included in the order 
that they will be administered. Starting on the next page, you will find the scoring 
instructions (where applicable) followed by study instruments in this order: 
 
(1) Montreal Cognitive Assessment (Nasreddine, 2011)  
Obtained from www.mocatest.org 
 
(2) Demographic Survey  
 
(3) Uncertainty Stress Scale (Hilton, 1994)  
 
(4) BriefCOPE (Carver, 1997) 
Obtained from http://www.psy.miami.edu/faculty/ccarver/sclBrCOPE.html  
 
(5) Symptom Questionnaire (Kellner, 1987) 
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Demographic Questionnaire 
Questions Answers 
1. What is your gender (Male, Female)?  
2. What is your age (Years)?  
3. What is your race/ethnicity 
(Caucasian/White, African 
American/Black, Hispanic/Latino, Asian, 
Other)? 
 
4. Are you single, married, divorced or 
widowed? 
 
5. How many years of school have you 
completed? 
 
6. What, if any, is your religious 
affiliation? (i.e. Catholic, Muslim, 
Methodist, etc) 
 
7. Are you currently employed? (Yes/No)  
8. What do you (or did you) do for work?  
9. How long have you been in (or were in) 
that profession?  
 
10. Which of the following best describes 
your annual income:  
Under $25,000 
$25,001 – 49,999 
$50,000 – 74,999 
$75,000 – 99,999 
$100,000 – 149,999 
Over $150,000 
Prefer not to say 
 
11. When were you diagnosed with MCI? 
(Month/Year) 
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BreifCOPE 
Retrieved from: http://www.psy.miami.edu/faculty/ccarver/sclBrCOPE.html 
Instructions: 
The Brief COPE contains 28 items which assess fourteen coping reactions (with two 
items for each for each reaction): active coping, planning, positive reframing, acceptance, 
humor, religion, using emotional support, self distraction, denial, venting, substance use, 
behavioral disengagement, and self-blame (Carver, 1997).  The fourteen coping reactions 
can be reduced into three sub-scales of coping: (1) emotion-focused coping (acceptance, 
emotional support, positive reframing, religion, and humor); (2) problem-focused coping 
(active coping, planning, instrumental support); and (3) dysfunctional coping (self-
distraction, venting, self-blame, behavioral disengagement, denial, and substance use) 
(McIlvane et al., 2008).   
 
Scales are computed as follows by totaling participant responses (with no reversals of 
coding): 
 
Sub-scales Coping reactions and instrument items 
Emotion-focused coping Use of emotional support, items 5 and 15 
Positive reframing, items 12 and 17 
Humor, items 18 and 28 
Acceptance, items 20 and 24 
Religion, items 22 and 27 
 
Problem-focused coping Active coping, items 2 and 7 
Use of instrumental support, items 10 and 23 
Planning, items 14 and 25 
 
Dysfunctional coping Self-distraction, items 1 and 19 
Denial, items 3 and 8 
Substance use, items 4 and 11 
Behavioral disengagement, items 6 and 16 
Venting, items 9 and 21 
Self-blame, items 13 and 26 
 
Instrument: 
These items deal with ways you've been coping with the stress in your life since you 
found out you have mild cognitive impairment.  There are many ways to try to deal with 
problems.  These items ask what you've been doing to cope with this one.  Obviously, 
different people deal with things in different ways, but I'm interested in how you've tried 
to deal with it.  Each item says something about a particular way of coping.  I want to 
know to what extent you've been doing what the item says.  How much or how 
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frequently.  Don't answer on the basis of whether it seems to be working or not—just 
whether or not you're doing it.  Use these response choices.  Try to rate each item 
separately in your mind from the others.  Make your answers as true FOR YOU as you 
can.  
 1 = I haven't been doing this at all  
 2 = I've been doing this a little bit  
 3 = I've been doing this a medium amount  
 4 = I've been doing this a lot  
1.  I've been turning to work or other activities to take my mind off things.  
2.  I've been concentrating my efforts on doing something about the situation I'm in.  
3.  I've been saying to myself "this isn't real.".  
4.  I've been using alcohol or other drugs to make myself feel better.  
5.  I've been getting emotional support from others.  
6.  I've been giving up trying to deal with it.  
7.  I've been taking action to try to make the situation better.  
8.  I've been refusing to believe that it has happened.  
9.  I've been saying things to let my unpleasant feelings escape.  
10.  I’ve been getting help and advice from other people.  
11.  I've been using alcohol or other drugs to help me get through it.  
12.  I've been trying to see it in a different light, to make it seem more positive.  
13.  I’ve been criticizing myself.  
14.  I've been trying to come up with a strategy about what to do.  
15.  I've been getting comfort and understanding from someone.  
16.  I've been giving up the attempt to cope.  
17.  I've been looking for something good in what is happening.  
18.  I've been making jokes about it.  
19.  I've been doing something to think about it less, such as going to movies,  
 watching TV, reading, daydreaming, sleeping, or shopping.  
20.  I've been accepting the reality of the fact that it has happened.  
21.  I've been expressing my negative feelings.  
22.  I've been trying to find comfort in my religion or spiritual beliefs.  
23.  I’ve been trying to get advice or help from other people about what to do.  
24.  I've been learning to live with it.  
25.  I've been thinking hard about what steps to take.  
26.  I’ve been blaming myself for things that happened.  
27.  I've been praying or meditating.  
28.  I've been making fun of the situation.  
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responsibility for any use you make of items owned by third 
parties without their permission. 
4. Licenses may be exercised anywhere in the world. 
5. You may not alter or modify the Licensed Material in any 
manner, except for the following: 
o The Licensed Material may be superficially modified 
within the scope of the license granted (color, layout, 
etc) to suit the style/format of the proposed 
republication provided that specific content or data are 
not altered, omitted, or selectively presented; 
modification must not alter the meaning of the 
material or in any way reflect negatively on the 
publisher, the journal, or author(s). 
o Within the scope of the license granted, the Licensed 
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the grant of license. 
6. Publisher reserves all rights not specifically granted in (i) the 
license details provided by you and accepted in the course of 
this licensing transaction, (ii) these terms and conditions, and 
(iii) CCC's Billing and Payment terms and conditions. 
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issuance of the license at the end of the licensing process for 
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(either by Publisher or by CCC) as provided in CCC's Billing 
and Payment terms and conditions. If full payment is not 
received on a timely basis, then any license preliminarily 
granted shall be deemed automatically revoked and shall be 
void as if never granted. Further, in the event that you breach 
any of these terms and conditions or any of CCC's Billing and 
Payment terms and conditions, the license is automatically 
revoked and shall be void as if never granted. Use of Licensed 
Materials as described in a revoked license, as well as any use 
of the Licensed Materials beyond the scope of an unrevoked 
license, may constitute copyright infringement and Publisher 
reserves the right to take any and all action to protect its 
copyright in the Licensed Materials. 
8. You must include the following copyright and permission 
notice in connection with any reproduction of the Licensed 
Material: "Copyright © (Year of Publication) American 
Medical Association. All rights reserved." 
9. THE LICENSED MATERIAL IS PROVIDED ON AN "AS 
IS" BASIS. PUBLISHER MAKES NO REPRESENTATIONS 
WITH RESPECT TO, AND DISCLAIMS ALL 
WARRANTIES, EXPRESS OR IMPLIED, RELATING TO, 
THE LICENSED MATERIAL, INCLUDING WITHOUT 
LIMITATION, IMPLIED WARRANTIES OF 
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10. You hereby indemnify and agree to hold harmless Publisher 
and CCC, and their respective officers, directors, employees, 
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as specifically authorized pursuant to this license, including 
claims for defamation or infringement of or damage to rights of 
copyright, publicity, privacy, or other tangible or intangible 
property. 
11. This license is personal to you and may not be sublicensed, 
assigned, or transferred by you to any other person without 
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12. This license may not be amended except in writing signed by 
both parties (or, in the case of Publisher, by CCC on Publisher's 
behalf). 
13. Publisher hereby objects to any terms contained in any 
purchase order, acknowledgement, check endorsement, or other 
writing prepared by you in which terms are inconsistent with 
these terms and conditions or CCC's Billing and Payment terms 
and conditions. These terms and conditions, together with 
CCC's Billing and Payment terms and conditions (which are 
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you and Publisher (and CCC) concerning this licensing 
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established by CCC's Billing and Payment terms and 
conditions, these terms and conditions shall prevail. 
14. This license and the licensing transaction shall be governed by 
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accordance with the American Arbitration Association's rules 
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License Number 
3483280918411 
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Licensed content publication 
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Licensed copyright line 
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Licensed content date 
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Terms and Conditions 
TERMS AND CONDITIONS 
This copyrighted material is owned by or exclusively licensed to John 
Wiley & Sons, Inc. or one of its group companies (each a"Wiley 
Company") or handled on behalf of a society with which a Wiley 
Company has exclusive publishing rights in relation to a particular work 
(collectively "WILEY"). By clicking �accept� in connection with 
completing this licensing transaction, you agree that the following terms 
and conditions apply to this transaction (along with the billing and 
payment terms and conditions established by the Copyright Clearance 
Center Inc., ("CCC's Billing and Payment terms and conditions"), at the 
time that you opened your Rightslink account (these are available at any 
time athttp://myaccount.copyright.com). 
 
Terms and Conditions 
 The materials you have requested permission to reproduce or 
reuse (the "Wiley Materials") are protected by copyright.  
 You are hereby granted a personal, non-exclusive, non-sub 
licensable (on a stand-alone basis), non-transferable, 
worldwide, limited license to reproduce the Wiley Materials for 
the purpose specified in the licensing process. This license is 
for a one-time use only and limited to any maximum 
distribution number specified in the license. The first instance 
of republication or reuse granted by this licence must be 
completed within two years of the date of the grant of this 
licence (although copies prepared before the end date may be 
distributed thereafter). The Wiley Materials shall not be used in 
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any other manner or for any other purpose, beyond what is 
granted in the license. Permission is granted subject to an 
appropriate acknowledgement given to the author, title of the 
material/book/journal and the publisher. You shall also 
duplicate the copyright notice that appears in the Wiley 
publication in your use of the Wiley Material. Permission is 
also granted on the understanding that nowhere in the text is a 
previously published source acknowledged for all or part of this 
Wiley Material. Any third party content is expressly excluded 
from this permission. 
 With respect to the Wiley Materials, all rights are reserved. 
Except as expressly granted by the terms of the license, no part 
of the Wiley Materials may be copied, modified, adapted 
(except for minor reformatting required by the new 
Publication), translated, reproduced, transferred or distributed, 
in any form or by any means, and no derivative works may be 
made based on the Wiley Materials without the prior 
permission of the respective copyright owner. You may not 
alter, remove or suppress in any manner any copyright, 
trademark or other notices displayed by the Wiley Materials. 
You may not license, rent, sell, loan, lease, pledge, offer as 
security, transfer or assign the Wiley Materials on a stand-alone 
basis, or any of the rights granted to you hereunder to any other 
person. 
 The Wiley Materials and all of the intellectual property rights 
therein shall at all times remain the exclusive property of John 
Wiley & Sons Inc, the Wiley Companies, or their respective 
licensors, and your interest therein is only that of having 
possession of and the right to reproduce the Wiley Materials 
pursuant to Section 2 herein during the continuance of this 
Agreement. You agree that you own no right, title or interest in 
or to the Wiley Materials or any of the intellectual property 
rights therein. You shall have no rights hereunder other than the 
license as provided for above in Section 2. No right, license or 
interest to any trademark, trade name, service mark or other 
branding ("Marks") of WILEY or its licensors is granted 
hereunder, and you agree that you shall not assert any such 
right, license or interest with respect thereto.  
 NEITHER WILEY NOR ITS LICENSORS MAKES ANY 
WARRANTY OR REPRESENTATION OF ANY KIND TO 
YOU OR ANY THIRD PARTY, EXPRESS, IMPLIED OR 
STATUTORY, WITH RESPECT TO THE MATERIALS OR 
THE ACCURACY OF ANY INFORMATION CONTAINED 
IN THE MATERIALS, INCLUDING, WITHOUT 
LIMITATION, ANY IMPLIED WARRANTY OF 
MERCHANTABILITY, ACCURACY, SATISFACTORY 
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, 
USABILITY, INTEGRATION OR NON-INFRINGEMENT 
AND ALL SUCH WARRANTIES ARE HEREBY 
EXCLUDED BY WILEY AND ITS LICENSORS AND 
WAIVED BY YOU 
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 WILEY shall have the right to terminate this Agreement 
immediately upon breach of this Agreement by you. 
 You shall indemnify, defend and hold harmless WILEY, its 
Licensors and their respective directors, officers, agents and 
employees, from and against any actual or threatened claims, 
demands, causes of action or proceedings arising from any 
breach of this Agreement by you.  
 IN NO EVENT SHALL WILEY OR ITS LICENSORS BE 
LIABLE TO YOU OR ANY OTHER PARTY OR ANY 
OTHER PERSON OR ENTITY FOR ANY SPECIAL, 
CONSEQUENTIAL, INCIDENTAL, INDIRECT, 
EXEMPLARY OR PUNITIVE DAMAGES, HOWEVER 
CAUSED, ARISING OUT OF OR IN CONNECTION WITH 
THE DOWNLOADING, PROVISIONING, VIEWING OR 
USE OF THE MATERIALS REGARDLESS OF THE FORM 
OF ACTION, WHETHER FOR BREACH OF CONTRACT, 
BREACH OF WARRANTY, TORT, NEGLIGENCE, 
INFRINGEMENT OR OTHERWISE (INCLUDING, 
WITHOUT LIMITATION, DAMAGES BASED ON LOSS 
OF PROFITS, DATA, FILES, USE, BUSINESS 
OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND 
WHETHER OR NOT THE PARTY HAS BEEN ADVISED 
OF THE POSSIBILITY OF SUCH DAMAGES. THIS 
LIMITATION SHALL APPLY NOTWITHSTANDING ANY 
FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED 
REMEDY PROVIDED HEREIN.  
 Should any provision of this Agreement be held by a court of 
competent jurisdiction to be illegal, invalid, or unenforceable, 
that provision shall be deemed amended to achieve as nearly as 
possible the same economic effect as the original provision, and 
the legality, validity and enforceability of the remaining 
provisions of this Agreement shall not be affected or impaired 
thereby.  
 The failure of either party to enforce any term or condition of 
this Agreement shall not constitute a waiver of either party's 
right to enforce each and every term and condition of this 
Agreement. No breach under this agreement shall be deemed 
waived or excused by either party unless such waiver or 
consent is in writing signed by the party granting such waiver 
or consent. The waiver by or consent of a party to a breach of 
any provision of this Agreement shall not operate or be 
construed as a waiver of or consent to any other or subsequent 
breach by such other party.  
 This Agreement may not be assigned (including by operation of 
law or otherwise) by you without WILEY's prior written 
consent. 
 Any fee required for this permission shall be non-refundable 
after thirty (30) days from receipt by the CCC.  
 These terms and conditions together with CCC�s Billing and 
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Payment terms and conditions (which are incorporated herein) 
form the entire agreement between you and WILEY concerning 
this licensing transaction and (in the absence of fraud) 
supersedes all prior agreements and representations of the 
parties, oral or written. This Agreement may not be amended 
except in writing signed by both parties. This Agreement shall 
be binding upon and inure to the benefit of the parties' 
successors, legal representatives, and authorized assigns.  
 In the event of any conflict between your obligations 
established by these terms and conditions and those established 
by CCC�s Billing and Payment terms and conditions, these 
terms and conditions shall prevail.  
 WILEY expressly reserves all rights not specifically granted in 
the combination of (i) the license details provided by you and 
accepted in the course of this licensing transaction, (ii) these 
terms and conditions and (iii) CCC�s Billing and Payment 
terms and conditions. 
 This Agreement will be void if the Type of Use, Format, 
Circulation, or Requestor Type was misrepresented during the 
licensing process. 
 This Agreement shall be governed by and construed in 
accordance with the laws of the State of New York, USA, 
without regards to such state�s conflict of law rules. Any legal 
action, suit or proceeding arising out of or relating to these 
Terms and Conditions or the breach thereof shall be instituted 
in a court of competent jurisdiction in New York County in the 
State of New York in the United States of America and each 
party hereby consents and submits to the personal jurisdiction 
of such court, waives any objection to venue in such court and 
consents to service of process by registered or certified mail, 
return receipt requested, at the last known address of such 
party.  
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals 
and in Subscription journals offering Online Open. Although most of the 
fully Open Access journals publish open access articles under the terms 
of the Creative Commons Attribution (CC BY) License only, the 
subscription journals and a few of the Open Access Journals offer a 
choice of Creative Commons Licenses:: Creative Commons Attribution 
(CC-BY) license Creative Commons Attribution Non-Commercial (CC-
BY-NC) license and Creative Commons Attribution Non-Commercial-
NoDerivs (CC-BY-NC-ND) License. The license type is clearly 
identified on the article. 
Copyright in any research article in a journal published as Open Access 
under a Creative Commons License is retained by the author(s). Authors 
grant Wiley a license to publish the article and identify itself as the 
original publisher. Authors also grant any third party the right to use the 
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article freely as long as its integrity is maintained and its original 
authors, citation details and publisher are identified as follows: [Title of 
Article/Author/Journal Title and Volume/Issue. Copyright (c) [year] 
[copyright owner as specified in the Journal]. Links to the final article 
on Wiley�s website are encouraged where applicable. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to 
copy, distribute and transmit an article, adapt the article and make 
commercial use of the article. The CC-BY license permits commercial 
and non-commercial re-use of an open access article, as long as the 
author is properly attributed. 
The Creative Commons Attribution License does not affect the moral 
rights of authors, including without limitation the right not to have their 
work subjected to derogatory treatment. It also does not affect any other 
rights held by authors or third parties in the article, including without 
limitation the rights of privacy and publicity. Use of the article must not 
assert or imply, whether implicitly or explicitly, any connection with, 
endorsement or sponsorship of such use by the author, publisher or any 
other party associated with the article. 
For any reuse or distribution, users must include the copyright notice 
and make clear to others that the article is made available under a 
Creative Commons Attribution license, linking to the relevant Creative 
Commons web page. 
To the fullest extent permitted by applicable law, the article is made 
available as is and without representation or warranties of any kind 
whether express, implied, statutory or otherwise and including, without 
limitation, warranties of title, merchantability, fitness for a particular 
purpose, non-infringement, absence of defects, accuracy, or the presence 
or absence of errors. 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC) 
License permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for 
commercial purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs 
License (CC-BY-NC-ND) permits use, distribution and reproduction in 
any medium, provided the original work is properly cited, is not used for 
commercial purposes and no modifications or adaptations are made. (see 
below) 
Use by non-commercial users 
For non-commercial and non-promotional purposes, individual users 
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may access, download, copy, display and redistribute to colleagues 
Wiley Open Access articles, as well as adapt, translate, text- and data-
mine the content subject to the following conditions: 
 The authors' moral rights are not compromised. These rights 
include the right of "paternity" (also known as "attribution" - 
the right for the author to be identified as such) and "integrity" 
(the right for the author not to have the work altered in such a 
way that the author's reputation or integrity may be impugned).  
 Where content in the article is identified as belonging to a third 
party, it is the obligation of the user to ensure that any reuse 
complies with the copyright policies of the owner of that 
content.  
 If article content is copied, downloaded or otherwise reused for 
non-commercial research and education purposes, a link to the 
appropriate bibliographic citation (authors, journal, article title, 
volume, issue, page numbers, DOI and the link to the definitive 
published version on Wiley Online Library) should be 
maintained. Copyright notices and disclaimers must not be 
deleted.  
 Any translations, for which a prior translation agreement with 
Wiley has not been agreed, must prominently display the 
statement: "This is an unofficial translation of an article that 
appeared in a Wiley publication. The publisher has not 
endorsed this translation."  
Use by commercial "for-profit" organisations 
Use of Wiley Open Access articles for commercial, promotional, or 
marketing purposes requires further explicit permission from Wiley and 
will be subject to a fee. Commercial purposes include: 
 Copying or downloading of articles, or linking to such articles 
for further redistribution, sale or licensing;  
 Copying, downloading or posting by a site or service that 
incorporates advertising with such content;  
 The inclusion or incorporation of article content in other works 
or services (other than normal quotations with an appropriate 
citation) that is then available for sale or licensing, for a fee (for 
example, a compilation produced for marketing purposes, 
inclusion in a sales pack)  
 Use of article content (other than normal quotations with 
appropriate citation) by for-profit organisations for promotional 
purposes  
 Linking to article content in e-mails redistributed for 
promotional, marketing or educational purposes;  
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resale, licence, loan, transfer or other form of commercial 
exploitation such as marketing products  
 Print reprints of Wiley Open Access articles can be purchased 
from:corporatesales@wiley.com  
Further details can be found on Wiley Online 
Libraryhttp://olabout.wiley.com/WileyCDA/Section/id-410895.html 
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